1
Status: Approved ,Date: 11 February 2019Janssen Research & Development *
Clinical Protocol
A Double -blind, Randomized, Active- controlled, Parallel -group Study of 
Paliperidone Palmitate 6- Month Formulation
Protocol R092670PSY 3015 ; Phase 3
Amendment 3
R092670 (paliperidone palmitate)
*Janssen Research & Development is a global organization that operates through different legal entities in 
various countries. Therefore, the legal entity acting as the Sponsor for Janssen Research & Development 
studies may vary, such as, but not limited to Janssen Biotech, I nc.; Janssen Products, LP; Janssen 
Biologics, BV; Janssen -Cilag International NV; Janssen Pharmaceutica NV ;Janssen, Inc; Janssen 
Sciences Ireland UC; or Janssen Research & Development, LLC. The term "Sponsor "is used throughout 
the protocol to represent t hese various legal entities; the S ponsor is identified on the Contact [CONTACT_23756].
This study will be conducted under [LOCATION_002] ( US)Food & Drug Administration (FDA) 
Investigational New Drug ( IND)regulations (21 Code of Federal Regulations [CFR] Part 312).
EudraCT Number :2017-001941 -28
Status: Approved
Date: 11 February 2019
Prepared by: [CONTACT_12945] & Development, LLC
EDMS number :EDMS- ERI-130495167, 5.0
Compliance: This study will be conducted in compliance with Good Clinical Practice (GCP) , and applicable regulatory 
requirements .
Confidentiality Statement
The information in this document contains trade secrets and commercial information that are privileged or confidential and may 
not be disclosed unless such disclosure is required by [CONTACT_784]. In any event, persons to whom the 
information is disclosed must be informed that the information is privileged or confidential and may not be further disclosed by 
[CONTACT_476]. These restrictions on disclosure will apply equally to all future information supplied to you that is indicated as priv ileged or 
confidential.
[STUDY_ID_REMOVED]
R092670 (paliperidone palmitate)
Clinical Protocol R092670PSY3015 Amendment 3
2
Approved , Date: [ADDRESS_22827] OF IN -TEXT T ABLES A ND FIGU RES ................................................................................................ 5
SYNOPSIS .................................................................................................................................................. 26
TIME AND EVENTS SCHE DULES ............................................................................................................ 33
A. Screening, Transition, and Maintenance Phases .......................................................................... 33
A.i. Subjects With Prestudy PP1M or PP3M Stability ....................................................................... 33
A.ii. Subjects Without Prestudy PP1M or PP3M Stability .................................................................. 34
B. Double -blind Phase (12 Months) ................................................................................................... 35
C. Follow -up Phase (for Subjects Who Discontinue, W ithdraw, or Relapse During the 
Double -blind Phase) ....................................................................................................................... 36
D. Keys and Footnotes (for All Time and Events Schedules) ............................................................ 37
ABBREVIA TIONS A ND TE RMS ................................................................................................................ 39
1. INTRODUCTION ................................................................................................................................ 41
1.1. Background .................................................................................................................................... 41
1.2. Overall Rationale for the Study ...................................................................................................... 44
2. OBJECTIVES, ENDPOINT S, AND HYPOTHESIS ........................................................................... 45
2.1. Objectives and Endpoints .............................................................................................................. 45
2.1.1. Objectives ................................................................................................................................... 45
2.1.2. Endpoints .................................................................................................................................... 46
[IP_ADDRESS]. Primary Endpoint ..................................................................................................................... 46
[IP_ADDRESS]. Relapse Criteria ....................................................................................................................... 46
[IP_ADDRESS]. Secondary Endpoints .............................................................................................................. [ADDRESS_22828] POPUL ATION.................................................................................................................. 55
4.1. Inclusion Criteria ............................................................................................................................ 56
4.2. Exclusion Criteria ........................................................................................................................... 59
4.3. Criteria for Entr y Into the Maintenance Phase ............................................................................... 63
4.4. Criteria for Entr y Into the Double -blind Phase ............................................................................... 64
4.5. Prohibitions, Restrictions, and Strong Recommendations ............................................................. 65
5. TREA TMENT A LLOCA TION AND BLINDING ................................................................................. 66
6. DOSA GE A ND A DMINISTR ATION.................................................................................................. 68
6.1. Dosage ........................................................................................................................................... 68
6.1.1. Screening Phase ........................................................................................................................ 68
6.1.2. Transition Phase ......................................................................................................................... 68
6.1.3. Maintenance Phase .................................................................................................................... 76
6.1.4. Double -blind Phase .................................................................................................................... 80
6.1.5. Treatment After the Study or in the Follow -up Phase ................................................................ 80
6.2. Administration ................................................................................................................................ 80
6.2.1. Administration During the Open -label Phases ........................................................................... 80
6.2.2. Administration During the Double- blind Phase ........................................................................... 81
R092670 (paliperidone palmitate)
Clinical Protocol R092670PSY3015 Amendment 3
3
Approved , Date: 11 February [ZIP_CODE]. TREA TMENT COMPLIA NCE ............................................................................................................ 81
8. PRESTUDY A ND CONCOMI TANT THERA PY................................................................................ 81
8.1. Prestudy Medical Therapy and Psychotherapy ............................................................................. 81
8.2. Concomitant Therapy ..................................................................................................................... 82
8.3. Prohibited Concomitant Medications ............................................................................................. 83
9. STUDY EVA LUATIONS .................................................................................................................... 84
9.1. Study Procedures ........................................................................................................................... 84
9.2. Efficacy  Evaluations ....................................................................................................................... 86
9.2.1. Qualified Raters .......................................................................................................................... 86
9.2.2. Positive and Negative Syndrome Scale ..................................................................................... 87
9.2.3. Clinical Global Impression - Severity .......................................................................................... 87
9.2.4. Personal and Social Performance Scale .................................................................................... 88
9.2.5. Satisfaction W ith Participation in Social Roles ........................................................................... 88
9.2.6. Abbreviated Treatment Satisfaction Questionnaire for Medication ............................................ 88
9.3. Pharmacokinetic and Pharmacodynamic Evaluations ................................................................... 88
9.3.1. Pharmacokinetic Evaluations ..................................................................................................... 88
9.3.2. Analytical Procedures ................................................................................................................. 89
9.3.3. Pharmacokinetic Parameters ..................................................................................................... 89
9.3.4. Pharmacodynamic Evaluations .................................................................................................. 90
9.4. Safety Evaluations ......................................................................................................................... 90
9.4.1. Adverse Events ........................................................................................................................... 90
9.4.2. Clinical Laboratory Tests ............................................................................................................ 90
9.4.3. Electrocardiograms ..................................................................................................................... 92
9.4.4. Vital Signs ................................................................................................................................... 93
9.4.5. Physical Examinations ................................................................................................................ 93
9.4.6. Extrapy ramidal Sy mptoms .......................................................................................................... 93
[IP_ADDRESS]. Abnormal Involuntary Movement Scale ................................................................................... 93
[IP_ADDRESS]. Barnes Akathisia Rating Scale ................................................................................................ 94
[IP_ADDRESS]. Simpson Angus Scale ............................................................................................................. 94
9.4.7. Colum bia Suicide Severity Rating Scale .................................................................................... 94
9.4.8. Evaluations of the Injection Site ................................................................................................ .94
[IP_ADDRESS]. Injection Site Evaluations by [CONTACT_9143] ..................................................................................... 94
[IP_ADDRESS]. Injection Site Evaluations and Follow -up by [CONTACT_4718] ...................................................... 95
9.5. Benefit -risk Evaluations .................................................................................................................. 96
9.6. Other Exploratory Evaluations ....................................................................................................... 96
9.6.1. Healthcare Resource Utilization Questionnaire .......................................................................... 96
9.6.2. Involvement Evaluation Questionnaire ....................................................................................... 97
9.6.3. Concomitant Substances Questions .......................................................................................... 97
9.6.4. Illness Management and Recover y Scale.................................................................................. 97
9.6.5. Schizophrenia Quality of Life Scale (Revision 4)....................................................................... [ADDRESS_22829] COMPLETION / DISCONTINUATION OF STUDY DRUG / WITHDRA WAL 
FROM THE STUDY ........................................................................................................................... 98
10.1. Completion ..................................................................................................................................... 98
10.2. Discontinuation of Study Drug / W ithdrawal From the Study ......................................................... [ADDRESS_22830] Information ...................................................................................................................... 103
11.2. Sample Size Determination ......................................................................................................... 103
11.3. Efficacy  Analyses ......................................................................................................................... 104
11.3.1. Primary Hypothesis and Efficacy Analy ses.............................................................................. 104
[IP_ADDRESS]. Double -blind Intent -to-Treat Analy sis Popula tion.................................................................. 104
[IP_ADDRESS].1. Primary Estimand ............................................................................................................... 104
[IP_ADDRESS].2. Primary Efficacy  Analy ses.................................................................................................. 105
R092670 (paliperidone palmitate)
Clinical Protocol R092670PSY3015 Amendment 3
4
Approved , Date: 11 February 201911.[IP_ADDRESS]. Sensitivity Analy ses for Primary  Efficacy ........................................................................... 105
[IP_ADDRESS]. Per-protocol Analy sis Population ........................................................................................... 105
[IP_ADDRESS].1. Estimand ............................................................................................................................ 105
[IP_ADDRESS].2. Analyses ............................................................................................................................. [ADDRESS_22831] ................................................. 120
16.2.3. Informed Consent ..................................................................................................................... 122
16.2.4. Privacy of Personal Data .......................................................................................................... 123
16.2.5. Countr y Selection ..................................................................................................................... 123
17. ADM INISTRA TIVE REQUI REM ENTS ............................................................................................ 123
17.1. Protocol Amendments .................................................................................................................. 123
17.2. Regulatory Documentation .......................................................................................................... 124
17.2.1. Regulatory Approval/Notification .............................................................................................. [ADDRESS_22832] Identification, Enrollment, and Screening Logs .............................................................. 125
R092670 (paliperidone palmitate)
Clinical Protocol R092670PSY3015 Amendment 3
5
Approved , Date: 11 February 201917.4. Source Documentation ................................................................................................................. 125
17.5. Electronic Case Report Form Completion ................................................................................... 126
17.6. Data Quality Assurance / Quality Control .................................................................................... [ADDRESS_22833] Retention ......................................................................................................................... 127
17.8. Monitoring .................................................................................................................................... 127
17.9. Study Com pletion/Termination ..................................................................................................... 128
17.9.1. Study Com pletion (End of Study) ............................................................................................. [ADDRESS_22834] OF A TTACHMENTS
Attachment 1: Guidelines for the Intramuscular Injection of Paliperidone Palmitate or 
Placebo During the Double -blind Phase .................................................................. 133
Attachment 2: Relapse Criteria for PANSS Total Score .................................................................. 134
Attachment 3: Anticipated Events for Study R092670 PSY3015 ..................................................... [ADDRESS_22835] OF IN -TEXT TA BLES A ND FIGU RES
TABLES
Table 1: Conversions Between Doses of the 1 -, 3-, and 6 -Month Formulations of Paliperidone 
Palmitate; Study R092670PSY3015 ......................................................................................... 41
Table 2: Doses of Paliperidone ER/PR Tablets and PP1M Needed to Attain Similar Steady -
state Paliperidone Exposure ..................................................................................................... 71
Table 3: Dosage and Administration Schedule for PP1M During the Transition Phase (Before 
Meeting the PP3M Prerandomization Target); Study R092670PSY3015 ................................ 73
Table 4: Dosage and Administration Schedule for PP1M During the Transition Phase (After 
Meeting the PP3M Prerandomization Target); Study R092670PSY3015 ................................ 74
Table 5: Administration of Study Agent During the Double -blind Phase; Study 
R092670PSY3015 .................................................................................................................... 81
Table 6: Maximum Allowable Benzodiazepi[INVESTIGATOR_23693]; Study R092670PSY3015 ..................... 83
Table 7: Timing of Resumption of PP1M/3M after the Double- blind Study or in Follow -Up 
Phase ...................................................................................................................................... 102
Table 8: Switching Conversion Table (Oral and LAI Paliperidone and Oral Risperidone) ................... 102
FIGURES
Figure 1:Schematic Overview; Study R092670PSY3015 ....................................................................... 50
Figure 2:Schematic Overview, Showing Additional Details for the Screening Phase and 
Transition Phase; Study R092670PSY3015 ............................................................................. 70
Figure 3:Schematic Overview, Showing Additional Details for the Maintenance Phase (Before 
Meeting the PP3M Prerandomization Target); Study R092670PSY3015 ................................ 78
Figure 4: Schematic Overview, Showing Additional Details for the Maintenance Phase (After 
Meeting the PP3M Prerandomiz ation Target); Study R092670PSY3015 ................................ 79
Figure 5: Post Study Medication Algorithm ............................................................................................ 101
R092670 (paliperidone palmitate)
Clinical Protocol R092670PSY3015 Amendment 3
6
Approved , Date: [ADDRESS_22836] recent amendment.
Amendment 3 (11 February 2019 )
The overall reason for the amendment: Tolimitthe duration of the Double -blind Phase to 12 months by 
[CONTACT_23757] -blind extension period, which is currently of a variable length of 12 -24 months; and to 
increase the estimated number of subjects entering the Transition/Maintenance Phasesfrom atarget sample size 
of 765 to 840.
Applicable Section(s) Descrip tion of Change(s)
Rationale: The rationale for limiting the Double -blind Phase to a fixedduration of 12 m onths is to align itwith 
the primary endpoint, ie, time to relapse during the Double -blind Phase which is based on the Kaplan -Meier 
estimate of percentage of subjects who remain relapse -free at Month 12 . 
Synopsis: 
Secondary Endpoints
OVERVIEW OF 
STUDY DESIGN
Dosage: Double -blind 
PhaseRemoved the greater than or equal to sign ‘ ≥’ to reflect that secondary endpoints beyond 
[ADDRESS_22837] expected duration is ~19 months and not 
>31months for subjects who complete the study without relapse as the variable duration 
of double -blind phase beyond the first [ADDRESS_22838] 12 months of the Double -blind Phase
Time and Events 
Schedules C
Time and Events 
Schedule C 
(originally Time and 
Events Schedule D)Deleted the original Time and Events Schedule C. Double -blind Phase (After the First 
12 Months) in its entirety as the Double -blind Phase is limited to 12 months per this 
amendment.
In the EOP column, removed “18 or 24” months after the subject’s first double -blind 
injection; removed text “( or at 6 -Month Time Points Thereafter, if Applicable)” ; deleted text 
in the foo tnote describing an example of Follow  up Phase visits for a subject who 
withdraws from the study in the Double -blind Phase beyond the 12 months. Also deleted 
text stating “… or at [ADDRESS_22839] 12 months of the Double -blind Phase”.Protocol Version Issue Date
Original Protocol [ADDRESS_22840] 2017
Amendment 1
Amendment 2
Amendment 321March 2018
28 September 2018
11 February 2019
R092670 (paliperidone palmitate)
Clinical Protocol R092670PSY3015 Amendment 3
7
Approved , Date: 11 February 2019Time and Events 
Schedule D: Keys and 
Footnotes (for All 
Time and Events 
Schedules) (originally 
Time and Events 
Schedule E)
[IP_ADDRESS]. Secondary 
Endpoints
3.1 Overview  of 
Study Design
Figure 1
3.2. Study Design 
Rationale
Study Phases
6.1.2. Transition 
Phase: Figure 2
6.1.3. Maintenance 
Phase: Figure 3 and 
Figure 4
6.1.4. Double- blind 
Phase
6.2.2. Administration 
During the Double -
blind Phase: Table 5Deleted footnote “aa”in Amendment 2 as it no longer applies with the elimination of 
variable double- blind phase beyond the 12 months.
Removed secondary endpoints beyond the 12 -month Double -blind Phase.
Removed the greater than or equal to sign ‘ ≥’ to reflect that secondary  endpoints beyond 
[ADDRESS_22841] 19 months of participation with exposure to paliperidone palmitate 
for subjects without relapse.
Limited the length of Double -blind Phase to 12 months only to align with the primary 
endpoint.
Footnote d: Removed text describing treatment during Double -blind Phase beyond [ADDRESS_22842] to follow -up or withdrawing c onsent .
Note: Deleted text stating that the Follow up Phase will end at [ADDRESS_22843] 
12 months of the Double -blind Phase.
R092670 (paliperidone palmitate)
Clinical Protocol R092670PSY3015 Amendment 3
8
Approved , Date: 11 February [ZIP_CODE].1. Study 
Procedures:
Double -blind Phase
10.2. Discontinuation 
of Study 
Drug/Withdrawal 
From  the Study
10.3. Antipsychotic 
Therapy After the 
Study or in the 
Follow -up Phase: 
Figure [ADDRESS_22844] 12 months of the Double -blind 
Phase.
Removed potential scheduled assessments beyond the 12 -month Double -blind Phase (ie, 
Visits beyond Visit 33 a).Removed text describing a scenario of w ithdrawal in which a 
subject has not entered the Double -blind Phase when the Sponsor terminates the study.
Removed Double- blind Time Point that is beyond 12 -month (last column).
(Note: section numbering has been updated as the original section 10.3 Withdraw al 
From  the Use of Research Samples is now deleted.)
Removed odd -numbered injections (5th, etc.) that are beyond the [ADDRESS_22845] 
randomized being los t to follow -up or withdraw ing consent
Rationale: To increase the estimated number of subjects entering the Transition and Maintenance Phases from 
approximately 765 to 84 0 to match current dropout/ enrollment rates and to meet the randomization target of [ADDRESS_22846] that the number of subjects entering the 
Transition/Maintenance Phases will exceed the previous target. The increase in the estimated number needed to 
achieve the randomization target is primarily  due to an increased dropout rate during Transition and Maintenance 
Phases.
3.1Overview  of 
Study Design;
11.2. Sample Size 
DeterminationSpecified that the number of subjects entering the Transition/Maintenance will be 
approximately 840.
Rationale: Toindicate data collection for “Concomitant substance testing and questions” at Visit 13 during the 
Double -blind Phase for consistency with footnote e andf of Tim e and Events Schedule B and with the text in 
section 9.4.2. 
Time and Events 
Schedule BAdded a time point for data collection at Visit 13 in the row of Concomitant substance 
testing and questions .
Rationale: To remove ECG collection at Visit 4 of the Maintenance Phase as routine ECG monitoring at this 
timepoint is not expected to enhance safety monitoring for subjects who are continuing the same medications in 
the Maintenance Phase.
Time and Events 
Schedule Ai
Time and Event 
Schedule AiiRemoved ECG data collection at Visit 4.
Removed ECG data collection at Visit 4.
Rationale: To provide guidance on the timing of EOP after relapse confirmation.
Time and Events 
Schedule D, footnote 
f 
9.1. Study ProceduresAdded text to state that the EOP visit is to occur as soon as possible after relapse 
confirmation (preferably the same day) .
Rationale: Toremove the EOP Visit from the Follow -up Phase to minimize potential confusion swith theEOP 
visit at the Double -blind Phase (33 a) and at the end of the Maintenance Phase (7 a).
R092670 (paliperidone palmitate)
Clinical Protocol R092670PSY3015 Amendment 3
9
Approved , Date: 11 February 2019Time and Events 
Schedule C
(Originally T ime and 
Events Schedule D)
Time and Events 
Schedule D
(Originally Time and 
Events Schedule E)
Figure 1
Section 10 .4Deleted the EOP Visit column from the Follow -up P hase.
Deleted footnote “bb” in Amendment 2
Deleted text related to the EOP Visit of the Follow -up P hase in Footnote d . 
Deleted text related to the EOP Visit of the Follow -up P hase
Rationale: To clarify that in inclusion criterion 11, the method of contraception referred to above (ie, criterion 
10) is for the female partner(s) of male subjects.
4.[ADDRESS_22847] agree that his female 
partner(s), rather than himself, use method of contracepti on as described in criterion 10.
Rationale: To remove the introduction sentence under Exclusion Criteria for clarity.
4.2 Exclusion Criteria Deleted the introduction sentence under Exclusion Criteria
Rationale: Toclarify that the excluded injectable formulations of neuroleptic drugs are long -acting injectable 
formulations.
4.2. Exclusion 
CriteriaAdded “long -acting ” to exclusion criterion 6 to state excluded injectable formulation of 
neuroleptic drugs as long-acting formulations .
Rationale: To clarify that the full content of the study drug should be administered as a single injection .
6.2.Administration Added text to state that the full content is to be administered in one injection, using only 
the supplies provided in the study drug kit.
Rationale: To add text to instruct the site of the first injection during the Maintenance Phase.
6.2.1. Administration 
During the Open -
label PhasesAdded a note to state Day [ADDRESS_22848] injection during the Maintenance Phase.
Rationale: Toadd tricyclic anti- depressants ,known to prolong QT interval, to the list of Prohibited Concomitant 
Medications; to minimize the risk of concomitant amantadine use, it is now explicitly cited as an example of a 
dopamine agonist ; to add non-antipsychotic dopamine antagonists to the list of Prohibited Concomitant 
Medications to minimize risk of EPS and akathisia.
8.3. Prohibited 
Concomitant 
MedicationsAdded tricyclic antidepressants , amantadine, andnonantipsychotic dopamine 
antagonists to the list of Prohibited Concomitant Medicat ions.
Rationale: To provide additional details forinjection site assessments .
[IP_ADDRESS]. Injection Site 
Evaluations and 
Follow -up by 
[CONTACT_23758] s regarding tenderness, 
erythema/redness, and induration/swelling .
Rationale: To provide investigators with detailed information on antipsychotic treatment options after the study 
or in the Follow -up Phase.
R092670 (paliperidone palmitate)
Clinical Protocol R092670PSY3015 Amendment 3
10
Approved , Date: [ADDRESS_22849] Study Medication Algorithm ; added Table 7, 
Timing of Resumption of PP1M/ PP3M after the Double -blind Study or in Follow -Up 
Phase ; added Table 8, Switching Conversion Table (Oral and LAI Paliperidone and oral 
risperidone).
Rationale: With a fixed duration of [ADDRESS_22850] relapse events . Therefore, collection of 
blood biomarkers is now removed from the protocol.
Time and Events 
Schedules A .i., A .ii. 
and B
Time and Events 
Schedule D: Keys and 
footnotes (Originally 
Time and Events 
Schedule E)
2.1.1 Objectives
Exploratory Objectives
3.2. Study Design 
Rationale
4.5. Prohibitions, 
Restrictions, and Strong 
Recommendations
9.1. Study Procedures
9.6. Biomarker 
Evaluations
10.3. Withdraw al From 
the Use of Research 
Samples
11.7. Biomarker 
Analysis
15. STUDY SPECIFIC 
MATERIALS
16.2. 4.Privacy of 
Personal Data
16.2. 5. Long -term 
Retention of Samples 
for Additional Future 
Research
17.11. Use of 
Information and 
PublicationRemoved text related to blood biomarkers under Collection of biofluids
Under footnote f, rem oved text related to blood biomarker sample collections.
Removed footnote “r”in Amendment 2 which was related to sample collections for 
blood biomarkers.
Removed text related to the exploratory objective to measure blood -based biomarkers.
Removed the Biomarkers sub section .
Removed text related to strong recommendations for blood biomarker sample 
collections.
Removed text related to blood s ample collections for biom arker s.
Removed original section 9.6 Biomarker Evaluations.
Deleted the entire original section 10.3 that was related to biomarker research samples.
Removed original section 11.7. Biomarker Analysis .
Removed text related to biomarkers under “Documentations” and “Supplies” .
Removed text related to exploratory biom arker research.
Removed the entire original section 16.2.5. that w as related to biomarkers .
Removed text related biomarker research data analysis and report.
R092670 (paliperidone palmitate)
Clinical Protocol R092670PSY3015 Amendment 3
11
Approved , Date: 11 February 2019Rationale: To add secondary endpoints in Synopsis and section [IP_ADDRESS]. Secondary Endpoints of the protocol to 
align secondary endpoints with section 9 Study Evaluation srelated to secondary endpoints to maintain 
consistency throughout the protocol .
Synopsis;
[IP_ADDRESS]. Secondary 
EndpointsListed additional secondary endpoints as described in section 9 of the protocol.
Rationale: To include an additional trade name [CONTACT_23873] .
6.1.2. Transition Phase Listed thetrade name [CONTACT_23874].
Rationale: To include a list of Investigational Medicinal Products (IMPs) and Noninvestigational Medicinal 
Products ( NIMPs) used in the study to facilitate protocol review .
Abbreviations and 
Term sListed IMPs and NIMPs used in the study
Rationale: Minor errors w ere noted /
Throughout the 
protocolMinor grammatical, formatting, or spelling changes were made.
R092670 (paliperidone palmitate)
Clinical Protocol R092670PSY3015 Amendment 3
12
Approved , Date: 11 February 2019Amendment 2 (28September 2018)
The overall reasons for the amendment:
To revise the number of prerandomization injections of PP1M from a total of 6 (ie, 5 -month duration) to a 
total of 5 (ie. 4 -month duration) required before subjects are randomized to either PP3M or PP6M treatment 
group in the Double -blind Phase. This change applies to subjects in the study’s Open -label phases being 
treated w ith PP1M after the PP3M prerandomization target has been met, since these subjects will be 
randomized directly from PP1M treatment. The change aligns with the minimum of 4 -month treatment with 
PP1M prior to the initiation of PP3M in previously completed pi[INVESTIGATOR_23694]3M trials and the approved posology 
for PP3M.   
To update and clarify supporting text, figures, and tables for consistency and corrects conflicting portions of 
the protocol that inadverten tly increased the minimum duration of PP1M treatment from 4 months to 5 months
To remove text related to optional salivary biomarkers research since the s ample size for this portion of the 
study is expected to be too low to generate conclusive results.
Other changes to the protocol are also made for clarity, consistency, or operational feasibility. (Note: in this 
table, newly added text to the protocol is in bold font and deleted text is in strikethrough.)
Applicable Section(s) Description of Change(s)
Rationale: To revise the minimum number of PP1M injections from 6 (ie,5 months) to 5 (ie, 4 months) prior to 
random assignment to treatment with either PP6M or PP3M in the Double -blind Phase.  This is to realign the protocol 
with the intended design in whi ch subjects receive a minimum of 4 -month treatment with PP1M in order to determine 
dose stability and to maintain clarity and consistency throughout the protocol.
6.1.2 Transition Phase, Figure 2, 
Table 3Revised Figure 2 and Table 3 (which now becomes Table 3 and Table 4 to 
illustrate the Dos age and Administration Schedule for PP1M During the 
Transition Phase before and after meeting the PP3M prerandomization target, 
respectively) to specify the minimum numbers of PP1M injections prior to 
randomization before or after the PP3M prerandomization target has been met. 
(Footnote f of Table [ADDRESS_22851] prestudy 
PP1M injection is now 30±7 days to align with section 6.1.3).
6.1.2. Transition Phase: Subjects 
Previously Treated With Oral 
AntipsychoticsThe follow ing text was added to explain and clarify the changes to the visit 
schedule after the PP3M prerandomization target is met: 
“After the PP3M prerandomization target is m et, these subjects will skip 
Visit 2e and proceed to Visit 2f if the subject is eligible to enter the 
Maintenance Phase (see Section 4.3, Criteria for Entry Into the 
Maintenance Phase). If not eligible to enter the Maintenance Phase, the 
subject will be withdrawn from  the study. ”
R092670 (paliperidone palmitate)
Clinical Protocol R092670PSY3015 Amendment 3
13
Approved , Date: 11 February [ZIP_CODE].1.2. Transitio n Phase: Subjects 
Previously Stabilized on Injectable 
Risperidone ( Biweekly – Risperdal 
CONSTA™ formulation )
6.1.2. Transition Phase: Subjects 
Previously Initiated (But Not on a 
Stable Regimen) With Moderate or 
Higher Doses of PP1M (Invega 
Sustenna ™ or Xeplion ™ 
formulation)
6.1.3. Maintenance Phase, Figure 4
Time and Events Schedules, A .ii.The follow ing text was added: “ After the PP3M prerandomization target is 
met, these subjects will skip Visit 2e and proceed to Visit 2f, if eligible to 
enter the Maintenance Phase (see Section 4.3, Criteria for Entry Into the 
Maintenance Phase).  If not eligible to enter the Maintenance Phase, the 
subject will be withdrawn from  the study.”
The follow ing text was added: “ After the PP3M prerandomization ta rget is 
met, subjects previously initiated on PP1M (but not on a stable regim en) 
who enter the study at Visit 2c or 2d will skip Visit 2e and proceed to Visit 
2f, if eligible to enter the Maintenance Phase (see Section 4.3, Criteria for 
Entry Into the Main tenance Phase). Subjects with ≥4prestudy PP1M 
injections with the last 2 doses being the same strength will enter the study 
at Visit 2f.  Subjects with ≥4prestudy PP1M injections with the last 2 doses 
being different (ie, do not have dose stability) will enter the study at Visit 2e.  
If not eligible to enter the Maintenance Phase, the subject will be withdrawn 
from  the study .”
Revised Figure [ADDRESS_22852] the minimum number of PP1M injections during the 
Transition Phase from a total of 5 to a total of 4. (A footnote w as also updated to 
reflect that the prerandomization targets of PP3M and PP1M groups were 
changed to approximately one -half from each group.)
Added the footnote cc for Visit number 2e of Transition Phase to state “ After
the PP3M prerandom ization target is m et, subjects who entered the study at 
Visits 2a, 2b, 2c, or 2d, will skip Visit 2e and proceed to Visit 2f if the 
subject is eligible to enter the Maintenance Phase (see Section 4.3, Criteria 
for Entry Into the Maintenance Phase).  If not e ligible to enter the 
Maintenance Phase, the subject will be withdrawn from  the study. Visit 2e 
remains available for subjects with ≥[ADDRESS_22853] dose stability.”
Rationale: To update the visit w indow  for Visits 8, 21, 34, and 43 to avoid overlaps with the window  of their 
respective previous visit.
Time and Events Schedules, B and 
CChanged visit window for Visits 8, 21, 34, and 43 from ± 1 to -1 to +3. 
Rationale: To update footnotes in Time and Event Schedule, E to align wi th text in section 6.1.3.
Time and Events Schedules, E Revised footnote g so that the intervals from the last prestudy PP1M and PP3M 
injections are now 30±7 days and 90±[ADDRESS_22854] prestudy PP1M 
injection is now  30±7 days and “Table 3” is changed to “Tables 3 and 4”.
Rationale: To achieve greater balance betw een the prerandomization proportions of each medication group. 
3.1. Overview  of Study Design The follow ing text was revised as follows:
“Of subjects entering the Double -blind Phase, the prerandomization targets are 
approximately one-half one quarter to one- third entering from a PP3M group, 
and one-half three -quarters to tw o-thirds entering from a PP1M group.
R092670 (paliperidone palmitate)
Clinical Protocol R092670PSY3015 Amendment 3
14
Approved , Date: [ADDRESS_22855] the approximately one- half pre -
randomization target from PP1M and PP3M groups. In addition, text was added 
to the number of PP3M entering the study if needed to maintain the approximate 
balance of PP1M and PP3M pre randomization targets: “In order to 
appropriately balance the number of PP1M and PP3M subjects in the 
Maintenance Phase and to com plete the study in a timely m anner, the 
pathway to study enrollm ent that includes subjects who enter the study with 
previous P P3M stability will be open for only a limited time. The Sponsor 
will inform  the sites when this pathway has closed to enrollm ent.”
Figure 3 updated so that the appearance and position of the box containing the 
“Low -dose exclusion groups” are aligned with those in Figure 1. A footnote 
was also updated to reflect the approximately one -half prerandomization target 
for the PP1M and PP3M group. 
Rationale: To simplify the sequence of procedures to be performed so that non -invasive safety assessments are 
compl eted before invasive tests to avoid influencing results and the sequence of procedures that is critical to quality is 
kept.    
9.1.Study Procedures The Time and Events Schedules summarize the frequency and timing of 
measurements applicable to this study . If multiple assessments are scheduled for 
the same visit, then ECG and vital signs should be collected prior to blood 
sample collections (eg,PK, biomarkers, and/or laboratory tests) and blood 
sample collections should be collected prior to procedures should be 
performed in the following sequence: subject -reported efficacy or exploratory 
scales; ECG; vital signs; sample collection for PK, biomarkers, a nd/or laboratory 
tests; clinical assessments of efficacy and safety; study  drug injection.  
Evaluations of the injection site occur after study drug injection, as 
described in Section 9.4.8. and then assessments of injection sites.  Actual dates 
and times of assessments will be recorded in the source documentation.
Rationale: To clarify the need to maintain the same dose level for eligibility, whether continuing PP1M or 
switching to PP3M.
4.3. Criteria for Entry Into the 
Maintenan ce PhaseThe follow ing text was modified in criterion for entry into the Maintenance 
Phase #[ADDRESS_22856] 
been 100 or 150 m g eq. and, in the investigator’s judgm ent, the subject 
should continue on the same dose level (ie, either the equivalent PP3M 
dose [before the PP3M prerandomization target is m et] or the sam e PP1M 
dose [after th e PP3M prerandomization target is m et]). must not be planned 
for adjustment in the foreseeable future and must have been [ADDRESS_22857] 2 doses
R092670 (paliperidone palmitate)
Clinical Protocol R092670PSY3015 Amendment 3
15
Approved , Date: 11 February 2019Rationale: To ensure a subject has dose stability to enter the DB Phase.
10.2. Discontinuation of Study 
Drug/ Withdrawal From the StudyThe follow ing text is added:
For subjects in the Maintenance Phase:
oIf the dose at Visit 2f is different from  the preceding dose or is 
not a dose equivalent of the preceding dose
Rationale: Toremove text related to optional saliva biomarkers as the sample size for this optional portion of the study 
is expected to be too low  to generate conclusive results.
Time and Events Schedules A .i.
Time and Events Schedules A .ii.
Time and Events Schedule B and 
C
Time and Events Schedule E: 
Keys and footnotes
2.1.[ADDRESS_22858]
16.2.3. Informed ConsentRemoved text related to saliva biomarkers for the Optional ICF under 
Screening/Administrative.
Removed text related to optional saliva biomarkers under Collection of biofluids
Removed text related to saliva biomarkers for the Optional ICF under 
Screening/Administrative.
Removed text related to optional saliva biomark ers under Collection of biofluids
Removed text related to optional saliva biomarkers under Collection of biofluids
Under footnote g, removed text related to optional saliva biomarker sample 
collections.
Removed text related to optional saliva based bio markers.
Removed text related to sample collections for optional saliva biomarkers under 
the Biomarkers subheading.
Deleted Inclusion Criterion 15 which is related to signing the ICF for the optional 
saliva biomarkers.
Removed text related to sample co llections for optional saliva biomarkers.
Removed text related to sample collections for optional saliva biomarkers.
Removed text related to sample collections for optional saliva biomarkers.
Deleted text related to the optional saliva biomarker research samples.
Deleted text related to optional saliva sample collections.
Removed text related to approval for the collection of optional saliva samples for 
research and for the corresponding ICF.
Removed text related to signing the ICF for the o ptional saliva biomarker 
research.
R092670 (paliperidone palmitate)
Clinical Protocol R092670PSY3015 Amendment 3
16
Approved , Date: 11 February 2019Rationale: To explicitly state that rescreening may be considered for some subjects who were withdrawn during the 
Transition or Maintenance Phases.
4. SUBJECT POPULATION
4.3. Criteria for Entry Into the 
Maintenance Phase
4.4. Criteria for Entry Into the 
Double -blind PhaseAdded the following text: “Rescreening is permitted with the medical 
monitor’s approval for subjects who were withdrawn during the Transition 
Phase or Maintenance Phase due to an incom plete injection or an 
unintended dosing or adm inistration of a study drug .”
Added the following text: “ If withdrawal is due to an incomplete injection or 
an unintended dosing or administration of a study drug, rescreening is 
permissible with the medical m onitor ’s approval .”
Added the following text: “ If withdrawal is due to an incomplete injection or 
an unintended dosing or administration of a study drug, rescreening is 
permissible with the medical m onitor’s approval .”
Rationale: To m inimize the risk of confusion related to the process of study closure.
9.1. Study Procedures Under the Double -blind Phase subtitle, removed text that may be confusing and 
instead provide a reference to section 10.5 w here the process for study closure is 
described in detail.
Rationale: To m onitor for appropriate eligibility on the basis of exclusionary medications and for correct timing and 
dosing of study injections with respect to prestudy PP1M and PP3M injections, w here applicable. 
8.2. Concomitant Therapy Text revised t o include that therapi[INVESTIGATOR_23695] 90 days prior to the study are also to 
be recorded.
Rationale: To state that although the form used to record concomitant substances use includes alcohol, nicotine, and 
illicit substances, only nicotine data w ill be analyzed.
9.7.3. Concomitant Substances 
QuestionsRemoved “alcohol” and “illicit substances” from analysis.
Rationale: To clarify the approximate number of subjects entering the Transition/Maintenance Phase s
3.1. Overview  of Study Design
11.2. Sample Size DeterminationRevised the following text as follow s: “The approximate participation targets are 
903subjects entering the Screening Phase, 765 subjects entering the 
Transition/ Maintenance Phase s, and 549 subjects entering the Double -blind 
Phase. ”
Revise d the following text as follow s: “Given these assumptions for 
discontinuation, the study targets approximately 765 subjects to enter the 
Transition/ Maintenance Phase s.”
Rationale: To include measurements of thyroid stimulating hormone to the Serum Chemistry  Panel
9.4.2. Clinical Laboratory T ests Added thyroid stimulating hormone to the Serum Chemistry Panel. 
Rationale: Improvements in the conduct of the protocol.
Throughout the protocol Changes for consistency between sections and for clarification were made that 
had no impact on safety .
R092670 (paliperidone palmitate)
Clinical Protocol R092670PSY3015 Amendment 3
17
Approved , Date: 11 February 2019Amendment 1 (21March 2018)
This amendment is considered to be nonsubstantial based on the criteria set forth in Article 10(a) of Directive 
2001/20/EC of the European Parliament and the Council of the European Union , in that it does not significantly 
impact the safety or physical/mental integrity of subjects, nor the scientific value of the study .  
The overall reason sfor the amendment:
to clarify which version of the Columbia Suicide Severity Rating Scale (C -SSRS) w ill be used at the 
screening and baseline visits , and all other visits ;
to update the visit window  for Visit 3 to avoid overlap w ith Visit 2;
to clarify that an alcohol breath test, and not a saliva test, will be performed to test for concomitant 
substances;
Figure 1 w as updated ;
to clarify that vital signs to be collected every 3 months (Q3) during double -blind (DB) phase;
to minimize risk of fetal exposure to study drug ;
to remove renal insufficiency as part of exclusion criterion #7 ;
to prevent unnecessary exclusion of patients with gaps in historical medical documents ;
to include exclusion criterion #26 as per Food and Drug Administration ( FDA )request for clarification ;
to maximize patient safety, exclude clinically unstable patients, and align with the R092670PSY3011 
protocol;
the first 3 bullets in Section [IP_ADDRESS] (Relapse Criteria) w ere previously in a different order and are now  
included in Section 4.3 (Criteria For Entry Into the Maintenance Phase) and in Section 4.4 (Criteria For 
Entry Int o the Double -blind Phase);
to include risperidone 3 mg/day as a valid alternative at an equivalent dose in countries for which the 
paliperidone extended -release (ER)/ prolonged -release (PR) formulations are not available;
to include additional text to the s ection subtitle ,to clarify the frequency of prestudy Risperdal injections ,
and to clarify that subjects taking branded long -acting injectables (LAI) of risperidone or paliperidone 
palm itate will be permitted to enter this phase of the study ;
to clarify th at the actual dates and times of electrocardiogram (ECG) and laboratory tests are not recorded 
in electronic case report form (eCRF);
to update text in the protocol for clarity and consistency with Time and Event sSchedules;
to provide clearer guidance on timing of the end -of-phase (EOP) visit;
to clarify text to include an accurate description of the Satisfaction With Participation in Social Roles 
Short Form 8a (SPSR) , and to allow  flexibility for regions to begin enrollment despi[INVESTIGATOR_23696] ;
to modify text to prevent the risk of unblinding study treatment while collecting prolactin samples for 
clinical laboratory testing ;
to update Attachment 1 with clear instructions regarding the administration of injection;
to remove controlling stratification by [CONTACT_23759] ;and
to add a formula to clarify the calculation of percent change of total PANSS score .
Applicable Section(s) Description of Change(s)
Rationale: To clarify which version of the C -SSRS willbe used at the screening and baseline visits , and all other 
visits.
R092670 (paliperidone palmitate)
Clinical Protocol R092670PSY3015 Amendment 3
18
Approved , Date: 11 February 2019Applicable Section(s) Description of Change(s)
Synopsis, Safety 
Evaluations; Time and 
Event s Schedule s –
Section A.i.Subjects 
with prestudy PP1M or 
PP3M stability ;
Section A.ii.Subjects 
without prestudy PP1M 
or PP3M stability ; 
Section E. Keys and 
Footnotes (for All Time 
and Events Schedules)In Section sA.i.(Subjects with prestudy PP1M or PP3M stability) , A.ii. (Subjects 
without prestudy PP1M or PP3M stability) , and E(Keys and Footnotes [for All Time 
and Events Schedules]) , the follow ingfootnote was modified for C -SSRS 
(strikethrough text deleted):
m.The C -SSRS is administered as the "Baseline" version during screening and as the 
"Since Last Visit" version at all other visits.   At the p atients first study visit ,the 
C-SSRS Baseline/S creening Form  will be used ;for all other visits ,the C -SSRS Since 
Last Visit F orm will be used.
Removed the other visits in this row  (Sections A.i and A.ii) and X, once before first 
dose (Section A.ii).
In Sections A.i. and A.ii., the Suicidality (C -SSRS)f,mrow has been changed to 
Suicidality (C -SSRS Baseline/Screening)f,m, and added a row to include Suicidality 
(C-SSRS Since Last Visit)f,mfor all other visits.
The follow ing text was modified i n the Synopsis (Safety Evaluations)(bold text 
added):
The study's standard safety evaluations will be physical examinations, vital signs, 
adverse events, electrocardiograms (ECGs), the Columbia Suicide Severity Rating 
Scale (C-SSRS Baseline/Screening and C- SSRS Since Last Visit ), the Abnormal 
Involuntary Movement Scale (AIMS), the Barnes Akathisia Rating Scale (BARS), the 
Simpson Angus Scale (SAS), clinical laboratory assessments (in full [including 
prolactin] at some time points, or for prolactin only at other time points), and injection 
site evaluations.
Rationale: To update the visit w indow  for Visit 3 to avoid overlap w ith Visit 2.
Time and Event s
Schedule s –
SectionA.i.Subjects 
with prestudy PP1M or 
PP3M stabilityIn the Time and Event sSchedule s(Section A.i , For Subjects w ith prestudy PP 1M or 
PP3M stability ), the visit window  was changed from ±2 day s to-1 to +2 days f or 
Visit 3.
Rationale: To clarify that an alcohol breath test, and not a saliva test, will be performed to test for concomitant 
substances .
R092670 (paliperidone palmitate)
Clinical Protocol R092670PSY3015 Amendment 3
19
Approved , Date: 11 February 2019Applicable Section(s) Description of Change(s)
Time and Event 
schedule -Section E -
Keys and Footnotes ; 
9.1.Study Procedures; 
9.4.2. Clinical 
Laboratory Tests; 15. 
Study Specific 
MaterialsThe follow ing text was modified in footnote e (bold text added; deleted text 
strikethrough):
e. These tests for concomitant substances (both a nsaliva test for alcohol breath test
and a urine drug screen for illicit substances), including marijuana (even where legal). 
Alcohol and illicit substances are strongly discouraged but are not exclusionary an d 
are not cause for w ithdrawal from the study.
The follow ing text was modified in footnote f (bold text added; deleted text 
strikethrough):
f. In addition to the indicated visits, suspected relapses during the Double -blind Phase 
should prompt all of the following assessments at all associated clinic visits, even if 
not designated on these schedules: a pharmacokinetics (PK) sample, the biomarker 
samples (plasma and serum for all subjects, and saliva for subjects who are 
participating in that optional part of the study), a full PANSS assessment, a CGI -S 
assessment, a C -SSRS assessment, and testing for concomitant substances (both a n 
saliva test for alcohol breath test and a urine drug screen for illicit substances).
In Section 9.1 (Study Procedures), the fo llowing bullet point text was modified (bold 
text added; deleted text strikethrough):
Testing for concomitant substances (both a nsaliva test for alcohol breath test and a 
urine drug screen for illicit substances), per Section 9.4.2 (Clinical Laboratory T ests).
In Section 9.4.2 (Clinical Laboratory Tests), the following bullet point text was 
modified (bold text added; deleted text strikethrough):
Urine drug screen kits (for illicit substances, including marijuana, even where legal) 
and alcohol saliva test kits breath tests will be provided for local use at the time 
points specified in the Time and Events Schedules.
In Section 15 (Study Specific Materials), the following bullet point text was modified 
(bold text added; deleted text strikethrough):
Alcohol breath test Saliva alcohol test kit
Rationale: Figure 1 was updated .
3.1. Overview  of Study 
DesignReplaced Figure 1 w ith a new figure.
Rationale: To clarify that v ital signs to be collected Q3 during DB phase.
Time and Event s
Schedule s, Section B .
Double -blind Phase 
(First 12 M onths) ;
Section C .Double -
blind Phase (After the 
First 12 Months)In the Time and Event sSchedule s, vital signs measurements (body w eight and waist 
circumference) were added to Visit 13 (Section B , Double- blind Phase [First 1 2 
Months] ), and also to Visit 39 (Section C , Double -blind Phase [After the First 12 
Months] ).  
Rationale: To minimize risk of fetal exposure to study drug.
R092670 (paliperidone palmitate)
Clinical Protocol R092670PSY3015 Amendment 3
20
Approved , Date: 11 February 2019Applicable Section(s) Description of Change(s)
4.1.Inclusion C riteri a The note follow ing inclusion criterion # 10 w as modified ( bold text added; deleted text 
strikethrough ):
10. Criterion m odified per Amendment 1
10.1…
Note: If the childbearing potential changes after start of the study or the risk of 
pregnancy changes (eg. A woman who is not heterosexually active becomes sexually 
active) a woman must begin consent to starting a highly effective method of 
contraception as described throughout this inclusion criterion after a negative 
pregnancy test. If reproductive status is questionable, additional evaluation 
should be considered. If the subject declines consent for start of a highly effective 
method of contraception, the subject must be withdrawn from  the study.
Rationale: To rem overenal insufficiency as part of exclusion criterion #7.
Synopsis, Subject 
Population; 4.2. 
Exclusion C riteri aThe follow ing text was modified in the Synopsis (Subject Population) and under 
exclusion criterion #7 ( bold text added; deleted text strikethrough):
7. Criterion m odified per Amendm ent [ADDRESS_22859] a clinically significant and unstable medical illness in history or at 
screening, including (but not limited to) cardiac arrhythmias or other cardiac disease, 
hematologic disease, coagulation disorders (including any abnormal bleeding or blood 
dyscrasias), significant pulmonary disease including bronchospastic respi[INVESTIGATOR_23697], diabetes mellitus (poorly controlled or requiring insulin), renal or hepatic 
insufficiency, thyroid disease (poorly controlled based on recent thyroid stimulating 
horm one [TSH] level),
Rationale: To prevent unnecessary exclusion of patients with gaps in historical medical documents.  
4.2.Exclusion Criteria The follow ing text was modified in exclusion criterion #12 (bold text added ;
strikethrough text deleted):
12. Criterion m odified per Amendment [ADDRESS_22860] a history of treatment resistance, defined as failure to respond to 2 
adequate trials with adequate doses of different antipsychotic medications (where an 
adequate trial is defined as a minimum of 4 weeks at a therapeutic do sage) .,based on 
theavailable m edical records. Final determination of eligibility is based on 
investigator judgm ent.
Rationale: To include exclusion criterion #[ADDRESS_22861] for clarification .
4.2.Exclusion C riteria The follow ing bullet point text w as added to exclusion criterion #26:
Must not have moderate to severe renal impairment (ie ,creatinine clearance, as 
estimated by [CONTACT_16424] -Gault method, of <60 mL/min).
Rationale: To maximize patient safety, exclude clinically unstable patients, and align with the R092670 PSY3011
protocol .
R092670 (paliperidone palmitate)
Clinical Protocol R092670PSY3015 Amendment 3
21
Approved , Date: 11 February 2019Applicable Section(s) Description of Change(s)
4.2.Exclusion C riteria; 
8.3.Prohibited 
Concomitant 
MedicationsThe follow ingbullet point text w as included in exclusion criterion # 27:
Subjects must not have the follow ing:
-Electroconvulsive therapy (ECT) w ithin60 days before screening
-Nonselective/irreversible monoamine oxidase inhibitors (MAOI) antidepressants 
within 30 days prior to screening .
-Other antidepressants unless at a s table dosage for 30 days before screening (If the 
dosage has been stable for less than [ADDRESS_22862] does not require the 
antidepressant, it can be washed out by [CONTACT_23760]; if the dosage has been stable 
for less t han [ADDRESS_22863] 
should not be included in this study).
The follow ing bullet point text w as included in exclusion criterion # 28:
Must not be concomitantly treated w ith mood stabilizers including lithium, or 
valproate, orother antiepi[INVESTIGATOR_23698]/anticonvulsants within [ADDRESS_22864] screening 
visit.
The exclusion criterion #29 was added:
Must not have been treated with a dopamine agonist (eg ,ropi[INVESTIGATOR_23699]) 
within [ADDRESS_22865] screening visit.
Thefollow ing bullet point text w as included in Section 8.3 (Prohibited Concomitant 
Medications) :
-Mood stabilizers and anticonvulsants including , but not limited to: lithium, 
valproate, lamotrigine, carbamazepi[INVESTIGATOR_050], phenytoin, and gabapentin .
-Antidepressan ts not taken at a stable dosage for 30 days before screening ,and all 
nonselective/irreversible MAOIs. Throughout the study , an antidepressant (other than 
a nonselective MAOI) may be initiated in rare circumstances only after consultation 
with the Medical Monitor. 
-Any prescription, herbal, or over -the-counter agents with psychotropic actions 
including any substances with stimulant and cognitive -enhancing properties.
-Dopamine agonists, including, but not limited to: ropi[INVESTIGATOR_11122], pramipexole, 
pergolide, c abergoline, and lisuride.
Rationale: The first 3 bullets in Section [IP_ADDRESS] (Relapse Criteria) w ere previously in a different order and are 
now included in Section 4.3 (Criteria For Entry Into the Maintenance Phase) and in Section 4.4 (Criteria For 
Entry Into the Double -blind Phase).
R092670 (paliperidone palmitate)
Clinical Protocol R092670PSY3015 Amendment 3
22
Approved , Date: 11 February 2019Applicable Section(s) Description of Change(s)
4.3.Criteria For Entry 
Into the Maintenance 
Phase ; 4.4.Criteria For 
Entry Into the Double -
blind PhaseThe follow ing text was modified in Section 4.3 (Criteria For Entry Into the 
Maintenance Phase)(bold text added ; strikethrough text deleted):
3. For subjects proceeding from the Transition Phase to the Maint enance Phase, they 
must not have during the Transition Phase : met any of the first 3 bullet points in 
Section [IP_ADDRESS] (Relapse Criteria) during the Transition Phase
a. required psychiatric hospi[INVESTIGATOR_059] (involuntary or voluntary adm ission to a 
psychiatric hospi[INVESTIGATOR_23700]’s schizophrenic 
symptoms), or 
b. inflicted deliberate self -injury or exhibited violent behavior resulting in 
suicide, clinically significant injury to him /her self or another person, or 
significant property dam age, or
c. had suicidal or homicidal ideation and aggressive behavior that is clinically 
significant (in frequency and severity) in the investigator’s judgme nt
The follow ing text was modified in Section 4.4 (Criteria For Entry Into the Double -
blind Phase)(bold text added; strikethrough text deleted):
5. Subjects must not have during the Maintenance Phase :met any of the first 3 
bullet points in Section 2.1.2 .2 (Relapse Criteria) during the Maintenance Phase
The sub -bullet points presented in Section 4.3 ( Criteria For Entry Into the 
Maintenance Phase ) arealso presented in Section 4.4 (Criteria For Entry Into the 
Double -blind Phase) .
Rationale: Paliperidone ER/PR are not available in all study countries.  Risperidone 3 mg/day is a valid 
alternative at an equivalent dose.
6.1.1 .Screening Phase The follow ing text was modified in Section 6.1.1 (Screening Phase) (bold text added ; 
strikethrough te xt deleted ):
To demonstrate oral tolerability, p Paliperidone ER/PR 6 mg tablets or risperidone 
3 mg/day (dose m ay be divided) will be given during the Screening Phase for [ADDRESS_22866] dose sw allow ed on or before Day -1.The 
recomm ended dose is paliperidone ER/PR of 6 m g/day or risperidone 3 mg/day 
(dose m ay be divided), but h igher doses of paliperidone or risperidone may be 
used if clinically indicated , based on investigator judgm ent.
Rationale: To include additional text to the section subtitle ,to clarify the frequency of prestudy Risperdal 
injections ,and to clarify that subjects taking branded LAI of risperidone or paliperidone palmitate will be 
permitted to enter this phase of the study .  
R092670 (paliperidone palmitate)
Clinical Protocol R092670PSY3015 Amendment 3
23
Approved , Date: 11 February 2019Applicable Section(s) Description of Change(s)
6.1.2. Transition Phase The fol lowing subtitle was modified (bold text added) :
Transition Phase: Subjects Previously Stabilized on Injectable Risperidone (Biweekly 
–Risperdal CONSTA™ formulation)
The follow ing subtitle was modified and text was included (bold text added):
Transition Phase: Subjects Previously Initiated (But Not on a Stable Regimen) With 
Moderate or Higher Doses of PP1M (Invega Sustenna ™ or Xeplion ™ 
form ulation)
In the Transition Phase, subjects who entered the study on PP1M as 100 or 150 mg 
eq., but w ho do not yet meet criteria for stabilization with those doses, are treated w ith 
additional doses of PP1M during the Transition Phase, as shown in Table 3.
Owing to potential differences in release characteristics, only subjects who are 
taking Invega Sustenna ™ or Xep lion ™ PP1M form ulations will be permitted to 
enter this phase of the study. Subjects who are taking non -branded formulations 
of once m onthly paliperidone LAI or other once m onthly LAIs will not be 
permitted to enter this phase.
Rationale: Actual dates and times of ECG and laboratory tests are not recorded in eCRF. This information would 
be recorded by [CONTACT_23761].
9.1.Study P rocedures The follow ing text was modified in Section 9.1 (Study Procedures , Overview )
(strikethrough text deleted) :
Actual dates and times of assessments will be recorded in the source documentation .
and eCRF
Rationale: Text w as updated in the protocol for clarity and consistency with Time and Event sSchedule .
Time and Event s
Schedule ,Section D.
Follow -up Phase; 
11.5.7 .Columbia 
Suicide Severity Rating 
ScaleThe follow ing text was added to the Time and Event sSchedule (Section D, Follow -up 
Phase) (bold text added):
12, [ADDRESS_22867]’s First Double -blind Injection (or at 6 -Month 
Time Points Thereafter, if Applicable)
The follow ing text was added to Section 11.5.7 (Columbia Suicide Severity Rating 
Scale) (bold text added):
C-SSRS Baseline/Screening Form  will be used at screening. C- SSRS Since Last 
Visit Form  will be used at other visits, as per Time and Event sSchedule s.  
Suicide -related thoughts and behaviors based on the C -SSRS scale will be summarized 
by [CONTACT_23762].  
Rationale: To provide clearer guidance on timing of the EOP visit .
R092670 (paliperidone palmitate)
Clinical Protocol R092670PSY3015 Amendment 3
24
Approved , Date: 11 February 2019Applicable Section(s) Description of Change(s)
Time and Events 
Schedule, Section C. 
Double -blind Phase 
(After the First 12 
Months); Section E. 
Keys and Footnotes 
(for All Time and 
Events Schedules)In Section C, the visit window of the EOP visit was changed from “Variable” to 
“±7bb”.
The follow ing text was modified in Section E, footnote aa (bold text added; 
strikethrough text deleted):
After completing the first 12 months of the Double -blind Phase, subjects who cannot 
proceed further in the Double -blind Phase (eg, if the study is clo sed) w ill complete the 
EOP Visit as an End -of-Study Visit. For subjects who can proceed to further treatment 
in the Double -blind Phase, Visit 33a is the same as Visit 33b, w ith the addition of 
another dose of study drug. Thereafter, subjects continue with this schedule until the 
Sponsor informs the sites that the study is closing, at which time subjects should be 
asked to return as soon as possible to the site for an EOP Visit, which becomes the 
End-of-Study Visit. The planned closure w ill be [ADDRESS_22868] has 
been randomized in the Double- blind Phase.  Refer to section 10.4 (Antipsychotic 
Therapy After the Study or in the Follow -up Phase) and 10.5 (Process for 
Planned Study Closure) for more information.
Footnote bb w as added:
bb. For E OP visits occurring during study closure (ie ,not a result of withdraw al or 
relapse), the visit window is specified as ±7 days.  In the event of study withdraw al or 
relapse, a visit window  (in days) for the EOP visit is not specified but is to occur as 
soon as possible.
Rationale: Text w as updated t o include an accurate desc ription of the SPSR Short Form 8a , and to allow  
flexibility for patient enrollment to begin in regions where translations are not yet available .
Time and Events 
Schedules, Section E. 
Keys and Footnotes; 
Synopsis, Efficacy 
Evaluations; 9.2.5 . 
Satisfaction W ith 
Participation in Social 
RolesIn Section E, footnote u, the follow ing text was added:
For subjects that require translation of the SPSR into their local language, the 
collection of the SPSR is optio nal until the final, approved translation is available.
The follow ing text was modified in the Synopsis (Efficacy Evaluations) (bold text 
added; deleted text strikethrough):
Subject -reported efficacy evaluations include the Satisfaction With Participatio n in 
Social Roles scale Short Form 8a (SPSR) and the abbreviated 9 -item Treatment 
Satisfaction Questionnaire for Medication (TSQM -9).
The follow ing text was modified in Section 9.2.5 (Satisfaction With Participation in 
Social Roles) (bold text added; deleted text strikethrough):
The Patient -Reported Outcomes Measurement Information System (PROMIS) group 
developed and evaluated the Satisfaction Wit h Participation in Social Roles scale
Short Form  8a(SPSR) with funding from the US National Institutes of Hea lth (NIH) 
and other academic and research grants.15A study in a diverse clinical population 
demonstrated the SPSR's responsiveness to change.15The SPSR asks subjects to 
consider the past 7 days and to rate 148items on 5 -point Likert scales with higher 
scores representing higher satisfaction. An example of the SPSR is provided in the 
Manual of Assessments.
Note: For subjects that require translation of the SPSR into their local language, 
the collection of the SPSR is optional until the final, approved t ranslation is 
available.
R092670 (paliperidone palmitate)
Clinical Protocol R092670PSY3015 Amendment 3
25
Approved , Date: 11 February 2019Applicable Section(s) Description of Change(s)
Rationale: To prevent the risk of unblinding study treatment while collecting prolactin samples for clinical 
laboratory testing .
9.4.2 . Clinical 
Laboratory TestsThe follow ing text was m odified in Secti on 9.4 .2 (Cli nical Laboratory Tests)
(strikethrough text deleted):
-prolactin, which will be blinded to the study -site personnel and Sponsor except by 
[CONTACT_23763] ; some samples will be for prolactin only (not the other 
analytes listed above), as designated in the Time and Events Schedules
Rationale: Because the choice of dose level in the maintenance was determined on the appropriate dose that 
subjects had been stabilized on, and which the investigators consider as appropriate from both efficacy and safety 
point of view, the KM curves analysis by [CONTACT_23764].  
This is consistent with the previous registration studies (R092670PSY3001, R092670PSY3011, and 
R092670PSY3012).
[IP_ADDRESS].2. Primary 
Efficacy AnalysesThe follow ing sentence was removed in Section [IP_ADDRESS].2 (Primary Efficacy 
Analyses) : 
The tests above are adjusted by [CONTACT_23765] (for 
moderate or higher dose).
Rationale: To update Attachment 1 with clear instructions regarding the administration of injection.
Attachment 1 The follow ing text was added to the Notes of the figure in Attachment 1:
Injections should be administered in the dorso -gluteal injection site only. 
Ventrogluteal injections are not permitted.
Rationale: To add a formula to clarify the calculation of percent change of total PANSS score.
Attachment 2 A formula for calculating percent change of total PANSS score w as added.
Rationale: Minor errors w ere noted .
Throughout the 
protocolMinor grammatical, formatting, or spelling changes were made.
R092670 (paliperidone palmitate)
Clinical Protocol R092670PSY3015 Amendment 3
26
Approved , Date: [ADDRESS_22869] that exhibits the characteristic dopamine Type 2 and 
serotonin Type 2A antagonism of the newer, or second -generation, atypi[INVESTIGATOR_23701] s. 
Paliperidone is the active metabolite of risperidone and isavailable as adaily -dose oral formulation. 
Paliperidone palmitate is an ester of paliperidone, and is available for intramuscular injection in the 
paliperidone palmitate 1-month (PP1M) product as the F013 formulation and the paliperidone palmitate 
3-month (PP3M) product as the F015 formulation. To further improve adherence and convenience, a 
paliperidone palmitate 6-month (PP6M) product is now under development .  
 
 (ie, PP3M may beadminist ered into either the deltoid or the 
gluteal muscle, but the larger volume associated with a PP6M dose requires injection into the larger 
gluteal muscle) .
Doses can be expressed in milligrams of paliperidone palmitate or in milligrams equivalent (mgeq.) to 
paliperidone. Conversions between products and between units are described in the table below.
Conversions Between Doses of the 1 -, 3-, and 6 -Month Formulations of Paliperidone Palmitate; Study R092670PSY3015
PP1M Dose PP3M Dose PP6M Dose
mg mg eq. mg mg eq. mg mg eq.
Low est-dose groupsa78 mg 50 mg eq. Not used in this study - - - - Not available - - - -
Low er-dose groups 117 mg 75 mg eq. Not used in this study - - - - Not available - - - -
Moderate -dose groups 156 mg 100 mg eq. 546 mg 350 mg eq. 1092 mg 700 mg eq.
Higher -dose groups 234 mg 150 mg eq. 819 mg 525 mg eq. 1560 mg 1000 mg eq.
Key: mg eq. = (paliperidone palmitate) milligrams equivalent (to paliperidone); PP1M = paliperidone palmitate 1 -month 
(product); PP3M =paliperidone palmitate 3 -month (product); PP6M = paliperidone palmitate 6-month (product).
aSome countries may also have an ultralow dose of PP1M (below the lowest dose stated here), but the ultralow dose is not 
used in this study.
OBJECTIVES, ENDPOINTS, AND HYPOTHESIS
Objectives
Primary Objective
 The primary efficacy objective is to demonstrate that injection cycles consisting of a single 
administration of PP6M (700 or 1000 mgeq.) arenot less effective than 2sequentially administered 
injections of PP3M (350 or 525mgeq.) for the prevention of relapse in subjects with schizophrenia 
previously stabi lized on corresponding doses of PP1M (100 or 150mgeq.) or PP3M (350 or 
525mgeq.).
Secondary Objectives
 To evaluate the safety and tolerability of PP6M (700 or 1000 mgeq.) in subjects with schizophrenia 
who have switched from corresponding doses of PP1M (100 or 150mgeq.) or PP3M (350 or 
525mgeq.).
 To assess the pharmacokinetic (PK)profile of PP6M (700 or 1000 mgeq.) administered in the 
gluteal muscle in subjects with schizophrenia who have switched from corresponding doses of PP1M 
(100 or 150 mgeq.) or PP3M (350 or 525 mgeq.).
 To evaluate the clinically assessed efficacy of PP6M (700 or 1000 mgeq.) versus PP3M (350 or 
525mgeq.) in maintaining symptom control, functioning personally and socially, and achieving or 
CCI
R092670 (paliperidone palmitate)
Clinical Protocol R092670PSY3015 Amendment 3
27
Approved , Date: [ADDRESS_22870] s with schizophrenia who were previously stabilized on corresponding 
doses of PP1M (100 or 150 mg eq.) or PP3M (350 or 525 mgeq.).
 To evaluate the subject -reported efficacy outcomes ofPP6M (700 or 1000 mgeq.) or PP3M (350 or 
525mgeq.) compared with treatment with previous oral antipsychotics in terms of satisfaction with 
medication and with participation in social roles.
Exploratory Objectives
Exploratory objectives are also defined in the full protocol, but are excluded from this synopsis for 
brevity .
Endpoints
Primary Endpoint
The primary endpoint is time to relapse during the Double- blind Phase .This noninferiority primary 
endpoint will be based on the difference in Kaplan- Meier 12-month estimate of survival (ie, percentage of 
subjects remaining relapse -free) between PP6M and PP3M.
Relapse Criteria
Relapse is defined as 1 or more of the following:
 Psychiatric hospi[INVESTIGATOR_059] (involuntary or voluntary admission to a psychiatric hospi[INVESTIGATOR_23702]’s schizophrenic symptoms), or
 For Positive and Negative Syndrome Scale for Schizophrenia (PANSS) total score:
 The subject has an increase of 25% in total PANSS score from randomization for 2 consecutive 
assessments separated by 3 to 7days if the s core at randomization was >40, or
 The subject has a 10-point increase in the total PANSS score from randomization for 
2consecutive assessments separated by 3 to 7days if the score at randomization was ≤40, or
 The subject inflicts deliberate self-injury or exhibits violent behavior resulting in suicide, clinically 
significant injury to him/her self or another person, or significant property damage, or 
 The subject has suicidal or homicidal ideation and aggressive behavior that is clinically significant 
(infrequency and severity) in the investigator’s judgment, or
 For PANSS items P1(delusions), P2(conceptual disorganization), P3(hallucinatory behavior), 
P6(suspi[INVESTIGATOR_23703]/persecution), P7 (hostility), and G8 (uncooperativeness):
 The subject has a score of ≥5 after randomization for 2consecutive assessments separated by 
3to 7days on any of the above items if the maximum score for the above PANSS items was ≤3 
at randomization, or
 The subject has a score of ≥[ADDRESS_22871] assessment for symptoms of relapse (not the date of 
confirmation).
Secondar y Endpoints
The secondary efficacy endpoints include the changes from baseline during the 12-month Double- blind 
Phase in the following scales: the PANSS total score and subscale scores, the Clinical Global Impression 
-Severity (CGI -S), and the Personal and Social Performance (PSP) scale. Additionally, the proportion of 
R092670 (paliperidone palmitate)
Clinical Protocol R092670PSY3015 Amendment 3
28
Approved , Date: 11 February 2019subjects during the Double -blind Phase who meet criteria for symptomatic remission will be summarized; 
the definition of remission is provided in the full protocol.
The secondary PK endpoint is plasma paliperidone exposure.
The secondary endpoints for satisfaction with medication and with participation in social roles are 
abbreviated Treatment Satisfaction Questionnaire for Medication (TSQM -9) and Satisfaction with 
Participation in Social Rol es (SPSR), respectively.
The secondary endpoints that measure safety and tolerability include physical examinations, vital signs, 
adverse events, electrocardiograms (ECGs), the Columbia Suicide Severity Rating Scale (C-SSRS 
Baseline/Screening and C-SSRS Since Last Visit), the Abnormal Involuntary Movement Scale (AIMS), 
the Barnes Akathisia Rating Scale (BARS), the Simpson Angus Scale (SAS), clinical laboratory 
assessments (in full [including prolactin] at some time points, or for prolactin only at other time points), 
and injection site evaluations.
Hypothesis
The primary hypothesis is that the efficacy ofPP6M is noninferior to PP3M for preventing relapse in 
subjects with schizophrenia who were previously stabilized on corresponding doses of PP1M or PP3M .
SUBJECT POPULATION
Eligibility criteria are presented as a detailed list in the full protocol. Afew important highlights are 
presented here in the synopsis:
 Must be 18years of age (or the legal age of consent in the jurisdiction in which the study is taking 
place) to 70years of age, inclusive ,at the time of informed consent .
 Must meet the diagnostic criteria for schizophrenia according to Diagnostic and Statistical Manual of 
Mental Disorders, Fifth Edition (DSM -5) for at least 6 months before screening.
 Must be receiving treatment with paliperidone palmitate (as either the PP1M or PP3M formulation), 
or injectable risperidone, or any oral antipsychotic .
a.If the treatment is paliperidone palmitate, then:
1) The dose strength must be PP1M as 100 or 150 mgeq. or PP3M as 350 or 525 mg eq.
2) The dose timing must fit the study schedule. The next injection must be due within [ADDRESS_22872] screening (or first rescreening) visit.
b. If the treatment is injectable risperidone, then the dose strength must be 50mg, the dosing cycle 
must be every [ADDRESS_22873] a valid reason to discontinue 
the previous treatment, such as problems with efficacy, safety ,or tolerability, or preference for a 
long-acting injectable medication.
 Criterion modified per Amendment 1
 7.1Must not have a clinically significant and unstable medical illness in history or at screening,
including (but not limited to) cardiac arrhythmias or other cardiac disease, hematologic disease, 
coagulation disorders (including any abnormal bleeding or blood dyscrasias), significant pulmonary 
disease including bronchospastic respi[INVESTIGATOR_3765], diabetes mellitus (poorly controlled or 
requiring insulin), hepatic insufficiency, thyroid disease (poorly controlled based on recent thyroid 
R092670 (paliperidone palmitate)
Clinical Protocol R092670PSY3015 Amendment 3
29
Approved , Date: 11 February 2019stimulating hormone [TSH ]level), neurologic or other psychiatric disease (except schizophrenia), 
infection, cancer, or any other illness that the investigator considers should exclude the subject or 
that could interfere with the interpretation of the efficacy or safety measurements.
If a subject does not meet all inclusion criteria (is a screen failure) with respect to dose level, dose 
duration, or dose timing of prestudy treatment with paliperidone palmitate or injectable risperidone , but at 
some point in the future is expected to meet these inclusion criteria, then the subject may be rescreened on 
1occasion. If a subject meets any exclusion criteria (is a screen failure) with respect to safety parameters,
then rescreening is not allowed.
OVERVIEW OF STUDY DESIGN
This is a randomized, double -blind, active- controlled, multicenter, interventional, parallel -group study. 
All eligible subjects who progress without relapse will participate in a Screening Phase (of up to 28 days), 
a Maintenance Phase that includes 1 injection cycle with either PP1M or PP3M (yielding a phase duration 
of 1or 3months, accordingly), and a Double -blind Phase (of 12 months). The Double -blind Phase is 
designed to include 2 injection cycles of PP6M (investigational drug with alternating placebo) or 
4injection cycles of PP3M (active control). In addition to standard participation as described above, 
further conditional/additional participation is possible as follows:
 Before the Maintenance Phase, some subjects will participate in a Transition Phase, with 1to 
5inject ions of PP1M, if they entered the study on an oral antipsychotic, on injectable risperidone, or 
on PP1M previously initiated but not yet stabilized.
 The planned closure will be 12months after the last subject has been randomized in the Double-
blind Phase .
 If a subject has already received at least 1dose of double -blind study drug but then has relapsed or 
has met other relevant conditions for withdraw alor discontinu ation , then the subject should enter a
Follow -up Phase. The Follow -up Phase ends 12months after the subject's first double -blind 
injection .The Follow -up Phase collects supplementary poststudy data from willing affected subjects, 
in an effort to document minimum safety information (ie, adverse events) and minimum efficacy  
information (ie, relapse status). The Follow -up Phase is designed to be as low-burden and 
noninvasive as possible, in order to encourage participation by [CONTACT_23766].
The duration of exposure to study drug (ie, the number of injections) and the duration of study 
participation are variable based on a subject's flow through treatment types, on participation in conditional 
phases or parts as described in the 3bullet points above, and on whether a subject experiences a relapse 
during the study .
For subjects who complete t he study without relapse, the longest expected duration is ~[ADDRESS_22874] expected duration is ~13 months, as described in the full protocol. For subjects who complete the 
study with relapse, the duration of exposure and participation depend on the timing of the relapse, and 
could even be (for example) only ~2months of injections with a variable duration of assessments 
thereafter, as described in the full protocol.
DOSAGE AND ADMINISTRATION
Dosage: Screening Phase
During the Screening Phase, subjects must have already been receiving PP1M at 100or 150mgeq., 
PP3M at 350 or 525mg eq., injectable risperidone at 50mg, or an oral antipsychotic atany dosage with a 
reason to change , as described in the inclusion criteria .
R092670 (paliperidone palmitate)
Clinical Protocol R092670PSY3015 Amendment 3
30
Approved , Date: 11 February 2019Dosage: Transition Phase
The Transition Phase is applicable only to subjects who entered the Screening Phase without previous 
PP1M or PP3M stability. These subjects may have been previously treated with oral antipsychotics ,
injectable risperidone , or a moderate or higher dose of PP1M with previous initiation but without
previous st abilizatio n (where stabilization is defined is at least [ADDRESS_22875] 2 doses 
being the same strengt h). A table in the full protocol provides further information about the PP1M 
administration schedule for subjects who participate in the Transition Phase.
Dosage: Maintenance Phase
For all subjects, the Maintenance Phase includes only 1dose of PP1M as 100or 150mgeq. or PP3M as 
350or [ADDRESS_22876]'s Maintenance Phase dose will be matched by [CONTACT_23767] 
(PP1M to PP1M, or PP3M to PP3M) or will be matched by [CONTACT_23768] (PP1M to PP3M) to 
the same dose that they had been receiving during the Screening Phase or at the end of the Transition
Phas e. Progression versus conversion will depend on prestudy treatment types and on the need to balance 
the PP1M and PP3M groups in the Maintenance Phase, as described in the full protocol .
Dosage: Double -blind Phase
The PP1M and PP3M dose levels that were administered in the Maintenance Phase will be converted to 
PP3M or PP6M dose levels for the Double -blind Phase as follows:
 For the active control group ,
 The open -label PP1M doses (100or 150mgeq.) will be converted to double -blind PP3M doses 
(350 or 525 mgeq.)in accordance with the approved prescribing information for PP3M.
 The open -label PP3M doses (350or 525mgeq.) will continue at the same double -blind dose 
level.
 For the investigational drug group,
 The open -label 100mgeq. PP1M and 350mgeq. PP3M doses will be converted to double -
blind 700 mgeq. PP6M doses.
 The open -label 150mgeq. PP1M and 525mgeq. PP3M doses will be converted to doub le-
blind 1000 mgeq.PP6M doses.
To maintain the blind, the subjects who are assigned to treatment with PP6M will receive injections of 
placebo at the 3-month time points between their 6-month doses of investigational drug. The placebo is 
20% Intralipi d®(200mg/mL) injectable emulsion. Therefore, the Double -blind Phase should include a 
total of 4 doses at 3 -month intervals, no matter which treatment group.
Administration
During the Transition Phase and Maintenance Phase , injections will be in the deltoid orgluteal muscles in 
accordance with the prescribing information for PP1M or PP3M, and will use injection kits equivalent to 
commercially available kits. During the Double -blind Phase, injections will be in the gluteal muscles
only, will use study -specific injection kits , and will rotate across sides of the body as described inthe full 
protocol.
PHARMACOKINETIC AND PHARMACODYNAMIC EVALUATIONS
Venous blood samples of approximately 4mL will be collected to obtain approximate ly 2mL of plasma, 
for measurement of plasma concentrations of paliperidone (and on selected samples, paliperidone 
palmitate ). The aim of thePK evaluations will beto characterize the time course of plasma paliperidone 
concentrations and PK parameters such as maximum and minimum plasma concentrations and timing . 
R092670 (paliperidone palmitate)
Clinical Protocol R092670PSY3015 Amendment 3
31
Approved , Date: [ADDRESS_22877] 
unscheduled PK samples associated with important efficacy or safety events, asdescribed in the full 
protocol.
EFFICACY EVALUATIONS
The clinical ly assessed efficacy evaluations include the PANSS (full and abbreviated), the CGI-S, the 
PSP scale , and other relapse criteria as described above. Subject -reported efficacy evaluations include the 
Satisfaction With Participation in Social Roles Short Form 8a (SPSR ) and the abbreviated 9-item 
Treatment Satisfaction Questionnaire for Medication (TSQM -9).
SAFETY EVALUATIONS
The study's standard safety evaluations will be physical examinations, vital signs, adverse events, 
electrocardiograms (ECGs ), the Columbia Suicide Severity Rating Scale (C-SSRS Baseline/Screening 
and C -SSRS Since Last Visit ), the Abnormal Involuntary Movem ent Scale (AIMS ), the Barnes Akathisia 
Rating Scale (BARS ), the Simpson Angus Scale (SAS), clinical laboratory assessments (in full [including 
prolactin] at some time points ,or for prolactin only at other time points), and injection site evaluations. In 
addition those standard evaluations, conditional evaluations also are described for special safety situations
that may occur; these include evaluations of injection site react ions or evaluations associated with 
initiations or changes in concomitant medications to manage extrapyramidal symptoms ( EPS).
EXPLORATORY EVALUATIONS
Exploratory evaluations are described in the full protocol, they are excluded from this synopsis for 
brevity.
STATISTICAL METHODS
Sample Size Determination
The sample size for the Double- blind Phase of the study is 549randomized subjects , based on 
determi nations toprovide a minimum of 80% power for the primary endpoint . The sample size 
determination includes the assumptions that the expected survival rate (percentage of subjects remaining 
relapse -free at 12 months ) in the PP3M group is 85%, and that the 1-sided significance level should be 
2.5%. Given these assumptions, 549subjects randomized in a 2:1ratio (PP6M:PP3M) are required to 
demonstrate with 80% power that PP6M is no worse than PP3M by a noninferiority margin of 10% for 
the percentage of subject s remaining relapse -freeat 12 months . This assumes that the efficacy observed in 
the PP3M group will be similar to the efficacy observed in the previous PP3M registrational Phase 3 
studies (R092670PSY301 1and R092670PSY3012).
Pharmacokinetic and Pharmacodynamic Analyses
Descriptive statistics will be calculated for the plasma concentrations of paliperidone and paliperidone 
palmitate and for the derived PK parameters, as applicable. Statistics will include sample size, mean, 
standard deviation, coefficient of variation, geometric mean, median, minimum, and maximum.
Population PK analysis of plasma concentration -time data of paliperidone will be performed using  
nonlinear mixed -effects modeling for PP6M , possibly using models previous ly developed from PP3M 
studies.
R092670 (paliperidone palmitate)
Clinical Protocol R092670PSY3015 Amendment 3
32
Approved , Date: [ADDRESS_22878] 1 of the criteria for relapse (as also described above) during the Double -blind Phase at the tim e of 
study completion for the primary analysis willbe considered to have had a relapse event. Subjects who do 
not have a relapse event in the Double- blind Phase will be considered as censo red.The statistics to test 
the primary hypothesis arebased on the percentage of subjects who remain relapse -free at Month 12 in 
the PP6M andPP3M groups per Kaplan- Meier estimate for the Double -blind Phase. The analysis will 
consider whether the lower limit of the 95% confidence interval of the difference in relapse -free rates 
between PP6M and PP3M exceeds thenoninferiority margin of -10%. Further details are provided in the 
full protocol.
Secondary Efficacy
Clinically assessed secondary efficacy analyses include maintaining symptom control , functioning 
personally and socially, and achieving remission ineach group (PP6M or PP3M, each sorted by [CONTACT_5264]) ; further details about these analyses are provided in the full protocol. Subject -reported secondary 
efficacy analyses include analyses ofthe SPSR and the TSQM -9; further details about these analyses may
be detailed in a separate document .
Safety Analyses
Descriptive statistics, summaries, tabulations, listings, etc will be provided for each outcome as 
appropriate. Analyses willfollow precedents per previous studies of PP3M and per established guidelines 
from Health Authorities.
Exploratory Analyses
Exploratory analyses are described in the full protocol, but are excluded from this synopsis for brevity.
END OF STUDY
A subject will be considered as having completed the study if he or she has had a relapse during the 
Double- blind Phase and has completed all End-of-Study Visit assess ments, or has remained relapse -free 
during the Double -blind Phase and has completed all End-of-Study Visit assessments .The study is 
considered completed with the last visit for the last subject participating in the study. 
R092670 (paliperidone palmitate)
Clinical Protocol R092670PSY3015 Amendment 3
33
Approved , Date: 11 February 2019TIME A ND EVENTS SCHE DULE S
A. Screening , Transition , and Maintenance Phases
A.i.Subjects With Prestudy PP1M or PP3M Stability
Phase ScreeningMaintenance Phase:
PP1M or PP 3M EOPs
Visit Number (of Study) 1 2 3 4 5 6 7as
Day (of Phase ), if Maintenance Phase is PP3M -28to-2 1 3 15 30 60 90
Day (of Phase), if Maintenance Phase is PP1M -28to-2 1 3 8 15 22 30
Visit Window , ±Days n/a -1 to + 2±3 ±3 ±3 ±3
Screening/ administrative
Main ICFaX
Optional ICFfor caregiver X
Inclusion/exclusion criteriabX X
Medical history and demographics X
Pregnancy testcX X X
Prestudy therapy Xd
Concomitant therapy - - - - - - - - - - - Continuous - - - - - - - - - - -
Concomitant substance testinge,fand questions X X X
Dosing
PP3M (after prestudy PP3M stability) Xg
PP3M (after prestudy PP1M stability, before PP3M prerandomization
target)Xg
PP1M (after prestudy PP1M stability, after PP3M prerandomization 
target)Xg
Safety assessments
Physical examination shX X
Vital signsiX X
12-lead ECG sjX X X X
Assessments of injection sitekX X X Xk
EPS assessments (AIMS, BARS, SAS)lX X X X
Suicidality (C -SSRS Baseline/Screening )f,mX
Suicidality (C -SSRS Since Last Visit) f,mX X X X
Adverse events - - - - - - - - - - - Continuous - - - - - - - - - - -
Efficacy assessments
Full PANSSf+ CGI -SfX X X X
Abbreviated PANSSn+ CGI -S X X
PSP X X X
Collection of biofluids
Blood for h ematology and serum chemistry XoXo
Urinalysis X X
Blood for p harmacokineticsf,pXqX X X X X
Additional exploratory a ssessments
HRU questionnaire,rIEQ, rSQLS X X
R092670 (paliperidone palmitate)
Clinical Protocol R092670PSY3015 Amendment 3
34
Approved , Date: 11 February 2019A.ii.Subjects With outPrestudy PP1M or PP3M Stability
Phase Screening Transition PhaseMaintenance Phase:
PP1M or PP3M EOPs
Visit Number (of Study) 1 2a 2b 2c 2d 2ez2f 3 4 5 6 7as
Day (of Phase), if Maintenance Phase is PP3M -28to-2 1 8 36 64 92 1u3 15 30 60 90
Day (of Phase), if Maintenance Phase is PP1M -28 to -2 1 8 36 64 92 1u3 8 15 22 30
Visit Window , ±Days n/a ±3 ±7 ±7 ± 7 ±3 -1 to +2 ±3 ±3 ±3 ±3
Screening/ administrative
Main ICFaX
Optional ICF for caregiver X
Inclusion/exclusion criteriabX X
Medical history and demographics X
Pregnancy testcX X X
Prestudy therapy Xd
Concomitant therapy - - - - - - - - - - - - - - - - - - - - Continuous - - - - - - - - - - - - - - - - - - - -
Concomitant substance testinge,fand questions X X X
Oral tolerability test Xor n/a
Dosing : Transition Phasev
PP1M (after prestudy oral antipsychotic) X X X X X n/a
PP1M (after prestudy injectable risperidone) n/a X X X X n/a
PP1M (after 2 prestudy PP1M injections) n/a n/a X X X n/a
PP1M (after 3 prestudy PP1M injections) n/a n/a n/a X X n/a
PP1M (after ≥4 prestudy PP1M injections) n/a n/a n/a n/a X n/a
Dosing: Maintenance Phase
PP3M (before PP3M prerandomization target ) n/a Xg
PP1M (after PP3M prerandomization target) n/a Xg
Safety assessments
Physical examinationshX X
Vital signsiX X
12-lead ECGsjX X X, once before first dose X X
Assessments of injection sitekX, after every dose X X X Xk
EPS assessments (AIMS, BARS, SAS)lX X, once before first dose X X X
Suicidality (C -SSRS Baseline/Screening )f,mX
Suicid ality (C-SSRS Since Last Visit) f,mX X X X
Adverse events - - - - - - - - - - - - - - - - - - - - Continuous - - - - - - - - - - - - - - - - - - - -
Efficacy assessments
Full PANSSf+ CGI-SfX X, once before first dose X X X
Abbreviated PANSSn+ CGI -S X X
PSP X X, once before first dose X X
Subject -reported: TSQM -9 and SPSRtX X
Collection of biofluids
Blood for h ematology and serum chemistry XoXo
Urinalysis X X
Blood for p harmacokineticsf,pXqX X X X X
Additional exploratory a ssessments
HRU questionnaire,rIEQ,rSQLS , and IMR scale 
t X X
R092670 (paliperidone palmitate)
Clinical Protocol R092670PSY3015 Amendment 3
35
Approved , Date: 11 February 2019B. Double -blind Phase (12Months)
Phase Double -blind Phase (12 Months): PP3M or PP6M
Visit Number (of Study) 7bs8 9 10 11 12 13 14 15 16 17 18 19 20 to 32 EOP/ 33a-
Day (of Phase) 1 3 22 29 36 60 92 120 148 155 162 169 176 183 to 358 365
Visit Window, ±Days ±3-1 to 
+3 ±3 ±3 ±3 ±7 ±7 ±7 ±3 ±3 ±3 ±3 ±3 Same as Previous 6 -Month Cycle±7Error! 
Reference source 
not found.
Screening/administrative
Pregnancy testcX Same as previous 6 -month cycle X
Concomitant therapy - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - Continuous - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
Concomitant substance testinge,fand questions X X Same as previous 6 -month cycle X
Dosi ng
PP3M & PP3M, or PP6M & placebo XwXxSame as previous 6 -month cycle
Safety assessments
Physical examinationshand vital signsiX X Same as previous 6 -month cycle X
12-lead ECGsjX X Same as previous 6 -month cycle X
Assessments of injection sitekX X X X X Same as previous 6 -month cycle Xk
EPS assessments (AIMS, BARS, SAS)lX X X X X Same as previous 6 -month cycle X
Suicidality (C-SSRS Since Last Visit) f,mX X X X X X Same as previous 6 -month cycle X
Adverse events - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - Continuous - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
Efficacy assessments
Full PANSSf+ CGI -Sf+ PSP X X Same as previous 6 -month cycle X
Abbreviated PANSSn+ CGI -S X X X X X X X X Same as previous [ADDRESS_22879] -reported: TSQM -9, SPSRtX X Same as previous 6 -month cycle X
Collection of biofluids
Blood for h ematology and serum chemistry XoXyXyXySame as previous 6 -month cycle Xo
Urinalysis X Same as previous 6 -month cycle X
Blood for p harmacokineticsf,pXqX X X X X XqX X X X X X Same as previous 6 -month cycle X
Additional exploratory assessments
HRU questionnaire,rIEQ, rSQLS, and IMR scaletX X Same as previous 6 -month cycle X
R092670 (paliperidone palmitate)
Clinical Protocol R092670PSY3015 Amendment 3
36
Approved , Date: 11 February 2019C. Follow -up Phase (for Subjects Who Discontinue, Withdraw, or Relapse During the Double -blind Phase)
Phase Follow -up Phase
Visit Number (of Study) Varies Per Subject
Month (of Phase)Quarterly (Every 3 Months) After the Subject's
Last Double -blind Injection
Visit Window, ± Weeks ±1
Concomitant therapy X
Adverse events X
Full PANSS + CGI -S + PSP X
Note: The Follow -up Phase is applicable only to subjects who have received at least [ADDRESS_22880] met other relevant conditions for 
withdrawal or discontinuation, as described in Section 10.2 (Discontinuation of Study Drug / Withdrawal From the Study). For relevant subjects, participation in the Follow -up Phase 
is encouraged but not required. The first visit of the Follow -up Phase should be scheduled to match the nearest equivalent quarterly assessment in the Double -blind Phase. Visits 
thereafter should be quarterly (every 3 months) until [ADDRESS_22881]'s first double -blind injection, For example, a subject who withdra ws from the Double -blind Phase on 
Day 29 / Month 1 (and completes an EOP / Early Withdrawal Visit on that day) should, if willing, have the first visit of the Follow -up Phase on the equivalent of Day 92 / Month 3, 
and then 3quarterly visits thereafter, fo r a total of 4Follow -up Phase visi ts. If a possible relapse is detected per PANSS criteria, as described in Section [IP_ADDRESS] (Relapse Criteria), the n 
the investigator should ask the subject to visit the clinical site 3 to 7days later for a PANSS reassessment, if possible.
R092670 (paliperidone palmitate)
Clinical Protocol R092670PSY3015 Amendment 3
37
Approved , Date: 11 February 2019D. Keys and Footnotes (for All Time and Events Schedules)
Keys: AIMS =Abnormal Involuntary Movement Scale; BARS =Barnes Akathisia Rating Scale; CGI -S = Clinical Global Impression -Severity; C-SSRS =Columbia Suicide Severity Rating Scale; 
ECG =electrocardiogram; EO P =End-of-Phase (Visit) , which may be conducted as a n End -of-Study Visit or an Early Withdrawal Visit when relevant (see Section 10[Subject Completion / 
Discontinuation of Study Drug / Withdrawal From t he Study) ; EPS = extrapyramidal symptoms; HRU =Healthcare Resource Utilization; ICF= Informed Consent Form; IEQ = Involvement 
Evaluation Questionnaire; IMR =Illness Management and Recovery; n/a=not applicable; PANSS = Positive and Negative Syndrome Scale; PP1M =paliperidone palmitate 1 -month ( product ); 
PP3M =paliperidone palmitate 3 -month ( product ); PP6M =paliperidone palmitate 6 -month ( product ); PSP = Personal and Social Performance (s cale); SAS =Simpson Angus Scale ; 
SPSR =Satisfaction With Participation in Social Roles (scale) ; SQLS =Schizophrenia Quality of Life Scale; TSQM -9 = abbreviated 9 -item Treatment Satisfaction Questionnaire for Medication .
Footnotes:
a. The main ICF must be signed before the first study -related activit y; the day that the main ICF is signed is considered to be the first day of the Screening Phase .
b. The minimum criteria for the availability of documentation supporting the eligibility criteria are described in Section 17.4 (Source Documentation). Check clinical status again before the first 
dose of study drug.
c. The pregnancy test is applicable only to women of childbearing potential. It will be a highly sensitive serum test at screening (via central laboratory) and a urine test at all other time points (via 
local testing) , and must be confirmed negative before study drug is adminis tered at the marked visits .
d. If subjects had been taking oral antipsychotics in addition to their PP1M or PP3M, then the oral antipsychotics should be tapered and discontinued during the Screening Phase , with the last oral 
dose swallowed on or before Day -1.If the prestudy therapy was PP1M or PP3M, then the next injection must be due within [ADDRESS_22882] screening (or first rescreening) visit.
e. These tests for concomitant substances are an alcohol breath test and a urine drug screen for illicit substances, including marijuana (even where legal). Alcohol and illicit substances are 
strongly discouraged but are not exclusionary and are not cause for withdrawal from the study. For any subject with a positive result for alcohol or illicit s ubstances, the study -site personnel 
should administer the relevant test again at subsequent visits (even if not marked) until a negative result is obtained. Afte r a negative result is obtained, the subject can resume testing at the 
standard frequency as indicated in these schedules.
f. In addition to the indicated visits, suspected relapses during the Double -blind Phase should prompt all of the following assessments at all associated clinic visits, even if not designated on these 
schedules: a pharmacokinetics (PK) sample , a full PANSS assessment ,a CGI -S assessment, a C -SSRS assessment, and testing for concomitant substances (both an alcohol breath test and a 
urine drug screen for illicit substances). If a possible relapse is detected per PANSS criteria, as described in S ection [IP_ADDRESS] (Relapse Criteria), then the investigator should ask the subject to 
visit the clinical site 3 to 7days later for a PANSS reassessmen t (if no such visit is already scheduled). The EOP visit is to occur as soon as possible after relapse confirmation (preferably the 
same day).
g. For subjects who enter the study with previous PP1M or PP3M stability, the dose in the Maintenance Phase should b e administered with timing appropriate to the subje ct's last prestudy dose 
(ie, 30±[ADDRESS_22883] prestudy PP1M dose, or 90±14days after the last prestudy PP3M dose) .For subjects who enter the study without previous PP1M or PP3M stability, the dose in the 
Maintenance Phase should similarly be administered with timing appropriate to the subject's last dose in the preceding Transi tion Phase (ie, 28±3 days after previous PP1M dose). For all 
subjects, the dose in the Maintenance Phase may be in the deltoid or gluteal muscle, but may not be in the left gluteal muscl e (because of the anticipated left gluteal injection at the beginning of 
the Double -blind Phase, as shown in Table 5).
h. Phys ical examinations include weight, waist circumference, and abnormalities at allmarked visits, plus height at screening only. (Height is used in calculatio ns of body mass index.)
i. Vital sign assessments will include blood pressure (first supi[INVESTIGATOR_050], then standing) , pulse /heart rate , respi[INVESTIGATOR_697], and temperature .Vital signs should be measured before any blood draws. See 
additional instructions in Section 9.4.4 (Vital Signs).
j. For ECGs, see Section 9.4.3 (Electrocardiograms). Note:
Before the first dose: [ADDRESS_22884] be completed by [CONTACT_23769] -2of the study (and assessed by [CONTACT_23770] ). Therefore, double Xs are 
shown in the Screening Phase column. Another ECG is completed by [CONTACT_23771] [ADDRESS_22885] dose of study drug. All 3 of these ECG results should 
be compared with the exclusion criteria.
After the first dose: if any clinically significant ECG abnormality is observed during the study , then the study -site personnel should add ECG assessments for that subject at subsequent 
visits (even if not marked) until the abnormality is resolved.
At any visit: i f blood sampling or vital sign measurement is scheduled for the same time point as ECG recording, then the procedures should be pe rformed in the following order: ECGs, 
vital signs, blood draw.
R092670 (paliperidone palmitate)
Clinical Protocol R092670PSY3015 Amendment 3
38
Approved , Date: [ADDRESS_22886] and the investigator assess the injection site at each marked time point , unless noted otherwise below .
The subject completes a Visual Analog Scale (VAS) to assess pain within [ADDRESS_22887] does not complete a VAS at the EO PVisit.
The invest igator or subin vestigator (but not other study -site personnel ) assesses the injection site for tenderness, erythema/redness, and induration/swelling , and should not review the 
subject's VAS rating of the injection site pain. The investigator /subinvestigato rshould complete these assessments within 30 minutes after the injection and at all marked visits 
thereafter; for any characteristic still rated mild, moderate, or severe at the last marked visit, the investigator/subinvestigator should add injection site assessments at subsequent visits 
(even if not marked) until all of the characteristics are ratedabsent. At the EOP V isit, the investigator assesses the site of the most recent injection. SeeSection [IP_ADDRESS] (Injection Site 
Evaluations and Follow -up by [CONTACT_4718] ) for additional details.
l. For antiparkinsonism medications, initiations or changes should be preceded by [CONTACT_23772], BARS, and SAS (even if not designated in these s chedules). If beta -adrenergic blockers or 
benzodiazepi[INVESTIGATOR_23704], then initiations or changes should be preceded by a BARS (even if not designated per these schedules).
m. At the patients first study visit, the C -SSRS Baseline/Screening Form will be used; for all other visits, the C -SSRS Since Last Visit Form will be used.
n. An abbreviated PANSS consists of the positive -symptom items P1 (delusions), P2 (conceptual disorganization), P3 (hallucinatory beha vior), P6 (suspi[INVESTIGATOR_23703]/persecution), and P7 (hostility) ,
and the g eneral -psychopathology item G8 (uncooperativeness). If the abbreviated PANSS indicates worsening since the last full PANSS assessmen t or if the subject meets one or more 
symptom criterion for relapse (as described in Section [IP_ADDRESS] [Relapse Criteria]) , then the full PANSS should be administered.
o. Subjects should be in fasted state (overnight or for at least 8 hours) for these clinical laboratory blood samples.
p. In addition to PK sampling time points indicated in these schedules, sites should collect PK samples (even if unscheduled) at time points associated with serious or severe adv erse events, and 
may collect other unscheduled PK samples at the investigator's discretion for other adverse events (even if the event is not serious or severe ).
q. These PK samples are collected before the dose is administered that day.
r. The HRU questionnaire and the IEQ are both administered as the baseline assessment versions during the Screening Phase and as the postbaseline asse ssment versions at all subsequent visits.
The HRU questionnaire is administered by [CONTACT_3449] -site personnel ; see details in Section 9.6.1 (Healthcare Resource Utilization Questionnaire).
The IEQ is completed by [CONTACT_23773]; see details in Section 9.6.2 (Involvement Evaluation Questionnaire).
s. At the end of the Maintenance Phase , subjects who are ineligible to proceed to the Double -blind Phase will complete the EOP Visit as an Early Withdrawal Visit .For subjects who are eligible 
to proceed, the EOP Visit in the Maintenance Phase (Visit 7a) is the same as the first visit of the Double -blind Phase (Visit 7b) .
t. The TSQM- 9, SPSR, and IMR scale resu lts will only be analyzed for subjects who entered the study on an oral antipsychotic. For consistency of practice in the Scr eening Phase, these scales 
are also administered to subjects who entered the study on injectable risperidone, even if the data will not be analyzed. For consistency of practice in the Double -blind Phase , these scales are 
administered to all subjects, even if the data will not be analyzed. For subjects that require translation of the SPSR into their local language, the collection of th e SPSR is optional until the final, 
approved translation is available.
u. The duration between the last visit of the Transition Phase (applicable only to subjects with reason to change or stabilize their previous antipsychotic) to the first visit of the Maintenance Phase 
is 28days.
v. Subjects previously treated with injectable risperidone or previously initiated but not on a stable regime nwith PP1M are not required to attend th evisitsmarked "n/a" in the Transition Phase.
For these subjects, the first visit in the Transition Phase should be schedule d for the day when the subject would have received the next injectable risperidone dose (14±3 days) or next PP1M 
dose (30±7 days) .See Table 3 and Table 4 for more information about dosing and dose -related eligibility in the Transition Phase .
w. This dose is active drug (PP3M or PP6M) in both treatment groups. Subjects are randomly assigned to their treatment group before dosing at Visit 7b. See Table 5 for more information.
x. This dose is active drug in the PP3M treatment group and placebo (to maintain the blind) in the PP6M treatment group. See Table 5for more information.
y. These laboratory samples are for prolactin only and do not require fasting.
z. After the PP3M prerandomization target is met, subjects who entered the study at Visits 2a, 2b, 2c, or 2d, will skip Visit 2e and proceed to Visit 2f if the subject is eligible to enter the 
Maintenance Phase (see Section 4.3, Criteria for Entry Into the Maintenance Phas e). If not eligible to enter the Maintenance Phase, the subject will be withdrawn from the study .Visit 2e 
remains available for subjects with ≥[ADDRESS_22888] dose stability.
R092670 (paliperidone palmitate)
Clinical Protocol R092670PSY3015 Amendment 3
39
Approved , Date: 11 February 2019ABBREVIA TIONS AND TERMS
AIMS Abnorm al Involuntary Movement Scale
BARS Barnes Akathisia Rating Scale
BMI body mass index
CGI-S Clinical Global Impression -Severity
CSR Clinical Study Report
C-SSRS Columbia Suicide Severity Rating Scale
DB double blind
DSM -5 Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition
ECG electrocardiogram
eCRF electronic Case Report Form
EPS extrapyramidal symptoms
ER/PR extended -release/prolonged -release
F013 a formulation of paliperidone palmitate, used in PP1M
FDA Food and Drug Administration
G[x] a general -psychopathology item of the PANSS scale, where x isthe number of the item
GCP Good Clinical Practice
HRU Healthcare Resource Utilization
ICF Informed Consent Form
ICH International Conference on Harmonisation / International Council for Harmonisation
IEC Independent Ethics Committee
IEQ Involvement Evaluation Questionnaire
IMR Illness Management and Recovery 
IRB Institutional Review Board
IWRS Interactive Web Response System
LAI long-acting injectable
MedDRA Medical Dictionary for Regulatory Activities
mg eq. (paliperidone palmitate) milligrams equivalent (to paliperidone)
N[x] a negative -symptom  item of the PANSS scale, where x is the number of the item
NIMH National Institute of Mental Health
P[x] a positive- symptom item of the PANSS scale, where x is the number of the item
PANSS Positive and Negative Syndrome Scale
PD pharmacodynamic(s)
PK pharmacokinetic(s)
PP1M paliperidone palmitate 1 -month (product)
PP3M paliperidone palmitate 3 -month (product)
PP6M paliperidone palmitate 6 -month (product)
PQC Product Quality Complaint
PSP Personal and Social Performance (scale)
Q3 every 3 months
QTc QT interval, corrected
QTcB QT interval, corrected according to Bazett's formula
QTcF QT interval, corrected according to Fridericia's formula
QTcLD QT interval, corrected according to the linear -derived formula
SAP statistical analysis plan
CCI
R092670 (paliperidone palmitate)
Clinical Protocol R092670PSY3015 Amendment 3
40
Approved , Date: 11 February 2019SAS Simpson Angus Scale
SCI-PANSS Structured Clinical Interview -PANSS
SPSR Satisfaction With Participation in Social Roles (Short Form 8a)
SQLS Schizophrenia Quality of Life Scale
S[LOCATION_003]R suspected unexpected serious adverse reaction
TSQM -9 abbreviated 9 -item Treatment Satisfaction Questionnaire for Medication
US [LOCATION_002]
VAS Visual Analog Scale
Investigational Medicinal Products (IMPs):
Test product: PP6M
Comparator product: PP3M
Placebo: 20% Intralipid® (200 mg/mL) injectable emulsion.
Noninvestigational Medicinal Products (NIMPs):
Rescue medications : Anti-EPS medications/ Benzodiazepi[INVESTIGATOR_1651] (Section 8.2: Concomitant 
Therapy)
Pretreatment medications: Oral antipsychotics including risperidone , paliperidone ER; 
injectable risperidone , PP1MandPP3M
R092670 (paliperidone palmitate)
Clinical Protocol R092670PSY3015 Amendment 3
41
Approved , Date: [ADDRESS_22889] that exhibits the characteristic dopamine Ty pe 2 and 
serotonin Type 2A antagonism of the newer, or second -generation, atypi[INVESTIGATOR_23705] s. Paliperidone is the active metabolite of risperidone and isavailable as adaily-dose 
oral formulation . Paliperidone palmitate is an ester of paliperidone, and is available for 
intramuscular injection in the paliperidone palmitate 1-month (PP1M) product as the 
F013 formulation and the paliperidone palmitate 3-month (PP3M) product as the 
F015 formulation. To further improve adherence and convenience, a paliperidone palmitate 
6-month (PP6M) product is now under development .  
 
(ie, PP3M may beadminist ered into either the 
deltoid or the gluteal muscle, but the larger volume associated with a PP6M dose requires 
injection into the larger gluteal muscle).
Doses can be expressed in milligrams of paliperidone palmitate or in milligrams equivalent 
(mgeq.) to paliperidone. Conversions between products and between units are described in 
Table 1.
Table 1: Conversions Between Doses of the 1 -, 3-, and 6 -Month Formulations of Paliperidone 
Palm itate; Study R092670PSY3015
PP1M Dose PP3M Dose PP6M Dose
mg mg eq. mg mg eq. mg mg eq.
Low est-dose groupsa78 mg 50 mg eq. Not used in this study - - - - Not available - - - -
Low er-dose groups 117 mg 75 mg eq. Not used in this study - - - - Not available - - - -
Moderate -dose groups 156 mg 100 mg eq. 546 mg 350 mg eq. 1092 mg 700 mg eq.
Higher -dose groups 234 mg 150 mg eq. 819 mg 525 mg eq. 1560 mg 1000 mg eq.
Key: mg eq. = (paliperidone palmitate) milligrams equivalent (to paliperidone); PP1M = paliperidone palmitate 1 -month 
(product); PP3M =paliperidone palmitate 3 -month (product); PP6M = paliperidone palmitate 6-month (product).
aSome countries may also have an ultralow dose of PP1M (below the lowest dose stated here), but the ultralow dose is not 
used in this study.
1.1. Background
The term "Sponsor" used throughout this document refers to the entities listed in the Contact 
[CONTACT_23774](s), which will be provided as a separate document.
All of the material in this "Background" section about the approved paliperidone and 
paliperidone palmitate products (oral paliperidone, PP1M, and PP3M) is summarized from the 
Investigator's Brochure , unless otherwise indicated . Statements about the investigational PP6M 
product may not yet be included in the Investigator's Brochure and/or may evolve with time.For 
the most comprehensive nonclinical and clinical information regarding paliperidone and 
paliperidone palmitate , alway s refer to the latest version of the Investigator's Brochure.
CCI
R092670 (paliperidone palmitate)
Clinical Protocol R092670PSY3015 Amendment 3
42
Approved , Date: 11 February 2019Nonclinical Studies
Pharmacologic Profile
Paliperidone is aracemic mixture. Binding affinities are similar between risperidone and 
paliperidone for serotonin Type 2Areceptors, dopamine Type 2 receptors, alpha-adrenergic 
receptor subfamilies Type 1 and 2, and histamine Type 1 receptors .In vitro, paliperidone was 
equipotent to risperidone in reversing the dopamine- induced suppression of prolactin release 
from anterior pi[INVESTIGATOR_23706], plasma 
coagulation, and fibrinoly sis. Paliperidone is devoi d ofantimuscarinic activity .
Toxicology
The nonclinical profile of paliperidone has been extensively evaluated during the development of 
the approved products. Paliperidone is associated with toxicologic effects that are typi[INVESTIGATOR_23707] 2receptor antagonists. Two 12-week studies in minipi[INVESTIGATOR_23708]1M and PP3M were comparable when tested up to the maximum 
dose level sforhuma ns (150 mg eq. for PP1M and 525 mg eq. for PP3M). The Sponsor is now 
conducting a 6-month local tolerabilit y study  in minipig s for  
 
to be tested in the current clinical study .  is administered 
unilaterally  or bilaterally  and yields a dose up to 141 mgeq./kg if tested in a (for example) [ADDRESS_22890] dose on a mg eq./kg basis that will tested in 
the current clinical study (1000 mgeq.,or 16.7 mgeq./kg ina [for example] [ADDRESS_22891]) .The 
results of the minipig study  now available in an addendum to the I nvestigator's Brochure.
Clinical Studies
Exposure
Beyond extensive studies of oral paliperidone and PP1M, the Sponsor completed 3registrational 
clinical studies of PP3M, . Atotal of 1,[ADDRESS_22892] 1dose of PP3M (F015) in 1 registrational Phase 1 study  (R092670PSY1005 ) 
and 2 registrational Phase 3 studies (R092670PSY3011 and R092670PSY3012), with 
319subjects receiving at least 48weeks of treatment with PP3M in the Phase [ADDRESS_22893] bee n conducted 
in humans using the mass and volume of the dose (and the resultant dosing interval) that 
characterize PP6M.
Pharmacokinetics
After injection, paliperidone palmitate dissolves slowly  before being hydroly zed to paliperidone, 
which then enters the systemic circulation. By [CONTACT_23775], the paliperidone palmitate formulation enables a dosing interval that achieves potentially 
therapeutic plasma concentrations of paliperidone for 1 month (PP1M), 3 months (PP3M), or
now potentially  6 m onths (PP6M); the duration depend s on the particle size, concentration, and 
injection volume.
CCI
CCI
CCI
CCI
R092670 (paliperidone palmitate)
Clinical Protocol R092670PSY3015 Amendment 3
43
Approved , Date: 11 February 2019The Sponsor developed a population pharmacokinetic (PK) model to describe the time course of 
plasma paliperidone concentrations after administration ofPP3M, using data from Studies 
R092670 PSY1005 and R092670PSY3012 . The model was subjected toexternal evaluations, 
extensive model diagnosti cs, and validations using data from Study  R092670PSY3011. The 
Sponsor used thispopulation PK model ing for PP3M to guide dose selection for PP6M,  
Efficacy
In addition to extensive studies of oral paliperidone and PP1M, the efficacy  of PP3M in the 
maintenance treatment in adults with schizophrenia was established in the 2registrational 
Phase 3 studies :
Study  R092670PSY3012 was a double -blind, placebo- controlled, long-term, randomized 
withdrawal study  designed to determine whether PP3M was more effective than placebo in 
delay ing the time to relapse of the symptoms of schizophrenia. Subjects progressed, as 
eligible, through a 17-week open -label PP1M treatment period (n=506), a 12-week open -
label PP3M maintenance period (n=379), then were randomized to continue PP3M (n=160) 
or toswitch to placebo (n=145) during the double -blind period. Relapses occurred in 3 times 
as many  subjects in the placebo group (29.0 %) as in the PP3M group (8.8%) . The hazard 
ratio of relapse of schizoph renia s ymptoms was 3.81 (95% confidence interval: 2.08 to 6.99) 
times higher for a subject switching to placebo than for a subject continuing to receive 
PP3M, indicating a 74% decrease in relapse risk associated with continued PP3M treatment. 
The time to r elapse was significant lydifferen t (p<0.001) in favor of PP3M over placebo ; the 
median estimated time to relapse was not estimable for subjects in the PP3M group but was 
395days for subjects who switched to placebo . The long time to relapse in subjects who 
switched from PP3M to placebo, in combination with their PK results, indicates that many 
subjects had sufficientl y therapeutic paliperidone plasma concentrations beyond their last 
PP3M dose .
Study  R092670PSY3011 was a double -blind, parallel- group, non inferiorit y study  comparing 
the PP1M and PP3M formulations in subjects with schizophrenia. Subjects progressed, as 
eligible, through a 17-week open -label PP1M treatment period (n=1,429 ) and then were 
randomized to receive PP1M (n=512) or PP3M (n=504) during a 48- week double -blind 
period. Relapse rates were low, occurring in8.1% ofPP3M subjects and 9.2% ofPP1M 
subjects . The lower bound of the 95% confidence interval (-2.7%) was greater than the 
prespecified noninferiority  margin of -15%, thus demonstratin g that PP3M was noninferior 
to PP1M.
Overall, the previous efficacy  outcomes with PP3M support the plans for this current study with 
PP6M , with the longer duration of efficacy  to be provided by [CONTACT_23776]1M, the safet y profile of PP3M was 
established in the 3registrational studies . The head -to-head comparison of PP3M and PP1M in 
Study R092670PSY3011 showed no clinicall y meaningful differences in their safety  profile s. In 
particular, results were similar between PP3M and PP1M in the types and incidences of adverse 
CCI
CCI
R092670 (paliperidone palmitate)
Clinical Protocol R092670PSY3015 Amendment 3
44
Approved , Date: 11 February 2019events, adverse drug reactions, andinjection site reactions. Across the development program for 
PP3M, no safety  signals were detected that r elated specificall y to the PP3M (F015) formulation.
Neither of the registrational Phase [ADDRESS_22894] based on his or her tolerabilit y 
and efficacy; those flexible doses then were convert edto a corresponding dose of PP3M . 
Therefore , any conclusion sabout dose-related PP3M safety  results during the double -blind
periods may be confounded by [CONTACT_23777] e PP1M in 
the preceding open-label periods. Still, selected exploratory  analyses of safet y outcomes 
stratified by [CONTACT_23778]3M dose level sin the double -blind periods of these studies did not 
show higher overall rates of adverse events related to extrapy ramidal symptoms (EPS) at the 
highest dose level relative to the lower dose levels, and did not show any evidence for a dose-
related effect on the investigator s'or subject s'ratings of the injection site s.
Adverse events of special interest with PP3M were investigated as follows: EPS -related adverse 
events ;diabetes mellitus and hypergly cemia -related adverse events ;potentially  prolactin- related 
adverse events ;suicidality ;aggression and agitation ;somnolence and sedation; seizures and 
convulsions ;neuroleptic malignant syndrome ;cardiac arrhythmias ;orthostatic hypotension; and 
adverse events suggestive of (or related to) proarrhy thmic potential, ischemia, rhabdom yolysis, 
overdose, weight gain, tachy cardia , injection sitereactions , QTprolongation ,and acute kidney 
injury .8Investigations for adverse events of special interest will be similar for PP6M and will be 
further elaborated in the Statistical Analy sis Plan (SAP).
Overall, the previous safety  and tolerability outcomes with PP3M support the plans for this 
current study with PP6M , with acceptable safety  and tolerability  expected to be possible  
1.2. Overall Rationale for the Study
Adherence to any medication regimen can be difficult for any patient, and can be especially  
problematic for patients with schizophrenia. With currentl y available oral antipsy chotics for 
schizophrenia, fullnonadherence occurs in approximately  40% to 50% of patients,23and partial 
adherence occurs in approximately  90% of patients.36One analysisfound thattreatment gaps of 
as little as 1to10dayscould double the odds of hospi[INVESTIGATOR_059] (p=0.00 4).36In contrast to oral 
formulations, the reliable drug delivery  associated with long-acting injectable (LAI) 
antipsy chotics has yielded a reduced risk of relapse and hospi[INVESTIGATOR_23709].16Because LAI antipsy chotics are administered by a  h ealthcare provider, LAIsoffer 
transparency  with respect to medication adherence, alerting healthcare professionals to the 
occurrence of nonadherence, and ensur ingthat patients with chronic psychotic illness receive a 
known quantity  of medication at appropriate dosing intervals.
Despi[INVESTIGATOR_23710] -acting oral formulations, the development 
of antipsy chotics has not achieved the same durations as some other medications. Many  LAI 
antipsy chotics are available with treatment intervals of 2 to 4weeks,32and one LAI antips ychotic 
(PP3M) is available with a treatment interval of 3months, but no LAI antipsy chotics are 
available with longer treatment intervals. This unmet medical need stands incontrast to other 
CCI
R092670 (paliperidone palmitate)
Clinical Protocol R092670PSY3015 Amendment 3
45
Approved , Date: 11 February 2019injectable or implantable medications for long-term use, such as 6-month and 1-year treatments 
for prostate cancer, a 1-year treatment for osteoporosis, and a 3-year treatment as hormonal 
contraception.32
The 6-month dosing interval with PP6M offers convenience tostabl y treated schizophrenia 
populations (for those who prefer a longer dosing interval) and offers benefits tounderse rved 
schizophrenia populations (for those with limited access to healthcare, with geographic or 
economic problems in coordinating transportation to clinic visits for injections, or with treatment 
access problems associated with homelessness). The current study is therefore designed to 
evaluate the efficacy , safety ,tolerability , and PK profile of PP6M versus PP3M.
2. OBJEC TIVES , ENDPOINTS, AND HYPOTHESIS
2.1. Objectives and Endpoints
2.1.1. Objectives
Primary  Objective
The primary  efficacy  objective is to demonstrate that injection cycles consisting of a single 
administration of PP6M (700 or 1000 mgeq.) arenot less effective than 2sequentially  
administered injections of PP3M (350 or 525mgeq.) forthe prevention of relapse in
subjects with schizo phrenia previously  stabilized on corresponding doses of PP1M (100 or 
150mgeq.) or PP3M (350 or 525 mgeq.).
Secondary  Objectives
To evaluate the safet y and tolerability  of PP6M (700 or 1000 mgeq.) in subjects with 
schizophrenia who have switched from corresponding doses of PP1M (100 or 150mgeq.) 
or PP3M (350 or 525 mgeq.).
To assess the pharmacokinetic (PK)profile of PP6M (700 or 1000mgeq.) administered in 
the gluteal muscle in subjects with schizophrenia who have switched from corresponding 
dosesof PP1M (100 or 150 mgeq.) or PP3M (350 or 525 mgeq.).
To evaluate the clinically  assessed efficacy  of PP6M (700 or 1000 mgeq.) versus PP3M 
(350 or 525mgeq.) in maintaining symptom control , functioning personally  and sociall y,
and achieving or sustai ning remission in subjects with schizophrenia who were previousl y 
stabilized oncorresponding doses of PP1M (100 or 150mg eq.) or PP3M (350 or 
525mgeq.).
To evaluate the subject -reported efficacy  outcomes ofPP6M (700 or 1000 mgeq.) or PP3M 
(350 or 525mgeq.) compared with treatment with previous oral antipsy chotics in terms of 
satisfaction with medication and with participation in social roles .
Exploratory  Objectives
To evaluate healthcare resource utilization during treatment with PP6M or PP3M versus
previous treatment .
To assess changes over time in use of nicotine- containing products.
R092670 (paliperidone palmitate)
Clinical Protocol R092670PSY3015 Amendment 3
46
Approved , Date: 11 February 2019To evaluate the perspectives of subjects during treatment with PP6M or PP3M versus 
previous treatment with oral antipsy chotics in terms of their ability  to manage their illness 
and achieve their personal goals .
To evaluate the caregiver's burden during the recipi[INVESTIGATOR_841]'s treatment with PP6M or PP3M 
versus previous treatment.
To evaluate health -related quality  of life during treatment with PP6M or PP3M versus 
previous treat ment.
2.1.2. Endpoint s
[IP_ADDRESS]. Primary  Endpoint
The primary  endpoint is time to relapse during the Double -blind Phase .This noninferiorit y 
primary  endpoint will be based on the difference in Kaplan -Meier 12-month estimate of survival 
(ie, percentage of subjects remaining relapse -free) between PP6M and PP3M.
[IP_ADDRESS]. Relapse Criteria
Relapse is defined as 1 or more of the following:
Psychiatric hospi[INVESTIGATOR_059] (involuntary  or voluntary  admission to a psychiatric hospi[INVESTIGATOR_23702]’s schizophrenic s ymptoms), or
For Positive and Negative Sy ndrome Scale for Schizophrenia (PANSS) total score:
The subject has an increase of 25% in total PANSS score from randomization for 2 consecutive 
assessments separated b y 3to 7days if the score at randomization was >40, or
The subject has a 10-point increase in the total PANSS score from randomization for 
2consecutive assessments separated b y 3to 7days if the score at randomization was ≤40, or
The subject inflicts deliberate self-injury  or exhibits violent behavior result ing in suicide, 
clinically  significant injury  to him/her self or another person, or significant propert y 
damage, or 
The subject has suicidal or homicidal ideation and aggressive behavior that is clinically  
significant (in frequency  and severit y) in the in vestigator’s judgment, or
For PANSS items P1(delusions), P2(conceptual disorganization), P3(hallucinatory 
behavior), P6 (suspi[INVESTIGATOR_23703]/persecution), P7 (hostility ), and G8 (uncooperativeness):
The subject has a score of ≥5 after randomization for 2consecutive assessments separated by 
3to 7days on any of the above items if the maximum score for the above PANSS items was≤[ADDRESS_22895] has a score of ≥[ADDRESS_22896] assessment for symptoms of relapse (not the 
date of confirmation).
R092670 (paliperidone palmitate)
Clinical Protocol R092670PSY3015 Amendment 3
47
Approved , Date: 11 February 2019The above criteria for relapse in this study are the same as the criteria in the Sponsor's pi[INVESTIGATOR_23711]3M.8,9
Refer to Section 9(Study Evaluations) for evaluations related to endpoints. See Attachment 2for 
the correct calculation of percentage change in full PANSS total scores relevant to relapse 
criteria.
[IP_ADDRESS]. Secondary  Endpoints
The secondary  efficacy  endpoints inc lude the changes from baseline during the 12 months of the 
Double- blind Phase in the following scales: the PANSS total score and subscale scores, the 
Clinical Global Impression -Severit y (CGI -S),and the Personal and Social Performance (PSP) 
scale. Additionally , the proportion of subjects during the Double -blind Phase who meet criteria 
for symptomatic remission will be summarized; the definition of remission is provided in 
Section 11.3.2 (Secondary Efficacy  Anal yses).
The secondary  PK endpoint is plasma paliperidone exposure.
The secondary  endpoints for satisfaction with medication and with participation in social roles 
are abbreviated Treatment Satisfaction Questionnaire for Medication (TSQM -9) and Satisfaction 
with Participation in Social Roles (SPSR), respectively.
The secondary  endpoints that measure safet y and tolerability  include phy sical examinations, vital 
signs, adverse events, electrocardiograms (ECG s), the Columbia Suicide Severity  Rating Scale
(C-SSRS Baseline/Screening and C-SSRS Since Last Visit), the Abnormal Involuntary 
Movement Scale (AIMS), the Barnes Akathisia Rating Scale (BARS), the Simpson Angus Scale 
(SAS), clinical laboratory  assessments (in full [including prolactin] at some time points, or for 
prolactin only  at other time points), and injection site evaluations.
2.2. Hypothesis
The primary  hypothesis is that the efficacy  of PP6M is noninferior to PP3M for preventing 
relapse in subjects with schizophrenia who were previously  stabilized on corresponding doses of 
PP1M or PP3M .See Section 11.3.1 (Primary  Hypothesis and Efficacy  Analy ses).
3. STUDY DESIGN A ND RA TIONA LE
3.1. Overview  of Study  Design
Thisis a randomized, double -blind , active -controlled , multicenter, interventional, parallel -group
study . All eligible subjects who progress without relapse will participate in a Screening Phase (of 
up to 28days), aMaintenance Phase that includes 1injection cycle with either PP1M or PP3M 
(yielding a phase duration of 1or 3months, accordingl y), and a Double -blind Phase (of 
12months). The Double- blind Phase is designed to include at least 2injection cycles of PP6M 
(investigational drug with alternating placebo) or 4injection cycles of PP3M (active control ). In 
addition to standard participation as described above , further conditional/additional participation 
is possible as follows :
R092670 (paliperidone palmitate)
Clinical Protocol R092670PSY3015 Amendment 3
48
Approved , Date: 11 February 2019Before the Maintenance Phase, some subjects will participate in a Transition Phase, with 
1to 5injections of PP1M, if they enter edthe study  on an oral antipsy chotic , on injectable 
risperidone , or on PP1M previously  initiated but not y et stabilized ).
The planned closure will be 12months after the last subject has been randomized in the 
Double- blind Phase.
If a subject has alread y receiv edat least 1dose of double -blind study  drugbut then has 
relapsed or has met other relevant conditions for withdraw alor discontinu ation, then the 
subject should enter a Follow -up Phase. The Follow -up Phase ends 12months after the 
subject's first double -blind injecti on.The Follow -up Phase collects supplementary  poststudy 
data from willing affected subjects ,in an effort to document minimum safet y information
(ie, adverse events) and minimum efficacy information (ie, relapse status) for at least 
6months after a possi blePP6M injection. The Follow -up Phase is designed to be as low-
burden and noninvasive as possible, in order to encourage participation by [CONTACT_23779].
The duration of exposure to study  drug (ie, the number of injections) and the duration of study 
participation are variable based on a subject's flow through treatment types, on participation in 
conditional phases or parts as described in the 3bullet points above , and on whether a subject
experiences a relapse during the stud y:
For subjects wit hout relapse,
The longest expected duration is for a subject who enters the study on an oral 
antipsy chotic and who enrolls early enough to be assigned to PP3M during the 
Maintenance Phase and then to participat ein12months in the Double- blind Phase . 
Sucha subject could have ~ 19months of participation with exposure to paliperidone 
palmitate (4months during the Transition Phase, 3months during the Maintenance 
Phase, 12 months of the Double- blind Phase .
The shortest expected duration for a subject who enters the study  with stability  on 
PP1M will be ~13months of participation with exposure to paliperidone palmitate 
(1month during the Maintenance Phase and 12 months during the Double -blind Phase).
For subjects with relapse, the duration of exposure and participation would be shorter and 
would depend on the timing of the relapse. For example, a subject might receive a first study  
injection providing 1month of treatment in the Maintenance Phase and a second study 
injection at the beginning of the Double- blind Phase ; if a relapse occurred a few weeks 
thereafter, then the subject would receive no further study  drug injections, but would have 
an End-of- Study  Visit associated with the confirmation of the relapse, and would contribute 
poststudy  Follow -up Phase data if willing for the remainder of the y early  cycle.
Due to the long-acting nature of the study  drugs, exposure to residual yet potentially 
subtherapeutic levels of paliperidone is expected to continue past the last study  assessment, as 
addressed in the eligibility  criteria, prohibitions, and restrictions that are relevant to the poststudy  
period (see Section 4[Subject Population]).
The approximate partic ipation targets are 903subjects entering the Screening Phase, 
approximately  840subjects entering the Transition/Maintenance Phase, and 549subjects
entering the Double- blind Phase .Of subjects entering the Double- blind Phase, the 
R092670 (paliperidone palmitate)
Clinical Protocol R092670PSY3015 Amendment 3
49
Approved , Date: [ADDRESS_22897] been 
met and when no further subjects should be enrolled; the subjects who are alread y enrolled at 
that point may  continue in the study  until the Sponsor gives instructions to the sites about how to 
begin closing the study .The Sponsor also will inform sites when phase -specific targets or limits 
have been met, as follows: when the PP3M prerandomization target has been met in the 
Maintenance Phase (see Section 6.1.3 [Maintenance Phase]), and when the pathway  to 
enrollment that includes the Transition Phase is closed (see Section 6.1.2 [Transition Phase]) .
At the start of the Double -blind Phase,
Subjects in the moderate -dose baseline groups (who had achieved stability before or durin g 
the study  with a PP1M dose of 100mgeq. or a PP3M dose of 350mgeq.) will be 
randomized in a 2:1ratio (with dose level as a stratification factor) to receive either the 
investigational PP6M at a 700mgeq. dose or the active control PP3M at a 350mg eq. dose.
Subjects in the higher -dose baseline groups (who had achieved stability  before or during the 
study  with a PP1M dose of 150mgeq. or a PP3M dose of 525mgeq.) will be randomized 
in a 2:1ratio (with dose level as a stratification factor) to receive either the investigational 
PP6M as a 1000 mgeq.dose or the active control PP3M as a 525mgeq.dose.
Safety, efficacy , and pharmacokinetics are monitored throughout the study , as specified in the 
Time and Events Schedules.
A diagram of the stu dy design is provided in Figure 1.
R092670 (paliperidone palmitate)
Clinical Protocol R092670PSY3015 Amendment 3
50
Approved , Date: 11 February 2019Figure 1: Schematic Overview; Study R092670PSY3015

R092670 (paliperidone palmitate)
Clinical Protocol R092670PSY3015 Amendment 3
51
Approved , Date: 11 February 2019Key: mg eq. = (paliperidone palmitate) milligrams equivalent (to paliperidone); PP1M = pali peridone palmitate 1 -month (product); PP3M = paliperidone palmitate 3-month (product); 
PP6M = paliperidone palmitate 6- month (product).
aDuring the Transition Phase, the dose levels and the number of injections will depend first on a subject's previous treatment and then on his or her individual efficacy and tolerability 
results, as described in Section 6.1.2 (Transition Phase). See Figure 2for more details.
bEntry to the Maintenance Phase requires eligibility as specified in Section 4.3(Criteria for Entry Into the Maintenance Phase) . Each subject's Maintenance Phase dose will be matched 
by [CONTACT_23767] (PP1M to PP1M, or PP3M to PP3M) or will be matched by [CONTACT_23768] (PP1M to PP3M) from the same dose that they had been receiving 
during the Screening Phase or at the end of the Transition Phase, as applicable . See Figure 3and Figure 4for more details.
cRandomization will occur on the day of the first double -blind injection (ie, 1 month after the Maintenance Phase injection of PP1M, or 3 months after the Maintenance Phase injection 
of PP3M). Only subjects who are eligible as specified in Section 4.4(Criteria for Entry Into the Double -blind Phase ) will be randomiz ed.
dThe Double -blind Phase includes 4 injections for all treatment groups . The active control groups receive 1 injection of PP3M every 3 months . The investigational drug groups receive 
1injection every 3 months in the following sequence: PP6M → placebo → PP6M → placebo .The planned closure will be [ADDRESS_22898] to be randomized and 
remain in the study completes 12 months of the Double -blind Phase , which will be marked by [CONTACT_23780] 33 aTheSponsor will inform the sites when th estudy is closing and 
no further dosing should be conducted i n the Double -blind Phase .
Note: This figure does not show the Follow -up Phase, which is applicable only to subjects who have received at least [ADDRESS_22899] met 
other relevant conditions for withdrawal or discontinuation, as described in Section 10.2 (Discontinuation of Study Drug /Withdrawal From the Study). The Follow -up Phase ends 
12months after the subject's first double -blind injection, 
R092670 (paliperidone palmitate)
Clinical Protocol R092670PSY3015 Amendment 3
52
Approved , Date: 11 February [ZIP_CODE].2. Study Design Rationale
Blinding and Control
An active control (PP3M) will be used to determine the sensitivity  of the clinical endpoints in 
this study . Randomization will be used to minimize bias in the assignment of subjects to 
treatment groups, to increase the likelihood that known and unknown subject attributes (eg, 
demographic and baseline characteristics) are evenly  balanced across treatment groups, and to 
enhance the validity  of statistical comparisons across treatment groups. Double-b linded 
treatment will be used to reduce potential bias during data collection and evaluation of clinical 
endpoints.
Additional special blinding conditions are as follows:
The Sponsor and all study -site personnel will be blinded to the results of PK measurements
(as described in Section 9.3.1 [Pharmacokinetic Evaluations] ) and prolactin measurements
(as described in Section 9.4.2 (Clinical L aboratory  Tests).
The Sponsor and all study -site personnel except for the study  drug administrator will be 
blinded to the administration of the study  drug during the Double -blind Phase, as described 
in Section 5(Treatment Allocation and Blinding). 
An investigator/subinvestigator who evaluates an injection site should not review the 
subject's Visual Analog Scale (VAS )ratings of pain associated with the injection site, as 
described in Section [IP_ADDRESS] (Injection Site Evaluations and Follow- up by  [CONTACT_4718]).
Cardiologists at thecentral electrocardiogram ( ECG )facility will be blinded to the treatment 
group assignment s of subjects, as described in Section 9.4.3 (Electrocardiograms).
The Sponsor will be blinded to the interim PK analysis, as described in Section 11.4
(Pharmacokinetic and Pharmacod ynamic Anal yses).
Study Phases
The phases in this study  are similar to phases in the Sponsor's pi[INVESTIGATOR_23712]3M 
(R092670PSY3011 and R092670PSY3012), with incorporation of lessons learned from those 
studies and feedback from Health Authorities. The early phases of this PP6M study  (Screening, 
Transition, and Maintenance) are similar to Study R092670PSY3012 ,9but with added flexibility  
(and therefore added complexity ) to allow either PP1MPP6M or PP1MPP3MPP6M 
treatment pathway s. The Double- blind Phase of this PP6M study  issimilar to 
Study R092670PSY3011,9but with more intensive safet y assessments around potential peak 
plasma paliperidone concentrations and more intensive efficacy  assessments around potential 
trough plasma paliperidone concen trations. For a subset of subjects with relapses, study 
withdrawals, or treatment discontinuations during the Double- blind Phase, asubsequent Follow -
up Phase is applicable. The Follow -up Phase in this PP6M study  is similar to the Follow -up Visit 
in Study R092670PSY3011,9but with additional visits and assessments to attempt to collect 
minimum safety  data (ie, adverse events) and minimum efficacy  data(ie, relapse status) until
12months after the first double -blind injection ,In this way, the Follow -up Phase canprovide 
information about the primary  efficacy  endpoint for 12months after a subject's first possible 
R092670 (paliperidone palmitate)
Clinical Protocol R092670PSY3015 Amendment 3
53
Approved , Date: 11 February 2019PP6M injection (see Section [IP_ADDRESS].3 [Sensitivity  Analyses for Primary  Efficacy ]) and can 
provide minimum information about efficacy  and safet y for at least [ADDRESS_22900]'s last 
possible PP6M injection (see Section 10.4 [Process for Planned Study  Closure]).
Dose Levels of Paliperidone Palmitate for Eligibility
To be eligible for randomizatio n, subjects must have stability  with either PP1M as100or 
150mg eq. or PP3M as350 or 525 mg eq., as described in the inclusion criteria . Both products 
are available in lower dose levels ;theeligible dose levels represent the second -highest and 
highest available doses of each product .These dose levels are the ones that have been most 
commonly  prescribed in postmarketing experience ,11and arethe ones that were most commonly  
selected by [CONTACT_23781]'s pi[INVESTIGATOR_23711]3M (Studies R092670 PSY3011 and R092670 PSY3012) .8,9Both pi[INVESTIGATOR_23694]3M 
studies included open -label, flexible -dose,lead-in, 17-week period swith PP1M; the doses of 
PP1M from those open -label periods then were converted to doses of PP3M for the subsequent 
double -blind periods .In those studies, the final open -label doses of PP1M were 150mg eq.for 
~40% to ~50% of subject s, 100mg eq. for ~40% to ~50% of subjects, 75mg eq.for≤9% of 
subjects , and 50 mg eq. for≤3% of subjects .The large percent ages for PP1M as 100 or 150 mg 
eq. in the open -label periods resulted insimilarl y large percentages for PP3M as 350 or 525 mg 
eq. in the double -blind periods .Given the frequent use of these moderate -dose and higher -dose 
levels in clinical studies and in postmarketing experience, the Sponsor selected these dose levels 
for eligibility in the current study .
Dose Levels of Paliperidone Palmitate for Investigation
The conversion of doses of PP1M or PP3M in the Maintenance P hase to doses of PP6M in the 
Double- blind Phase was based onpopulation PK simulations.  
 
 
The population PKmodel thatdescribe sthe time course of plasma paliperidone concentrations 
after PP3M administration was developed by [CONTACT_23782] 1 study  
(R092670 PSY1005) and aPhase 3 study  (R092670 PSY3012).7This model was internally  and 
externally  evaluated, not only by [CONTACT_23783], but also by [CONTACT_23784] 3 study  
(R092670 PSY3011 ).Using that previousl y developed and validated population PK model for 
PP3M , new population PK simulations were performed to project the optimal dose levels for 
PP6M that would correspond to similar trough paliperidone concentrations of the PP3M dose 
levels of 350and 525mg eq., while remaining at or below the recommended maximum 5.0-mL 
volume for aqueous intramuscular injections .10The results indicated that investigational PP6M 
dose levels should be 700and1000 mg eq.
Population PK modeling was used to compare the investigational PP6M dosages against the 
highest and lowest approved dosages of other products that contain paliperidone or risperidone.
CCI
R092670 (paliperidone palmitate)
Clinical Protocol R092670PSY3015 Amendment 3
54
Approved , Date: 11 February 2019The higher investigational PP6M dosage is [ADDRESS_22901] approv ed dosage of 
oral risperidone in the [LOCATION_002] and some other countries is 16 mg/day  (as 8mg twice a 
day).aThe maximum plasma concentration of paliper idone associated with PP6M as 
1000 mgeq. was calculated to be lower than the maximum plasma concent ration of active 
moiety  associated with oral risperidone 16mg/day (as 8mg twice a day), and in line with 
the maximum plasma concentration associated with oral risperidone 6mg/day (as 3mg 
twice a day ).
The lower investigational PP6M dosage is 700mgeq.The lowest approved dosage of the 
oral paliperidone extended -release /prolonged -release (ER/PR)bformulation in the United 
States and some other countries is 3mg/day .cThe minimum plasma concentration of PP6M 
as 700mg eq. was calculated to be higher than the minimum plasma concentration of oral 
paliperidone ER/PR formulation as 3mg/day .
Site of Administration
Although PP1M and PP3M are approved for administration into either the deltoid or the gluteal 
muscle, the larger volume associated with a PP6M dose requires injection into the larger gluteal 
muscle. The PP6M product will be provided in a syringe prefilled with 700mgeq. (3.5mL)or 
1000mgeq. (5.0mL). These volumes are expected to be well tolerated as gluteal injections, for 
the following reasons:
The maximum volume is aligned with the guidance in "Intramuscular injections: a review of 
best practice for mental health nurses ,"which states that "relatively  large doses up to 5mL 
can be given."10
The Sponsor's previous Study  R092670PSY1005 indicated no clinically  meaningful 
difference in tolerability  of the largest -volume dose of PP3M (2.625 mL) versus the smaller 
doses, by [CONTACT_23785] y assigned PP3M dose level. Most pain ratings were below 10mm on a 
100-mm scale.
Paliperidone palmitate is provided as an aqueous suspension, unlike early oil-based LAI 
antipsychotic formulations that were that were often associated with pain after injection.6,[ADDRESS_22902] on the benefit -risk balance, the 
benefits and risks of PP6M will be assessed using a structured approach to benefit -risk 
assessment following the principles described both in the Benefit -risk Action Team Framework, 
                                                
aRISPERDAL®[[LOCATION_002] Prescribing Information]. Titusville, NJ: Janssen Research & Development. 
www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020272 . 
Accessed 19June 2017.
bThe terminology for ER versus PR varies by [CONTACT_1606]; t herefore, both terms are used together in this protocol.
cINVEGA®[[LOCATION_002] Prescribing Information]. Titusville, NJ: Janssen Research & Development. 
www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021999 . 
Accessed 19June 2017.
R092670 (paliperidone palmitate)
Clinical Protocol R092670PSY3015 Amendment 3
55
Approved , Date: 11 February 2019a general platform for benefit -risk assessment ,25,26and in the relevant guideline from the 
International Conference on Harmonisation / International Council for Harmonisation (I CH).d
Timing of PK Samples
The PK profile of PP3M has been well characterized. After a single intramuscular injection of 
PP3M over the dose range of 175to 525mg eq., the plasma concentrations of paliperidone 
graduall y rose to a maximum at approximately  30 to 33 day s.7Similarly , the Sponsor's modeling 
for PP6M has indicated that the maximum plasma paliperidone concentration at stead y state 
should occur approximately  1month after injection of PP6M . Therefore, PK sampling (and the 
associated safet y evaluations) are scheduled in this study  at weekl y time points (ie, more 
intensive) near the expected peak . Thereafter, the PK sampling is conducted at monthl y time 
points (ie, less intensive) throughout the elimination phase . Finall y, the PK sampling (and the 
associated efficacy  evaluations) resumes weekly  time points (ie, more intensive) when 
approaching the end of the 6 -month dosing interval .
Overall Study Evaluations
The efficacy , safet y, pharmacokinetic, pharmacody namic, benefit -risk, and exploratory 
evaluations for PP6M in this study  are similar to evaluations for PP3M in the Sponsor's pi[INVESTIGATOR_23713] (R092670PSY3011 and R092670PSY3012), with incorporation of lessons learned from 
those studies. The study  evaluations have also incorpo rated feedback from Health Authorities.
4. SUBJECT POPULA TION
Screening for eligible subjects will be performed within the period from 28to 2days before the 
firstadministration of the study  drug.
The inclusion and exclusion criteria for enrolling subjects in this study  are described in the 
following [ADDRESS_22903] does not meet all inclusion criteria (is a screen failure) with respect to dose level, 
dose duration, or dose timing of prestud y treatment with paliperido ne palmitate or injectable 
risperidone , but at some point in the future is expected to meet these inclusion criteria, then the 
subject may be rescreened on [ADDRESS_22904] number, will undergo the informed consent process, and then will restart theScreening 
Phase. Conditions that are permissible for rescreening include the following:
                                                
dICH. ICH Harmonized Tripartite Guideline M4E(R2): Revision of M4E guideline on enhancing the format and 
structure of benefit -risk information in ICH.
www.ich.org/fileadmin/Public_Web_Site/ICH_Products/CTD/M4E_R2_Efficacy/M4E_R2__Step_4.pdf . 
Dated15June 2016. Accessed 19June 2017.
R092670 (paliperidone palmitate)
Clinical Protocol R092670PSY3015 Amendment 3
56
Approved , Date: 11 February 2019Duration/stability  of prestudy  dosing . For example, if a potential subject has not been treated 
with the same dose for the minimum amount of time, then the potential subject may return 
for rescreening after the minimum duration as specified in the inclusion criteria .
Strength/level of prestudy  dosing . For example, if a potential subject is being treated with a 
dose that is too low for eligibility , but insufficient efficacy with a lower dose means that a 
higher dose is alread y planned, then the subject may return for rescreening after being 
treated with an eligible dose level for the minimum duration as specified in the inclusion 
criteria .
Timing of the last prestudy  dose. For example, if the last prestud y dose was not within the 
appropriate window, then the potential subject may return for rescreening at an appropriate 
time.
If a subject meets any exclusion criteria (is a screen failure) with respect to safet y parameters,
then rescreening is not allowed. However, retesting may be permitted for results (eg, laboratory 
or ECG values) that may be transient orinaccurate in the opi[INVESTIGATOR_871] . This 
exceptional and limited retesting of abnormal screening values that lead to exclusion isallowed 
only once using an unscheduled visit during the S creening Phase, to reassess eligibility .
Rescreening is permitted with the medical monitor’s approval for subjects who were withdrawn 
during the Transition Phase or Maintenance Phase due to an incomplete injection or an 
unintended dosing or administration of a study  drug .
4.1. Inclusion Criteria
Each potential subject must satisfy all of the following criteria to be enrolled in the study :
1. May be either ma leorfemale .
2.Must be 18years of age (or the legal age of consent in the jurisdiction in which the study  is 
taking place) to 70years of age, inclusive , at the time of informed consent .
3.Must meet the diagnostic criteria for schizophrenia according to Diagnostic andStatistical 
Manual of Mental Disorders, Fifth Edition (DSM -5) for at least 6months before screening.
R092670 (paliperidone palmitate)
Clinical Protocol R092670PSY3015 Amendment 3
57
Approved , Date: [ADDRESS_22905] be receiving treatment with paliperidone palmitate (as either the PP1M or PP3M 
formulation) , or injectable risperidone, or an y oral antipsychoti c.
a.If the treatment is paliperidone palmitate, then:
1) The dose strength must be PP1M as 100or 150 mgeq. or PP3M as 350 or 525 mg eq .
2) The dose timing must fitthe study  schedule . The next injection must be due within 
28days of the first screening (or first rescreening) visit.
b. If the treatment is injectable risperidone, then the dose strength must be 50mg, the 
dosing cycle must be every  [ADDRESS_22906] a full PANSS score of <[ADDRESS_22907] a body  mass index (BMI) between 17 and 40 kg/m2 (inclusive) and must have a 
body  weight of at least [ADDRESS_22908] a negative highly sensitive serum 
(-human chorionic gonadotropin) at screening.
10. Criterion modified per Amendment [ADDRESS_22909] be either:
a. Not of childbearing potential, defined as being either postmenopausal or permanentl y 
sterile, as foll ows:
R092670 (paliperidone palmitate)
Clinical Protocol R092670PSY3015 Amendment 3
58
Approved , Date: 11 February 2019oPostmenopausal: A postmenopausal state is defined as no menses for 12months 
without an alternative medical cause. A high follicle stimulating hormone (FSH) 
level (>40 IU/L or mIU/mL) in the postmenopausal range may be used to confirm 
a postmenopausal state in women not using hormonal contraception or hormonal 
replacement therapy, however in the absence of 12months of amenorrhea, a 
single FSH measurement is insufficient.
oPermanently  sterile: Permanent sterilization methods include hyster ectomy, 
bilateral salpi[INVESTIGATOR_1656], bilateral tubal occlusion/ligation procedures, and 
bilateral oophorectomy.
b. Of childbearing potential, but meeting the contraception requirements as follows:
oPracticing a highly  effective method of contraception (failure rate of <1% per y ear 
when used consistently  and correctly ). Examples of highl y effective 
contraceptives include the following:
User -independent methods: Implantable progestogen-onl y hormone 
contraception associated with inhibition of ovulation; intrauterin e device 
(IUD); intrauterine hormone -releasing system; vasectomized partner; sexual 
abstinence (sexual abstinence is considered a highly effective method only if 
defined as refraining from heterosexual intercourse during the entire period 
of risk associate d with the study drug; the reliability of sexual abstinence 
needs to be evaluated in relation to the duration of the study and the 
preferred and usual lifestyle of the subject ).  
User -dependent methods: combined (estrogen -and progestogen- containing) 
hormonal contraception associated with inhibition of ovulation: oral, 
intravaginal, and transdermal; progestogen- only hormone contraception 
associated with inhibition of ovulation: oral and injectable.
Typi[INVESTIGATOR_23714] u sed consistently and 
correctly. Use should be consistent with local regulations regarding the use of 
contraceptive methods for subjects participating in clinical studies.
oAgreeing to remain on a highl y effective method throughout the study  and for at 
least [ADDRESS_22910] dose of study  drug. A woman using oral 
contraceptives should use an additional birth control method (see inclusion 
criterion text in the sub -bullet above).
Note: If the childbearing potential changes after start of the study  or the risk of pregnancy  
changes (eg, a woman who is not heterosexually active becomes active), a woman must 
consent to starting a highly  effective method of contraception after a negative pregnancy  
test.If the subject declines consent for start of a highl y effective method of contraception, 
the subject must be withdrawn from the study .
R092670 (paliperidone palmitate)
Clinical Protocol R092670PSY3015 Amendment 3
59
Approved , Date: [ADDRESS_22911] dose of study  drug, his female partner(s) will use a highl y effective 
method of contraception as described above, and:
He must, if being sexually  active with a woman of childbearing potential, use a barrier 
method of contraception (eg, condom with spermicidal 
foam/gel/film/cream/suppository ).
He must, if being sexually  active with a woman who is pregnant, use a condom.
He must agree not to donate sperm.
12.Must sign an informed consent form (ICF) indicating that he or she understands the 
purpose of, and proce dures required for, the study and is willing to participate in the study ; 
and must be able to provide his or her own consent (ie, consent cannot be provided by a 
legal representative of the subject).
13. Must have a stable place of residence for the previ ous 3months prior to screening and in 
the for eseeable future.
14. Must be fluent in the language of the investigator, study  staff, and raters.
15. Criterion deleted per Amendment 2.
16. Must have an identified support person (eg, family member, social worker, caseworker, or 
nurse) considered reliable by [CONTACT_23786], outpatient visits, and protocol procedures, including 
alerting trial staff to an y signs of impending relaps e.
4.2. Exclusion Criteria
1. Must not be receiving any form of involuntary  treatment, such as involuntary  psychiatric 
hospi[INVESTIGATOR_059] , parole -mandated treatment, or court -mandated treatment.
2. Must not have attempted suicide within 12months before screening and must not be at 
imminent risk of suicide or violent behavior, as clinically  assessed by [CONTACT_23787] .
3. Must not have a DSM -5 diagnosis of moderate or severe substance use disorder (except 
for nicotine and caffeine) within 6 months of screening; however, acute or intermittent 
substance use prior to screening is not exclusionary , depending upon the clinical 
judgment of the investigator.
4. Must not have a history  of neuroleptic malignant sy ndrome or tardive d yskinesia .
R092670 (paliperidone palmitate)
Clinical Protocol R092670PSY3015 Amendment 3
60
Approved , Date: [ADDRESS_22912] been treated with long acting injectable formulations of neuroleptic 
drugs based on active ingredients other than risperidone or paliperidone (eg, haloperidol 
decanoate, fluphenazine decanoate, etc)during the [ADDRESS_22913] a clinically  significant and unstable medical illness in history  or at 
screening, including (but not limited to) cardiac arrhythmias or other cardiac disease, 
hematologic disease, coagulation disorders (including any abnormal bleeding or blood 
dyscrasias), significant pulmonary  disease including bronchospastic respi[INVESTIGATOR_23715], 
diabetes mellitus (poorl y controlled or requiring insulin), hepatic insufficiency , thyroid 
disease (poorl y controlled based on recent thyroid stimulating hormone [TSH ]level), 
neurologic or other psychiatric disease (except schizophrenia), infection, cancer, or any 
other illness that the investigator considers should exclude the subject or that could 
interfere with the interpretation of the efficacy  or safet y measurement s.
8. Must not have a primary , active DSM -5 diagnosis other than schizophrenia (eg, 
dissoci ative disorder, bipolar disorder, major depressive disorder, schizoaffective 
disorder, schizophreniform disorder, autistic disorder, primary  substance -induced 
psychotic disorder) and must not have dementia -related ps ychosis .
9. Must not have clinically significant abnormal values during screening for hematology , 
serum chemistry  (including aspartate aminotransferase or alanine aminotransferase 
greater than 2times the upper limit of normal), or urinal ysis, as deemed appropriate by
[CONTACT_093].
10. Must not have clinically  relevant abnormality  in the physical examination, vital signs ,or 
12-lead electrocar diogram (ECG) during screening, as deemed appropriate by [CONTACT_1275] .
11. Must not have known allergies, hypersensiti vity, or intolerance topaliperidone palmitate , 
paliperidone, risperidone, Intralipid (the placebo), or any excipi[INVESTIGATOR_840] (refer to the 
Investigator's Brochure for details) of the formulations, which include soybean oil, egg 
yolk, phospholipi[INVESTIGATOR_805], and gl ycerol.
R092670 (paliperidone palmitate)
Clinical Protocol R092670PSY3015 Amendment 3
61
Approved , Date: [ADDRESS_22914] a history  of treatment resistance ,defined as failure to respond to 
2adequate trials with adequate doses of different antipsy chotic medications (where an 
adequate trial is defined as a minimum of 4weeks at a therapeutic dosage) , based on the 
available medical records. F inal determination of eligibility  is based on investigator 
judgment.
13. Must not have been treated in the last 2months with clozapi[INVESTIGATOR_23716]- resistant or 
treatment -refractory  illness.
14. Must not have a history  of unresponsiveness to (lack of efficacy  with) any risperidone or 
paliperidone products.
15. Must not have a history  of intolerance to doses ≥9mg/day of oral paliperidone or 
≥6mg/day of oral risperidone, where the intolerance was treatment -limiting (ie, leading 
to discontinuation or reduction of dose) .
16. Must not have a history or presence of circumstances that may increase the risk of the 
occurrence of torsade de pointes and/or sudden death in association with the use of drugs 
that prolong the QTc interval, including:
a.Heart rate <50bpm, based on 12 -lead ECG and/or vital signs, on repeated occasions 
(2or more times) during the screening and before the f irst dosing day  of the study .
b.Prolonged QTc interval corrected according to Fridericia's formula (QTcF) 
>450 msec, based on 12- lead ECG, on repeated occasions (2or more times) during 
screening or from prior medical record within the past year) .
c.Cardiac conditions as follows: brady cardia, sick sinus syndrome, complete 
atrioventricular block, congestive heart failure, or polymorphic ventricular 
tachycardia.
d.Electrol yte conditions as follows: clinically  relevant hypocalcemia, hypokalemia, or 
hypomagnesemia.
e.Concomitant use of drugs that prolong the QTc interval, such as Class IA 
antiarrh ythmics (eg, disopy ramide , quinidine , or procainamide ) and Class III 
antiarrh ythmics (eg, amiodarone or sotalol) ;some antihistamines; some antibiotics 
(eg, fluoroquinolones like moxifloxacin or ciprofloxacin );some antimalarials (eg, 
mefloquine) ;and some antipsy chotics (eg, chlorpromazine or ziprasidone).
f.Congenital prolongation of the QT interval (Romano -Ward syndrome or Jervell and 
Lange -Nielsen s yndrome).
R092670 (paliperidone palmitate)
Clinical Protocol R092670PSY3015 Amendment 3
62
Approved , Date: [ADDRESS_22915] not concomitantly  use anyinducer sof proteins involved in the metabolism of 
paliperidone (ie, cytochrome P450 3A4) or the excretion of paliperidone (ie, 
p-glycoprotein), such as rifampi[INVESTIGATOR_2513], carbamazepi[INVESTIGATOR_050], oxcarbazepi[INVESTIGATOR_050], barbiturates, 
pheny toin, troglitazone, orSt.John 's Wort ,within 14days prior to the first screening 
visit.
18. Must not have any primary  movement disorders (such as Parkinson 's disease, 
Huntington 'sdisease , or others )that could, in the investigator 's judgment ,affect the 
safet y or tolerability forthe subject or affect the results of the study .
19. If an oral tolerability  test is required (ie, if the subject has no documented tolerability  to 
any oral or injectable risperidone or paliperidone formulations), then the subject must not 
have a history  of any severe pre-existing gastrointestinal narrowing (pathologic or 
iatrogenic) or inabilit y to swallow oral paliperidone ER/PR tablets whole with the aid of
water.
20. Must not have received an investigational drug or have used an invasive investigational 
medical device within 3months or within a period less than 5times the drug's half-life, 
whichever is longer, before the planned first dose of study  drug. This criterion does not 
apply  if the prestudy  investigational drug was PP1M or PP3M.
21. Must not, if a woman, be pregnant, breastfeeding, or planning to become pregnant while 
enrolled in this study  or within [ADDRESS_22916] (eg, compromise the well-being) or that 
could prevent, limit, or confound the protocol -specified assessments.
26. Must not have modera te to severe renal impairment (ie ,those with creatinine clearance as 
estimated by  [CONTACT_3158]- Gault of <60 mL/min).
R092670 (paliperidone palmitate)
Clinical Protocol R092670PSY3015 Amendment 3
63
Approved , Date: [ADDRESS_22917] the following:
-Electroconvulsive therapy  (ECT) within 60 day s before screening
-Nonselective/irreversible monoamine oxidase inhibitors (MAOI) antidepressants 
within 30 days before screening
-Other antidepressants unless at a stable dosage for 30 days before screening (If 
the dosage has been stable for less than [ADDRESS_22918] does not require 
the antidepressant, it can be washed out by [CONTACT_23760]; if the dosage has 
been stable for less than [ADDRESS_22919] should not be included in this study )
28. Must not be concomitantly  treated with mood stabilizers including lithium, or valproate, 
or other antiepi[INVESTIGATOR_23698]/anticonvulsants within [ADDRESS_22920] (eg,ropi[INVESTIGATOR_23699]) 
within [ADDRESS_22921] screeni ng visit.
NOTE: Investigators should ensure that all study enrollment criteria have been met at screening. 
If a subject's clinical status changes (including any available laboratory  results or receipt of 
additional medical records) after screening but before the first dose of study  drug is given such 
that he or shenolonger meet sall eligibility  criteri a, then the subject should be excluded from 
participation in the study . Section 9.1(Study  Procedures) , describes options for retesting. 
Section 17.4 (Source Documenta tion)describes the required documentation to support meeting 
the enrollment criteria.
4.3. Criteria for Entry  Into the Maintenance Phase
1. On Day [ADDRESS_22922] a full PANSS total score of 
<70points.
2. Criterion modified pe r Amendment [ADDRESS_22923] been 100 or 150 mg eq.
and, in the investigator’s judgment, the subject should continue on the same dose level (ie,
either the equivalent PP3M dose [before the PP3M prerandomization target is met]or the 
same PP1M dose [after the PP3M prerandomization target is met ]).
R092670 (paliperidone palmitate)
Clinical Protocol R092670PSY3015 Amendment 3
64
Approved , Date: [ADDRESS_22924] during the Transition Phase:
a.required psychiatric hospi[INVESTIGATOR_059] (involuntary or voluntary  admission to a 
psychiatric hospi[INVESTIGATOR_23700]’s schizophrenic symptoms), 
or 
b.inflicted deliberate self-injury  or exhibited violent behavior resulting in suicide, 
clinically  significant injury  to him/her self or another person, or significant 
propert y damage, or
c.had suicidal or homicidal ideation and aggressive behavior that is clinically 
significant (in frequency  and severit y) in the investigator’s judgment
4.For subjects proceeding from the Screening Phase directly  to the Maintenance Phase, the 
PP1M dose or PP3M dose must not be planned for adjustment in the foreseeable future and 
must have been unchanged in the recent past (as described in "a" and "b" below) . The 
specific dose stabilit y criteria are as follows:
a.For PP1M , at least 3months of injections with the last 2doses being the same 
strength before the S creening Phase .
b.For PP3M, at least 1 injection cy clebefore the S creening Phase .
Subjects who do not meet the criteria above will be withdrawn from the study , will undergo End -
of-Phase Visit / Early Withdrawal V isit procedures, and will be treated thereafter according to 
clinical judgment for acceptable standard of care. If withdrawal is due to an incomplete injection 
or an unintended dosing or administration of a study  drug, rescreening is permissible with the 
medical monitor’s approval.
4.4. Criteria for Entry  Into the Double -blind Phase
Eligibility  to enter the Double -blind Phase requires all of the following:
1.For the last 2assessments before randomization (ie, at Visit 6 and Visit 7a/b) , subjects 
must have a PANSS total score of <[ADDRESS_22925] 2assessments before randomization (ie, at Visit 6 and Visit 7a/b) , subjects 
must have scores of ≤4 points for PANSS items P1(delusions), P2(conceptual 
disorganization), P3(hallucinatory  b ehavior), P6(suspi[INVESTIGATOR_23703]/ persecution), 
P7(hostility ), G8 (uncooperativeness), and G14 (poor impulse control).
3.Subjects must not, per investigator judgment, have significant EPS despi[INVESTIGATOR_23717]-EPS medications, based on standard clinical evaluation and 
information from the Abnormal Involuntary  Movement Scale (AIMS)for dyskinesia, the 
Barnes Akathisia Rating Scale (BARS )for akathisia, and the Simpson Angus Scale (SAS)
for parkinsonism .
4. Subjects must not have received any oral antipsy chotic supplementation during the 
Maintenance Phase.
R092670 (paliperidone palmitate)
Clinical Protocol R092670PSY3015 Amendment 3
65
Approved , Date: [ADDRESS_22926] during the Maintenance Phase:
a.required psychiatric hospi[INVESTIGATOR_059] (involuntary or voluntary  admission to a 
psychiatric hospi[INVESTIGATOR_23700]’s schizophrenic symptoms), 
or 
b.inflicted deliberate self-injury  or exhibited violent behavior resulting in suicide, 
clinica lly significant injury  to him/her self or another person, or significant 
propert y damage, or
c.had suicidal or homicidal ideation and aggressive behavior that is clinically 
significant (in frequency  and severit y) in the investigator’s judgment
Subjects who do not meet the criteria above for entry  into the Double -blind Phase will be 
withdrawn from the study , will undergo End -of-Phase Visit / Early  Withdrawal Visit procedures, 
and will be treated thereafter according to clinical judgment foracceptable standard of care.
These subjects do not need to enter the Follow -up Phase, since they do not receive any double -
blind treatment. If withdrawal is due to an incomplete injection or an unintended dosing or 
administration of a study  drug, rescreening is perm issible with the medical monitor’s approval .
4.5. Prohibitions , Restrictions , and Strong Recommendations
Prohibitions and Restrictions
Potential subjects must be willing and able to adhere to the following prohibitions and 
restrictions during the course of the study  to be eligible for participation:
1. Must follow Section 8.3(Prohibited Concomitant Medications ),regarding prohibited and 
restricted therap y during the study.
2.Must agree to follow all requirements that must be met during the study as noted in the 
Inclusion and Exclusion Criteria (eg, contraceptive requirements ).
3. Must, if a woman of childbearing potential ,continue using an appropriate method of 
contraception ,as described in Section 4.1(Inclusion Criteria) ,during participation in the 
study  and for at least [ADDRESS_22927] dose of study  drug. (Women who have a 
positive pregnancy  test during the study will be withdrawn from the study .)
4. Must, if a man, continue using the measures described in Section 4.1(Inclusion Criteria) to 
prevent women from being exposed to his sperm or conceiving his child during the study 
and for [ADDRESS_22928] dose of study  drug.
Strong Recommendations
Potential subjects should also be willing and able to adhere to the following strong 
recommendations (which are not strict prohibitions orrestrictions) during the course of the 
study :
R092670 (paliperidone palmitate)
Clinical Protocol R092670PSY3015 Amendment 3
66
Approved , Date: [ADDRESS_22929] 6months after 
completion of the study .
3.Should not use alcohol, illicit substances, or recreational marijuana (even where legal) 
during the entire study .(Recreational marijuana is a strong recommendation, but medical 
marijuana is a prohibition; see S ection 8.3[Prohibited Concomitant Medications ]).
4. Criterion modified per Amendment 3.
4.1. Should not eat before blood laboratory  full panel sampling. (Nonfasting exceptions 
should be noted ; fasted states are overnight or for at least 8 hours).
5. Deleted per Amendment 3.
6. Deleted per Amendment 2. 
5. TREA TMENT ALLOCA TION AND BLINDING
See also the "Blinding and Control" subheading under Section 3.2(Study  Design Rationa le).
Treatment Allocation : Procedures for Ran domization and Stratification
At entry  into the Double -blind Phase , subjects who had received a moderate dose in the 
Maintenance Phase will be randomly  assigned to 1 of 2treatment groups (active control or 
investigational drug as moderate doses ) and subjects who had received a higher dose in the 
Maintenance Phase will be randomly  assigned to 1 of 2 treatment groups (active control or 
investigational drug as higher doses) , based on a computer -generated random ization schedule 
prepared before the study  by [CONTACT_23788]. The randomization 
(2:1ratio, PP6M:PP3M) will be balanced by [CONTACT_23789] . Based on this 
randomization code, the study drug will be packaged and labeled for each subject. Medication kit 
numbers will be preprinted on the study  drug labels and assigned as subjects qualify  for the 
Double- blind Phase and are randomly  assigned to treatment.
Central randomization will be implemented in this study . TheInteractive Web Response System 
(IWRS) will assign a unique treatment code, which will dictate the treatment assignment and 
matching study  drug kit for the subject. The requ estor must use his or her own user identification 
and personal identification number when contact[CONTACT_23790], and will then give the relevant 
subject details to uniquely  identify  the subject. Details regarding use of the IWRS will be 
provided in the I WRS Manual.
UnblindedStudy Drug Administrator
Special precautions will be used to reduce potential bias during data collection and evaluation of 
clinical endpoints. Differences in syringe sizes for PP3M versus PP6M pose a potential for the 
R092670 (paliperidone palmitate)
Clinical Protocol R092670PSY3015 Amendment 3
67
Approved , Date: [ADDRESS_22930]'s treatment assignment. The subject 
and study  staff, other than the study  drug administrator, should not be allowed to view the 
syringe or needle or to observe the injection. (The subject must be instructed to look away  during 
the injection and related steps before and after.) To minimize the potential for unblinding, the 
study  drug administrator will be allowed to perform only  the following study -related procedures: 
preparing injections, administe ring injections, contact[CONTACT_23791], receiving subject medication kit 
numbers, and keepi[INVESTIGATOR_23718]. The study  drug 
administrator will not be allowed to perform any other study -related procedures (including 
efficacy , safet y, or other study  evaluations) or to communicate subject -related information to 
study -site personnel, including the investigator. If the subject informs the study  drug 
administrator of any adverse events that occurred since the last injection, the subject should be 
instructed to provide the same information to other study  staff. The investi gator must explain to 
the subjects that the only subject -facing role for the study  drug administrator is to administer the 
injections.
In exceptional circumstances, where an assigned study  drug administrator is not available to 
administer study  drug, anoth er adequatel y trained investigational staff member may administer 
study  drug during the Maintenance Phase only. As with the study  drug administrator, any other 
person responsible for study  drug administration will not be allowed to perform any other study -
related procedures (including efficacy , safet y, or other study  evaluations) or to communicate 
subject -related information to study -site personnel, including the investigator.
Blinding : Investigational Staff
The investigator will not be provided with random ization codes. The codes will be maintained 
within the IWRS, which has the functionality  to allow the investigator to break the blind for an 
individual subject.
Data that may potentially  unblind the treatment assignment (ie, study  drug serum concentrations
orprolactin levels ) will be handled with special care to ensure that the integrit y of the blind is 
maintained and the potential for bias is minimized. This can include making special provisions, 
such as segregating the data in question from view by [CONTACT_473], clinical team, or others 
as appropriate until the time of database lock and unblinding.
The investigator/subinvestigator who assesses the injection site for tenderness, ery thema/redness, 
and induration/swelling should not review the subject's VAS rating of the injection site pain. 
(This is not applicable to other study -site personnel.)
Intentional Unblinding
Under normal circumstances, the blind should not be broken until all subjects have completed 
the study  and the database is finalized. Otherwise, the blind should be broken only if specific 
emergency  treatment or emergent course of action would be dictated by [CONTACT_23792]. In such cases, the investigator or designee may in an emergency  determine 
the identity  ofthe treatment by[CONTACT_23793]. It is recommended that the investigator 
contact [CONTACT_23794], before breaking 
R092670 (paliperidone palmitate)
Clinical Protocol R092670PSY3015 Amendment 3
68
Approved , Date: [ADDRESS_22931] be documented in the appropriate 
section of the electronic Case Report Form (eCRF) and in the source document. The 
documentation received from theIWRS indicating the code break must be retained with the 
subject's source documents in a secure manner . Subjects who have had their treatment 
assignment unblinded should be withdrawn from the study .
6. DOSA GE A ND A DMINISTR ATION
6.1. Dosage
6.1.1. Screening Phase
During the Screening Phase, subjects must have alread y been receiving PP1M at 100or 
150mgeq., PP3M at 350 or 525mg eq., injectable risperidone at 50 mg, or an oral antipsy chotic 
at an y dosage wit h a reason to change , as described in Section 4.1(Inclusion Criteria).
Ifsubjects have nodocumented tolerability  to any oral or injectable risperidone or palipe ridone
formulations, then an oral tolerability  test should be conducted. To demonstrate oral tolerability , 
paliperidone ER/PR 6 mg tablets or risperidone 3 mg/day  (dose may be divided) will be given 
during the Screening Phase for [ADDRESS_22932] dose swallowed on or before 
Day -1. The recommended dose is paliperidone ER/PR of 6 mg/day  or risperidone 3mg/day 
(dose may be divided), but higher doses of paliperidone or risperidone may be used if clinicall y 
indicated, based on investigator judgment. Oral tolerability  testing may be concurrent with any 
required washout of other medications. Tapering of oral tolerability  medication during this 
period is not required. Subjects should be instructed not to chew, divide, dissolve, or crush the 
paliperidone ER/PR tablets, since an effect on the release profile is possible. The oral tolerability 
test will allow the investigator to assess possible problems with tolerabilit y (including allergic or 
hypersensitivity  reactions) that may  be related to paliperidone. Examples of problems that would 
lead to exclusion of the subject would include intolerable sedation, clinically  symptomatic 
orthostatic hy potension, torticollis or other severe EPS, orevidence of an allergic reaction.
For subjects with previously  established tolerability  to at least 1oral or injectable risperidone or 
paliperidone formulation , the appropriate documentation may include medical or pharmacy 
records, a letter from a previo us provider, or a written statement by [CONTACT_23795] a credible 
report from the subject or subject's identified support person. These records must be filed in the 
source documents.
6.1.2. Transition Phase
The Transition Phase is applicable only to subjects who entered the Screening Phase without 
previous PP1M or PP3M stability . These subjects may have been previously  treated with oral 
antipsy chotics, injectable risperidone , or a moderate or higher dose of PP1M with previous 
initiation but without previous stabilizatio n (where stabilization is defined is at least 3months of 
injections with the last 2doses being the same strengt h),as shown in Figure 2and as described 
below. In order to appropriately  balance study  groups at the Double- blind Phase baseline and to 
R092670 (paliperidone palmitate)
Clinical Protocol R092670PSY3015 Amendment 3
69
Approved , Date: [ADDRESS_22933] closed to enrollment.
See also Section 6.2.1 (Administration During the Open -label Phases) .
R092670 (paliperidone palmitate)
Clinical Protocol R092670PSY3015 Amendment 3
70
Approved , Date: 11 February 2019Figure 2: Schematic Overview, Showing Additional Details for the Screening Phase and Transition Phase; Study R092670PSY3015
Key: mg eq . =(paliperidone palmitate) milligrams equivalent (to paliperidone); PP1M =paliperidone palmitate 1 -month ( product ); PP3M =paliperidone palmitate 
3-month ( product ); PP6M =paliperidone palmitate 6-month ( product ).
aIf subjects in this group have no documented tolerability to any oral or injectable risperidone or paliperidone formulations, then an oral tolerability test should be 
conducted during the Screening Phase.
bAfter meeting the PP3M prerandomization target.
cBefore meeting the PP3M prerandomization target .
Note: See Figure 1for other relevant explanatory notes.

R092670 (paliperidone palmitate)
Clinical Protocol R092670PSY3015 Amendment 3
71
Approved , Date: 11 February 2019Transition Phase: Subjects Previously Treated With Oral A ntipsychotic s
In the Transition Phase, s ubjects previousl y treated with oral antipsy chotic s will receive PP1M as
150mgeq.on Day 1 and 100mgeq. on Day 8.Thereafter, the PP1M doses on Days 36, 64, 
and92will be flexibl e (as 50, 75, 100, or 150mgeq.), based on clinical judgment and shared 
decision- making .Days 1, 8, 36, 64, and 92 correspond to Visits 2a, 2b, 2c, 2d, and 2e, 
respectivel y (see Table 3and Table 4). Administration should be in the deltoid muscle on Day s1 
and8 and may be either in the deltoid or gluteal muscles on Days 36, 64,and92, as shown in 
Table [ADDRESS_22934] is eligible to enter the Maintenance Phase (see Section 4.3, Criteria for 
Entry  Into the Maintenance Phase). If not eligible to enter the Maintenance Phase, the subject 
will be withdrawn from the study .  
If a subject was previously  treate d with oral paliperidone ER/PR tablets and had acceptable 
efficacy  and tolerability, then the Day 36 dose of PP1M may be based on the conversion 
provided in Table 2.If the previous dosage of oral paliperidone had insufficient efficacy , then 
the investigator may consider a higher dosage of PP1M. If the previous dosage of oral 
paliperidone caused problems with intolerability, then the investigator may consider a lower 
dosage of PP1M.
Table 2: Doses of Paliperidone ER/PR Tablets and PP1M Needed to Attain Similar Steady -state 
Paliperidone Exposure
Previous Paliperidone ER/PR Tablet, Once Daily PP1M Injection, Once Every 4 Weeks
12 mg 150 mg eq.
9mg 100 mg eq.
6 mg 75 mg eq.
3 mg 50 mg eq.
Key: ER/PR =extended -release/prolonged -release; mg eq . =(paliperidone palmitate) milligrams equivalent 
(to paliperidone) ; PP1M = paliperidone palmitate 1 -month (product ).
Source: Adapted from the [LOCATION_002] Prescribing Information for PP1M .ethe low est dose of PP1M is 
omitted because it is not relevant to this study .
Transition Phase: Subjects Previously Stabilized on Injectable Risperidone (Biweekly –
Risperdal CONSTA™ formulation, also named as RISPERDAL CONSTA 50 mg powder 
and solvent for prolonged -release suspension for injection formulation in certain countries)
In the Transition Phase, subjects previously  stabilized on injectable risperidone 50mg are not 
required to attend the Day [ADDRESS_22935]'s next planned injectable 
risperidone dose would have been administered (ie, 14±[ADDRESS_22936] prestud y dose) ,
PP1M 100mgeq. is administered instead. ( This conversion scheme is established in the 
                                                
eeINVEGA SUSTENNA®[[LOCATION_002] Prescribing Information]. Titusville, NJ: Janssen Research & Development. 
www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=02 2264 . Accessed 19June 2017.
R092670 (paliperidone palmitate)
Clinical Protocol R092670PSY3015 Amendment 3
72
Approved , Date: 11 February 2019prescribing information of some countries.f) Thereafter, the PP1M doseson Days 36, 64 , and92
will be flexibl e(50, 75, 100, or 150mgeq.), based on clinical judgment and shared decision-
making .Administration should be in the deltoid muscle onDay 8 and may be either in the 
deltoid or gluteal muscles on Day s36, 64, and 92, as shown in Table 3 and Table 4 .
After the PP3M prerandomization target is met, these subjects will skip Visit 2e and proceed to 
Visit 2f, if eligible to enter the Maintenance Phase (see Section 4.3, Criteria for Entry  Into the 
Maintenance Phase). If not eligible to enter the Maintenance Phase, the subject will be 
withdrawn from the study.
Transition Phase: Subjects Previously Initiated (But Not on a Stable Regimen ) With 
Moderate or Higher Doses of PP1M (Invega Sustenna ™ or Xeplion ™ formulation)
In the Transition Phase, subjects who enter edthe study  on PP1M as 100or 150mgeq., but who 
do not yet meet criteria for stabilization with those doses, are treated with additional doses of 
PP1M during the Transition Phase , as shown in Table 3and Table 4 .
After the PP3M prerandomization target is met, subjects previousl y initiated on PP1M (but not 
on a stable regimen) who enter the study  at Visit 2c or 2d will skip Visit 2e and proceed to Visit 
2f, if eligible to enter the Maintenance Phase (see Section 4.3, Criteria for Entry  Into the 
Maintenance Phase). Subjects with ≥4prest udy PP1M injections with the last 2 doses being the 
same strength will enter the study  at Visit 2f. Subjects with ≥4prestud y PP1M injections with 
the last 2 doses being different (ie, do not have dose stability ) will enter the study  at Visit 2e. If 
not el igible to enter the Maintenance Phase, the subject will be withdrawn from the study .
Owing to potential differences in release characteristics, only subjects who are taking Invega 
Sustenna ™ or Xeplion ™ PP1M formulations will be permitted to enter this phase of the study . 
Subjects who are taking non -branded formulations of once monthly  paliperidone LAI or other 
once monthly  LAIs will not be permitted to enter this phase.
                                                
fXEPLION®[European Union Product Information]. Beerse, Belgium: Janssen -Cilag International. 
www.ema.europa.eu/ema/index.jsp%3Fcurl%3Dpages/medicines/human/medicines/002105/human_med_001424.jsp. 
Accessed 19June 2017.
R092670 (paliperidone palmitate)
Clinical Protocol R092670PSY3015 Amendment 3
73
Approved , Date: 11 February 2019Table 3: Dosage and Administration Schedule for PP1M During the Transition Phase (Before Meeting the PP3M Prerandom ization Target) ;
Study R092670PSY3015
Phase Screening Transition; PP1M
Visit Number (of Study) 1 2a 2b 2c 2d 2e
Day (of Phase) a-28 to -2 1 8 36orEW 64orEW 92 or EWb
Visit Window, ±Days n/a ±3 ±7 ±7 ±7
PP1M after prestudy oral antipsychotic
   Treatment/doseLast prestudy dose of oral 
antipsychotic150mgeq. 100mgeq. 50,c75, 100,
or 150 mg eq.50,d75,d100,
or150mgeq.50,d75,d100,
or150mgeq.
   Injection site not applicable D D D or G D or G D or G
   Day (of participation)a-[ADDRESS_22937] 8th 36th 64th 92nd
PP1M after prestudy injectable risperidone
   Treatment/doseLast prestudy dose of injectable 
risperidone, 50 mgSkip 100mgeq.50, 75, 100,
or 150 mg eq.50,d75,d100,
or150mgeq.50,d75,d100,
or150mgeq.
   Injection site D or G Skip D D or G D or G D or G
   Day (of participation)a-14 to -2 Skip 1ste29th 57th 85th
PP1M after 2 prestudy PP1M injections
   Treatment/doseLast prestudy dose of PP1M, 
100or 150 mgeq.Skip Skip 100 or 150 mgeq. 100 to 150 mgeq. 100 to 150 mgeq.
   Injection site D or G Skip Skip D or G D or G D or G
   Day (of participation)a-28 to -2 Skip Skip 1stf29th 57th
PP1M after 3 prestudy PP1M injections
   Treatment/doseLast prestudy dose of PP1M, 
100or 150 mgeq.Skip Skip Skip 100 or 150 mgeq. 100 or 150 mgeq.
   Injection site D or G Skip Skip Skip D or G D or G
   Day (of participation)a-28 to -2 Skip Skip Skip 1stf29th
PP1M after ≥4prestudy PP1M injectionsg
   Treatment/doseLast prestudy dose of PP1M, 
100or 150 mgeq.Skip Skip Skip Skip 100 or 150 mgeq.
   Injection site D or G Skip Skip Skip Skip D or G
   Day (of participation)a-28 to -2 Skip Skip Skip Skip 1stf
(See Keys below Table 4)
R092670 (paliperidone palmitate)
Clinical Protocol R092670PSY3015 Amendment 3
74
Approved , Date: 11 February 2019Table 4: Dosage and Administration Schedule for PP1M During the Transition Phase (After Meeting the PP3M Prerandom ization Target) ; 
Study R092670PSY3015
Phase Screening Transition; PP1M
Visit Number (of Study) 1 2a 2b 2c 2d 2e
Day (of Phase) a-28 to -2 1 8 36 or EW 64 or EW 92 or EWb
Visit Window, ±Days n/a ±3 ±7 ±7 ±7
PP1M after prestudy oral antipsychotic
   Treatment/doseLast prestudy dose of oral 
antipsychotic150mgeq. 100mgeq. 50,c75, 100,
or 150 mgeq.50,d75,d100,
or150mgeq.
   Injection site not applicable D D D or G D or G
   Day (of participation)a-[ADDRESS_22938] 8th 36th 64th Skip
PP1M after prestudy injectable risperidone
   Treatment/doseLast prestudy dose of 
injectable risperidone, 50 mgSkip 100mgeq.50, 75, 100,
or 150 mgeq.50,d75,d100,
or150mgeq.
   Injection site D or G Skip D D or G D or G
   Day (of participation)a-14 to -2 Skip 1ste29th 57th Skip
PP1M after 2 prestudy PP1M injections
   Treatment/doseLast prestudy dose of PP1M, 
100or 150 mgeq.Skip Skip 100 or 150 mgeq. 100 to 150 mgeq. 
   Injection site D or G Skip Skip D or G D or G
   Day (of participation)a-28 to -2 Skip Skip 1stf29th Skip
PP1M after 3 prestudy PP1M injections
   Treatment/doseLast prestudy dose of PP1M, 
100or 150 mgeq.Skip Skip Skip 100 or 150 mgeq.
   Injection site D or G Skip Skip Skip D or G
   Day (of participation)a-28 to -2 Skip Skip Skip 1stfSkip
PP1M after ≥4prestudy PP1M injections g
   Treatment/doseLast prestudy dose of PP1M, 
100or 150 mgeq.Skip Skip Skip SkipSkip or 100 or 
150mgeq.
   Injection site D or G Skip Skip Skip Skip D or G
   Day (of participation)a-28 to -2 Skip Skip Skip Skip 1stf
R092670 (paliperidone palmitate)
Clinical Protocol R092670PSY3015 Amendment 3
75
Approved , Date: 11 February 2019Keys for Table 3 and Table 4 : D = deltoid muscle; EW = Early Withdrawal; G = gluteal muscle; mg eq. = (paliperidone palmitate) milligrams equivalent (to paliperidone); 
PP1M =paliperidone palmitate 1 -month (formulation).
aBecause some subjects skip visits during the Transition Phase, the day of the phase will not match the day of a subject's par ticipation in all cases, as shown in this table.
bDose flexibility is permitted at this visit in order to accommo date individual needs for efficacy and tolerability, but if the dose at Day [ADDRESS_22939] will later be ineligible to proceed to the next phase, as described in Section 4.3(Criteria for Entry Into the Maintenance Phase). If the dose at Day [ADDRESS_22940] the Day 92 visit as an Early Withdrawal Visit. See Section 10.2
(Discontinuation of Study Drug / Withdrawal From the St udy).
cThe [ADDRESS_22941] is 
unlikely to later achieve the 100 or 150 mg eq. dose required for eligibility to proceed to the next phase, as described in Section 4.3(Criteria for Entry Into the Maintenance Phase). If 
the [ADDRESS_22942] the visit as an Early Withdrawal Visit. See 
Section 10.2 (Discontinuation of Study Drug /Withdrawal From the Study).
dThe 50 and 75 mgeq. doses are permitted at these visits in order to accommodate individual needs for efficacy and tolerability, but use of th ese doses at these visit s shows that subjects 
will later be ineligible to proceed to the next phase, as described in Section 4.3(Criteria for Entry Into the Maintenance Phase). If these doses are administered, then study-site 
personnel should anticipate the future ineligibility of the subject and should conduct the visit as an Early Withdrawal Visit .See Section 10.2 (Discontinuation of Study Drug /
Withdrawal From the Study).
eThis visit should be scheduled to match the subject's next planned injectable risperidone dose (ie, 14±[ADDRESS_22943] prestudy dose).
fThis visit should be scheduled to match the subject's next planned PP1M dose (ie, 30±[ADDRESS_22944] prestudy dose).
gSubjects with ≥4prestudy PP1M injections may be eligible to skip the Transition Phase and proceed from the Screening Phase direct ly to the Maintenance Phase, if they have already 
achieved dose stability as described in Section 4.3(Criteria for Entry Into the Maintenance Phas e). If they have not , then the dose in this Transition Phase can be used to establish dose 
stability.
R092670 (paliperidone palmitate)
Clinical Protocol R092670PSY3015 Amendment 3
76
Approved , Date: [ADDRESS_22945]'s Maintenance Phase dose will bematched by 
[CONTACT_23767] (PP1M to PP1M, or PP3M to PP3M) or will be matched by 
[CONTACT_23768] (PP1M to PP3M) to the same dose that they had been receiving during 
the Screening Phase or at the end of the Transition Phas e. Progression versus conversion will 
depend on prestud y treatment types and on the need to balance the PP1M and PP3M groups in 
the Maintenance Phase, as described below.
To properl y characterize outcomes when switching to PP6M from either PP1M or PP3M, 
adequate numbers of subjects treated with either PP1M or PP3M must be available during the 
Maintenance Phase for randomiza tion to the Double -blind Phase. However, low enrollment of 
subject s previously  treated with PP3M is expected. To address this issue, some subjects (after 
appropriate treatment with PP1M) will be switched to PP3M during the Maintenance Phase . This 
will occur early in the course of the study , until the target of approximat ely one-halfofthe total 
Maintenance Phase sample is treated with PP3M. In this document, the target is referred to as the 
"PP3M prerandomization target." The process is described in more detail below and is shown in 
Figure 3and Figure 4.
Throughout the study, subjects who were receiving PP3M as 350or 525mgeq. before the 
study  will receive the same formulation and strength in the Maintenance Phase.
Early in the study (before the PP3M prerandomization target ismet), subjects with 
PP1M stability  achieved before the study  or during the Transition Phase will be converted to 
PP3M in the Maintenance Phase in accordance with the approved prescribing information. 
That is, subjects who were receiving PP1M as 100or 150mgeq. will receive PP3M as 
350or 525mgeq.See Figure 3. The Sponsor will inform sites when they should stop using 
this pathway .
Later in the study (after the PP3M prerandomization target ismet), s ubjects with PP1M 
stability  achieve d before the study  or during the Transition Phase will progress with PP1M
in the Maintenance Phase .That is, subjects who were receiving PP1M as 100or 150mgeq. 
will again receive PP1M as 100or 150mgeq. SeeFigure 4The Sponsor will inform sites 
when they  should start using this pathway .
For subjects who enter the study  with previous PP1M or PP3M stability , the dose in the 
Maintenance Phase should be adm inistered with timing appropriate to the subject's last prestud y 
dose (ie, 30±7days after the last prestudy  PP1M dose, or 90±14daysafter the last prestud y 
PP3M dose).In order to appropriatel y balance the number of PP1M and PP3M subjects in the 
Maintena nce Phase and to complete the study  in a timely  manner, the pathway  to study  
enrollment that includes subjects who enter the study  with previous PP3M stability  will be open 
for only a  limited time. The Sponsor will inform the sites when this pathway  hasclosed to 
enrollment.
R092670 (paliperidone palmitate)
Clinical Protocol R092670PSY3015 Amendment 3
77
Approved , Date: [ADDRESS_22946]'s last 
dose in the preceding Transition Phase (ie, 28±3 days after previous PP1M dose ).
See also Section 6.2.1 (Administration During the Open -label Phases).
R092670 (paliperidone palmitate)
Clinical Protocol R092670PSY3015 Amendment 3
78
Approved , Date: 11 February 2019Figure 3: Schem atic Overview, Showing Additional Details for the Maintenance Phase (Before Meeting the PP3M Prerandom ization Target); 
Study R092670PSY3015
Key: mg eq . =(paliperidone palmitate) milligrams equivalent (to paliperidone); PP1M =paliperidone palmitate 1 -month (product); PP3M =paliperidone palmitate 3 -month 
(product); PP6M =paliperidone palmitate 6-month (product).
Note: See Figure 1and Figure 2for other relevant explanatory notes.
Note: The grayed -out treatment pathway  in the Maintenance Phase is not applicable before the meeting the PP3M prerandomization target, but is shown here for consistency  
with other figures, especially  Figure 4.Of subjects entering the Double -blind Phase, the prerandomization targets are approximately one- halfentering from a PP3M group, 
and one-halfentering from a PP1M group.

R092670 (paliperidone palmitate)
Clinical Protocol R092670PSY3015 Amendment 3
79
Approved , Date: 11 February 2019Figure 4:Schematic Overview, Showing Additional Details for the Maintenance Phase ( After Meeting the PP3M Prerandom ization Target); 
Study R092670PSY3015
Key: mg eq . =(paliperidone palmitate) milligrams equivalent (to paliperidone); PP1M =paliperidone palmitate 1 -month ( product ); PP3M =paliperidone palmitate 
3-month ( product ); PP6M =paliperidone palmitate 6-month ( product ).
Note: See Figure 1and Figure 2for other relevant explanatory notes .
Note: Of subjects entering the Double -blind Phase, the prerandomization targets are approximately one -half entering from a PP3M group, and one-halfentering from a 
PP1M group.

R092670 (paliperidone palmitate)
Clinical Protocol R092670PSY3015 Amendment 3
80
Approved , Date: 11 February [ZIP_CODE].1.4. Double -blind Phas e
The PP1M and PP3M dose levels that were administered in the Maintenance Phase will be 
converted to PP3M or PP6M dose levels for the Double -blind Phase as follows:
For the active control group,
The open -label PP1M doses (100or 150mgeq.) will be converted to double -blind PP3M doses 
(350 or 525 mgeq.)in accordance with the approved prescribing information for PP3M.
The open -label PP3M doses (350 or 525mgeq.) will continue at the same double -blind dose 
level.
For the investigational drug group,
The open -label 100mgeq. PP1M and 350mgeq. PP3M doses will be converted to double -blind 
700mgeq. PP6M doses.
The open -label 150mgeq. PP1M and 525mgeq. PP3M doses will be converted to doub le-blind 
1000 mgeq.PP6M doses .
To maintain the blind, the subjects who areassigned to treatment with PP6M will receive 
injections of placebo at the 3-month time point s between their 6-month doses of investigational
drug. The placebo is 20% Intralipid®(200mg/mL) injectable emulsion. Therefore, the 12month 
Double- blind Phase should include a total of 4doses at 3-month intervals, no matter which 
treatment group .
Conversions between doses are summarized in Table 1. The actual dates and times of each study  
drug administration will be recorded in the eCRF.
6.1.5. Treatment After the Study or in the Follow -up Phase
See Section 10.3 (Antipsy chotic Therap y After the Study  or in the Follow -up Phase ).Such 
treatments are nonstudy  treatments and therefore are not described here.
6.2. Administration
For each dose, a stud y-site personnel member must shake the s yringe vigorously with the tip 
facing up and with a loose wrist for at least [ADDRESS_22947] 15 seconds to resuspend the dose .The full content is to be 
administered in one injection, using only  the supplies provided in the study  drug kit.
6.2.1. Administration During the Open -label Phases
During the Transition Phase and Maintenance Phase , injections will be in the deltoid orgluteal 
muscles in accordance with the prescribing information for PP1M or PP3M, and will use 
injection kits equivalent to commerciall y available kits.For the Transition Phase, see also 
Table 3and Table 4for more information about sites (deltoid or gluteal) .For the Maintenance 
Phase, the injection may be in the deltoid or gluteal muscle (note: Day 1 injection should not be 
R092670 (paliperidone palmitate)
Clinical Protocol R092670PSY3015 Amendment 3
81
Approved , Date: [ADDRESS_22948] injection) , but may not be in the left gluteal muscle 
(because of the anticipated left gluteal injection at the beginning of the Double- blind Phase, as 
shown in Table 5).
6.2.2. Administration During the Double -blind Phase
During the Double- blind Phase, injections will be in the gluteal muscles only, will use study -
specific injection kits, and will rotate across sides of the body as described inTable 5 .
Table 5: Administration of Study Agent During the Double -blind Phase; Study R092670PSY3015
Time Point in
Double -blind Phase Day [ADDRESS_22949] Fourth
Active Control Groups
   Agent PP3M PP3M PP3M PP3M
   Body side Left Right Right Left
Investigational Groups 
   Agent PP6M Placebo PP6M Placebo
   Body side Left Right Right Left
Key: PP3M = paliperidone palmitate 3 month (product); PP6M = paliperidone palmitate 6 month (product).
Note: All administrations are gluteal during the Double -blind Phase.
See Attachment 1for more details about administration during the Double -blind Phase .
7. TREA TMENT COMPLIA NCE
The study  drug administrator will administer the injections throughout the study  and will record 
the date/time of dosing as well as the injection site (right or left side, and deltoid or gluteal 
muscle) in the eCRF.
8. PRESTUDY AND CONCOMITA NT THERAPY
8.1. Prestudy  Medical Therapy  and Psy chotherapy
Except as described in Section 4.2 (Exclusion Criteria), Section 4.5 (Prohibitions and 
Restrictions) , Section 8.2(Concomitant Therapy), and Section 8.3(Prohibited Concomitant 
Medications), medications that are ongoing and stable at screening may be allowed to continue
thereafter into the study . Ongoing ps ychotherapy and other psychosocial interventions are 
allowed to continue .For psy chiatric medications of special interest at study  entry :
Antipsy chotics: Other than PP1M or PP3M, no concomitant antipsy chotic medications being 
used at screening are allowed to continue. Oral antipsy chotics, including those being taken 
concomitantly  with PP1M or PP3M, should be tapered and discontinued during the 
Screening Phase , with the last oral dose swallowed on or before Day -1. The appropriate
tapering and washout schedule is at the discretion ofthe treating physician. Note that 
subjects who enter the study  on oral antips ychotic(s) alone (without PP1M or PP3M being 
used concomitantly )must have a valid reason to discontinue the oral antipsy chotic(s), such 
R092670 (paliperidone palmitate)
Clinical Protocol R092670PSY3015 Amendment 3
82
Approved , Date: 11 February 2019as problems with efficacy , safety, or tolerability , or preference for a LAI medication, as 
described in Section 4.1(Inclusion Criteria).
Other psychiatric medications: Other medications taken for the treatment of psychiatric 
conditions are allowed at screening and to continue thereafter .
It is preferable that no changes have been made to any treatments (for psychiatric or other 
medical conditions) in the 30 days before screening .
8.2. Concomitant Therap y
All therapi[INVESTIGATOR_014] (prescription or over-the-counter medications, including vaccines, vitamins, herbal 
supplements; nonpharmacologic therapi[INVESTIGATOR_23719], acupuncture, special 
diets, exercise regimens) administered and/or used within [ADDRESS_22950] prestud y dose would be 90±14daysprior to the first study  drug 
dose, so its last date of administration must be recorded, even if >[ADDRESS_22951] into the study .
Except as listed in Section 4.2(Exclusion Criteria) and Section 8.3(Prohibited Concomitant 
Medications) , concomitant medications may be initiated during the study  for medical or 
psychiatric reasons. New psy chotherapi[INVESTIGATOR_23720].
Anti- EPS medications: For antiparkinsonism medications, initiations or changes should be 
preceded by [CONTACT_23772], BARS, and SAS (even if not designated per Time and Events
Schedules ). If beta-adrenergic blockers or benzodiazepi[INVESTIGATOR_23704], then 
initiations or changes should be preceded by a BARS (even if not designated per Time and 
Events Schedules ).See Section 9.4.6 (Extrapy ramidal Symptoms). The use of anti-EPS 
medications should be re-evaluated at regular intervals, and investigators and subjects 
should work together to lower and discontinue doses if clinically  indicated.
Benzodiazepi[INVESTIGATOR_1651]: For the control of agitation , anxiety , akathisia, etc, lorazepam is the 
preferred benzodiazepi[INVESTIGATOR_23721]-drug interactions and its 
relativel y short half-life. If lorazepam is unavailable, then another equivalent short -acting 
benzodiazepi[INVESTIGATOR_23722]; examples of allowed types and dosages are shown inTable 6, 
and others are similarly  allowed per clinical judgment . Long-acting benzodiazepi[INVESTIGATOR_1651]
(specifically , chlordiazepoxide, flurazepam, diazepam, and clorazepate )are prohibited. 
Investigators are encouraged to use the lowest dose of benzodiazepi[INVESTIGATOR_23723] . Benzodiazepi[INVESTIGATOR_23724] 8hours preceding anyscheduled 
efficacy  assessment or rating scale. If clinically  needed, an injectable (intramuscular or 
intravenous) dose of lorazepam may be given through the first 4weeks of study 
participation.
If benzodiazepi[INVESTIGATOR_23725] y during the Screening Phase, then the benzodiazepi[INVESTIGATOR_23726] 6. Use 
of benzodiazepi[INVESTIGATOR_23727] .
R092670 (paliperidone palmitate)
Clinical Protocol R092670PSY3015 Amendment 3
83
Approved , Date: 11 February 2019Table 6: Maximum Allowable Benzodiazepi[INVESTIGATOR_23693]; Study R092670PSY3015
Benzodiazepi[INVESTIGATOR_23728], m gMaximum Daily Dosage ( mg/day)
Screening Phase and 
First [ADDRESS_22952] (even if unscheduled), as described in Section [IP_ADDRESS]
(Barnes Akathisia Rating Scale).
Sleep aids: For insomnia or sleep -related difficulties, subjects may use zolpi[INVESTIGATOR_6730], zaleplon ,
zopi[INVESTIGATOR_11123] , or eszopi[INVESTIGATOR_23729] . The frequency  should not exceed once daily  and the duration should not exceed 
7 consecutive days without reasse ssme nt. Sleep aid medications should not be used in the
8hours preceding an yscheduled efficacy  assessment or rating scale.
8.3. Prohibited Concomitant Medications
The concomitant medications described below may not be used during the study .
Concomitant oral and injectable antipsy chotics are prohibited as follows :
After the Screening Phase, oral or injectable risperidone formulations and supplementary  oral or 
injectable paliperidone formulations are prohibited.
During the Maintenance Phase, if any oral antipsy chotic is required, then the subject is not 
eligible to continue to randomization.
During the Double -blind Phase, if any oral antipsy chotic is required, then the subject should be 
evaluated according to parameters in Section [IP_ADDRESS] (Relapse Criteria).
During any phase (including the Screening Phase, during determination of eligibility ), injectable
formulations of neuroleptic drugs based on active ingredients other than risperidone or 
paliperidone (eg, haloperidol decanoate, fluphenazine decanoate, etc)are prohibited .
Concomitant a ntipsy chotics are prohibited even if they  are used for nonpsychotic indications (eg, 
nausea, sleep, depression, etc) .
Although concomitant antipsy chotics are prohibited during the study  as described above, these
medication smay be initiated at the discretion of the investigator if considered necessary  for the 
safet y or wellbeing of the subject . If a concomitant antipsy chotic is initi ated, then:
oSection [IP_ADDRESS] (Relapse Criteria) is relevant if the subject is completing the study 
related to the need for an antipsy chotic, or
oSection 10.2 (Discontinuation of Study  Drug / Withdrawal From the Study ) is 
relevant if the subject is withdrawing from the study  related to the need for an 
antipsy chotic.
R092670 (paliperidone palmitate)
Clinical Protocol R092670PSY3015 Amendment 3
84
Approved , Date: 11 February 2019Medicinal products known to prolong the QT interval -such as Class IA antiarrhy thmics 
(eg, disopy ramide , quinidine, or procainamide ) and Class III antiarrhy thmics (eg, 
amiodarone orsotalol) ;some antihistamines; some antibiotics (eg, fluoroquinolones like 
moxifloxacin or ciprofloxacin); some antimalarials (eg, mefloquine ); and some 
antipsy chotics (eg, chlorpromazine or ziprasidone )and tricyclic anti-depressants are 
prohibited. (All concomitant antipsy chotics are prohibited for reasons related to assessment 
of efficacy as described in the bullet points above, but antips ychotics that prolong the QT 
interval are specifically  restated here due to relevance to safety .)
Inducers of proteins involved in the metabolism of paliperidone (ie, cytochrome P450 3A4) 
or the excretion of paliperidone (ie, p-glycoprotein) -such asrifampi[INVESTIGATOR_2513], carbamazepi[INVESTIGATOR_050], 
oxcarbazepi[INVESTIGATOR_050], barbiturates, phen ytoin, troglitazone, and St. John' s Wort -are prohibited.
Systemic antifungals are prohibited .
Antineoplastic agents are prohibited .
Medical marijuana is prohibited .
Long -acting benzodiazepi[INVESTIGATOR_050] s (specifically , chlordiazepoxide, flurazepam, diazepam, and 
clorazepate )are prohibited.
Mood stabilizers and anticonvulsants including, but not limited to: lithium, valproate, 
lamotrigine, carbamazepi[INVESTIGATOR_050], phen ytoin, and gabapentin.
Antidepressants not taken at a stable dosage for 30 days before screening, and all 
nonselective/irreversible MAOI s. Throughout the study , an antidepressant (other than a 
nonselective MAOI) may be initiated in rare circumstances only after consultation with the 
Medical Monitor.
Any prescription, herbal, or over-the-counter agents with psychotropic actions, including 
any substances with stimulant and cognitive -enhancing properties.
Dopamine agonists, including, but not limited to: ropi[INVESTIGATOR_11122], pramipexole, pergolide, 
cabergoline, lisu rideand amantadine.
Nonantipsy chotic dopamine antagonists, including, but not limited to, antiemetic 
medications with dopamine-blocking activity.
The Sponsor must be notified in advance (or as soon as possible thereafter) of any instances in 
which prohibi ted therapi[INVESTIGATOR_23730].
9. STUDY EVA LUATIONS
9.1. Study Procedures
Overview
The Time and Events Schedule ssummarize the frequency  and timing of measurements 
applicable to this study . If multiple assessments are scheduled for the same visit , then ECG and 
vital signs should be collected prior to blood sample collections (eg,PK, and/or laboratory  tests) 
and blood sample collections should be collected prior to study  drug injection . Evaluations of the 
injection site occur after study  drug injection, as descr ibed in Section 9.4.8 . Actua l dates and 
times of assessments will be recorded in the source documentation.
R092670 (paliperidone palmitate)
Clinical Protocol R092670PSY3015 Amendment 3
85
Approved , Date: [ADDRESS_22953]'s participation in 
the study .
For any 6months of participation inthe study , the total blood volume to be collected from each 
subject is expected to be less than 400mL.Repeat or unscheduled samples may be taken for 
safet y reasons or for technical issues with the samples.
Screening Phase
Screening procedures are outlined in the Time and Events Schedule sand in associated text 
descriptions. For exclusion criteria relating to safety  parameters, rescreening is not allowed, but 
retesting may be permitted, as described in Section 4(Subject Population). For inclusion criteria 
related to prestudy  medication parameters, rescreening is permitted once, as described in 
Section 4(Subject Population).
Transition Phase
The Transition Phase is applicable only to subjects who entered the Screening Phase without 
previous PP1M or PP3M stability . These subjects may have been previously  treated with oral 
antipsy chotics, injectable risperidone , or a moderate or higher dose of PP1M with previous 
initiation but without previous stabilizatio n (where stabilization is defined is at least 3months of 
injections with the last 2doses being the same strengt h).During this phase, subjects will be 
initiate dand/orstabilized on PP1M, as shown in the relevant Time and Events Schedule and in 
associated text descriptions. At the end of this phase, subjects with adequate efficacy  and 
tolerability  on PP1M as 100or 150mgeq. may be eligible to continue to the Maintenance Phase
(see Section 4.3[Criteria for Entry  Into the Maintenance Phase]) ; subjects receiving PP1M as 
50or 75mgeq. will exit the study .If possible, the subject 's identified support person should 
accompan y the subject to the first visit in this phase.
Maintenance Phase
The procedures for the Maintenance Phase are outlined in the Time and Events Schedule sand in 
associated text descriptions. At the end of this phase, subjects who do not meet the criteria for 
randomization (see Section 4.4[Criteria for Entry Into the Double- blind Phase]) must withdraw 
from thestudy  and have End-of- Phase Visit / Early  Withdrawal Visit assessments performed ,as 
outlined in the Time and Events Schedule s.For subjects who did not take part in the Transition 
Phase, the subject 's identified support person should accompan y the subject to the first visit in 
this phase, if possible.
Double -blind Phase
The procedures for the Double -blind Phase are outlined in the Time and Events Schedule sand in 
associated text descriptions. During this phase, investigators should asksubjects to return to the 
clinical site for unscheduled visits as required for any assessment of symptom worsening or 
possible adverse events. If a possible relapse is detected per PANSS criteria at a scheduled or 
unscheduled visit, as described inSection [IP_ADDRESS] (Relapse Criteria) , then theinvestigator should 
R092670 (paliperidone palmitate)
Clinical Protocol R092670PSY3015 Amendment 3
86
Approved , Date: [ADDRESS_22954] to visit the clinical site 3to 7days later for a PANSS reassessment (if no such 
visit is already scheduled) .Suspected relap ses should prompt all of the following assessments at 
all associated clinic visits , even if not designated on the Time and Events Schedule s:
A PK sampl e, per Section 9.3.1 (Pharmacokinetic Evaluations) ,
A full PANSS assessment , per Section 9.2.2 (Positive and Negative Sy ndrome Scale),
A CGI -S assessment, per Section 9.2.3 (Clinical Global I mpression -Severity ), 
A Columbia Suicide Severity  Rating Scale (C-SSRS )assessment , per Section 9.4.7
(Columbia Suicide Severity  Rating Scale) , and
Testing for concomitant substances (both an alcohol breath test anda urine drug screen for 
illicit substances), per Section 9.4.2 (Clinical L aboratory  Tests).
The EOP visit is to occur as soon as possible after relapse confirmation (preferabl y the same 
day).
Follow -up Phase
The procedures for the Follow -upPhase are outlined in the Time and Events Schedule sand in 
associated text description s. The Follow -up Phase, when applicable, is supplementary  after study  
completion. For relevant subjects, participation in the Follow -up Phase is encouraged but not 
required. No protocol deviations or violations are applicable during this phase. The Follow -up 
Phase is designed to be as low-burden and noninvasive as possible , in order to encourage 
participation by [CONTACT_23796].
Accordingl y during the Follow -up Phase, suspected relapses do not prompt the additional 
breadth of assessments (as described for the Double -blind Phase above), but should prompt the 
additional frequ ency  of assessments if relevant (ie, if PANSS scores indicate potential relapse, 
then PA NSS assessments should repeated 3 to 7days later to confirm a relapse event).
9.2. Efficacy  Evaluations
9.2.1. Qualified Raters
Only  a qualified rater may  administer the PANSS, CG I-S, and PSP scale s. If possible, for a given 
subject, the same rater should administer the scale sat all visits.
A qualified rater must be locally  licensed to practice, alone or under supervision, in one of the 
following disciplines:
Psychiatry  (eg, MD or DO), or
Senior Psy chiatry  Resident (eg, MD or DO) who fulfills the other requirements, or
Psychology  (eg, PhD), or
Clinical specialty  (at least a Master's degree; eg, MS or PhD) where patient care is a central 
component (eg, social work, counseling, psychology , nurse practitioner) and the practitioner 
is independently  licensed.
R092670 (paliperidone palmitate)
Clinical Protocol R092670PSY3015 Amendment 3
87
Approved , Date: [ADDRESS_22955] had:
Recent experience in performing PANSS ratings in psy chiatry  clinical studies,gand
At least 3 years of experience in evaluating pati ents with schizophrenia in an inpatient or 
outpatient setting, and
Qualification training in performing PANSS assessments (per certification by [CONTACT_1034]) 
and CGI -S assessments (per training by  [CONTACT_1034]), and
Overall completion of the Sponsor' s rater training.
9.2.2. Positive and Negative Sy ndrome Scale
Full PANSS
The neurops ychiatric symptoms of schizophrenia will be assessed using the 30-item PANSS 
scale,20which provides a total score (sum of the scores for all 30 items) and scores for 
3subscales: the 7-item positive -symptom (P) subscale, the 7-item negative -symptom (N) 
subscale, and the 16 -item general -psychopathology symptom (G) subscale. Each item is rated on 
a scale from 1 (absent) to 7(extreme). A trained clinician experienced in the treatment of 
subjects with schizophrenia will administer the PANSS. An example of a full PANSS is 
provided in the Manual of Assessments. A full PANSS score should be administered at the time 
points indicated in the Time and Events Schedules, and at any clinic visit associated with a 
suspected relapse ; see Section [IP_ADDRESS] (Relapse Criteria) . The full PANSS should be administered 
using the Structured Clinical Interview (SCI -PANSS) format, or using an equivalent structured 
interview format to be provided by  [CONTACT_1034].
Abbreviated PANSS
At some time points (indicated in the Time and Event sSchedule), an abbreviated form of the 
PANSS will be used to assess for change in symptoms. An abbreviated PANSS consists of the 
positive -symptom items P1(delu sions), P2(conceptual disorganization), P3(hallucinatory 
behavior), P6(susp iciousness/persecution), and P7(hostility ), and the general -psychopathology
item G8 (uncooperativeness). If the abbreviated PANSS indicates worsening since the last full 
PANSS assessment or if the subject meets one or more symptom criterion for relapse, then the 
full PANSS should be administered (as the SCI-PANSS). For abbreviated PANSS assessments, 
raters should use the relevant questions from the SCI -PANSS or equivalent format.
9.2.3. Clinic al Global Impression -Severity
The CGI-S is included in the Early  Clinical Development Evaluation Unit Assessment Manual 
that was published by [CONTACT_23797] (NIMH).13This study  uses a 
versi on of the CGI -S that is slightly  modified from the original (to be more specific to psy chosis, 
not general for mental illness) , as was done in the Sponsor's other studies.8,9Thismodified 
                                                
gIf a rater meets all criter iaexcept the experience requirement, and is a subinvestigator at a study site where an
investigator does meet the experience requirement , then the experience requirement can be w aived for the 
subinvestigator, in order to facilitate training of raters.
R092670 (paliperidone palmitate)
Clinical Protocol R092670PSY3015 Amendment 3
88
Approved , Date: [ADDRESS_22956]'s psychotic disorder on a 
scale from 1 =not ill to 7 =extremely  severe, as shown in the Manual of Assessments .A CGI-S 
score should be recorded at the time points indicated in the Time and Events Schedules, and at 
any clinic visit associated with a suspected relapse .
9.2.4. Personal and Social Performance Scale
The PSP scale assesses the degree of dysfunction a subject exhibits within 4 domains of 
behavior: (a) socially useful activities, (b) personal and social relationships, (c) self-care, and (d) 
disturbing and aggressive behavior. The results of the assessment are converted to a numerical 
score from 1 to 100 points, which can be interpreted in 10-point intervals as excellent 
functioning (91to 100 points), good functioning (81 to 90 points), mild difficulties (71 to 
80points), etc, as shown in the Manual of Assessments . Scores from 31 to 70 points indicate 
varying degrees of difficulty , and scores below 30 point s indicate functioning so poor that 
intensive support or supervision is needed.29Individual domain items of the PSP will be 
collected and recorded in the eCRF .
9.2.5. Satisfaction With Participation in Social Roles
The Patient- Reported Outcomes Measurement Information System (PROMI S) group developed 
and evaluated the Satisfaction With Participation in Social Roles Short Form 8a (SPSR) with 
funding from theUS National Institutes of Health (NIH) and other academic and research 
grants .14A study  in a diverse clinical population demonstrated the SPSR's responsiveness to 
change .14The SPSR asks subjects to consider the past 7days and to rate 8items on 5 -point 
Likert scales, with higher scores representing higher satisfaction. An example of the SPSR is 
provided in the Manual of Assessments.
Note: For subjects that require translation of the SPSR into their local language, the collection of 
the SPSR is optional until the final, approved translation is available.
9.2.6. Abbrev iated Treatment Satisfaction Questionnaire for Medication
The 9-item abbreviated Treatment Satisfaction Questionnaire for Medication (TSQM -9) was 
found to be a reliable and valid measure to assess treatment satisfaction in naturalistic study  
designs.5Items are scored on 5-or 7-point Likert scale s, with higher scores representing higher 
satisfaction. Subjects are asked to consider the time frame of the last 2 to 3 weeks, or since the 
lasttime the medication was used.An example of the TSQM -9 is provided in the Manual of 
Assessments.
9.3. Pharmacokinetic and Pharmacody namic Evaluations
9.3.1. Pharmacokinetic Evaluations
Venous blood samples of approximately  4mL will be collected to obtain approximate ly 2mL of 
plasma, for measurement of plasma concentrations of paliperidone (and on selected samples, 
paliperidone palmitate )at the time points indicated in the Time and Events Schedule s.During 
the study , the nominal sample collection times may be changed by [CONTACT_23798] 
R092670 (paliperidone palmitate)
Clinical Protocol R092670PSY3015 Amendment 3
89
Approved , Date: [ADDRESS_22957] be 
recorded on the laboratory  requisition form. Information about the collection, handling, and 
shipment of biological (PK) samples will be provided in a Laboratory  Manual . Genetic analyses 
will not be performed on these PK samples. Subj ect confidentiality  will be maintained.
The aim of thePK evaluations will beto characterize the time course of plasma paliperidone 
concentrations and PK parameters such as maximum and minimum plasma concentrations and 
timing . Therefore, 3PK samples are scheduled weekl y around the expected paliperidone peak at 
approximately  [ADDRESS_22958] unscheduled PK samples associated with important efficacy  or safety  events, as follows:
If a relapse event occurs or is suspected ,as defined in Section [IP_ADDRESS] (Relapse Criteria),
then a PK sample should be collected in associat ionwith this efficacy  outcome.
If a serious or severe adverse event occurs, then a PK sample should be collected in 
associ ation with this safety  outcome.
At the investigator's discretion, an unscheduled PK sample related to an adverse event 
may be collected even if the event is not serious or severe.
To preserve the treatment blind, the results of any PK sample swill not be revealed to the 
Sponsor or the study -site personnel (until use by [CONTACT_23799] -blinded interim PK analy sis and then by  [CONTACT_23800]).
9.3.2. Analytical Procedures
Plasma samples will be analy zed to determine concentrations of paliperidone at all indicated 
time points (and paliperidone palmitate at 2days after injections) using a validated, specific, and 
sensitive method ( eg,liquid chromatograph ywith tandem mass s pectrometry ),by [CONTACT_23801]. If deemed necessary  to explain the study  results, drug concentrations 
may be determined for paliperidone palmitate (at time points in addition to 2days after 
injections), for paliperidone enantiome rs, or for other antips ychotics (such as risperidone).
9.3.3. Pharmacokinetic Parameters
Based on the individual plasma concentration- time data, using the actual dose taken and the 
actual sampling times, PK parameters and exposure information ofpaliperidone willbe derived 
using population PKmodeling. Baseline covariates (eg, body  weight, age, sex, creatinine 
clearance , race) may be included in the model, if relevant. The PK analy ses will be detailed in 
R092670 (paliperidone palmitate)
Clinical Protocol R092670PSY3015 Amendment 3
90
Approved , Date: 11 February 2019one or more separate methods plans (outside the standard SAP) and one or more separate results 
reports (outside the standard Clinical Study  Report [CSR]).
9.3.4. Pharmacody namic Evaluations
Samples collected for PK evaluations may also be used for pharmacod ynamic (PD)evaluations. 
For safet y outcomes, pharmacokinetic -pharmacody namic (PK-PD) relationships may be 
evaluated in terms of any potential clustering of adverse events around the time of the maximum
plasma paliperidone concentration after a dose of PP6M. For efficacy  outcomes such as relapse , 
PK-PD relationships m aybe evaluated, if appropriate. Any PK/PD analy ses would be performed 
after database lock. The PK-PD analysesmay be detailed in one or more separate methods plans 
(outside the standard SAP) and one or more separate results reports (outside the standard CSR ).
9.4. Safety  Evaluations
Any clinically  relevant changes occurring during the study  must be recorded on the Adverse 
Event section of the eCRF. Any clinicall y significant abnormalities persisting at the end of the 
study /early  withdrawal will be followed by [CONTACT_23802] a clinically  
stable endpoint is reached.
The study  will include evaluations of safet y and tolerability as described below andaccording to 
the time points provided in the Time and Events Schedule s.
9.4.1. Adverse Events
Adverse events will be reported by [CONTACT_423] (or, when appropriate, by a caregiver, surrogate, 
or the subject's legall y acceptable representative) for the duration of the study . Adverse events 
will be followed by  [CONTACT_23803] 12(Adverse Event Reporting).
9.4.2. Clinical Laboratory  Tests
Blood samples for serum chemistry  and hematology  and urine samples for urinal ysis will be 
collected. The investigator must review the laboratory  results, document this review, and record 
any clinically  relevant changes occurring during the study  in the adverse event section of the 
eCRF. The laboratory  reports (except for prolactin results, which are blinded to study -site 
personnel and Sponsor ) must be filed with the source documents.
The tests below will be performed by  [CONTACT_2237] .For full panels, subjects should be in 
fasted state overnight or for at least 8 hours (and nonfasting exceptions should be noted) . For the 
prolactin -only samples, fasting is not required. Information about the collection, handling, and 
shipment of biological (laboratory  test) samples will be provided in a Laboratory  Manual.
R092670 (paliperidone palmitate)
Clinical Protocol R092670PSY3015 Amendment 3
91
Approved , Date: 11 February 2019Hematology Panel
-hemoglobin -red blood cell count
-hematocrit -white blood cell count with differential
-platelet count -hemoglobin A1c (onl y during the Screening 
Phase and the Double -blind Phase )
Serum Chemistry Panel
-sodium -bilirubin
-potassium - alkaline phosphatase
-chloride -creatine phosphokinase
- bicarbonate -lactic acid deh ydrogenase
-blood urea nitrogen - uric acid
-creatinine -calcium
-glucose -phosphate
- aspartate aminotransferase -albumin
-alanine aminotransferase - total protein
-gamma -glutam yltransferase -magnesium
 
- prolactin, which will be blinded to the study -site personnel and Sponsor ; some samples 
will be for prolactin onl y (not the other analytes listed above), as designated in the Time 
and Events Schedule s.
-thyroid stimulating hormone .
Urinalysis
Dipstick Sediment (performed if dipstick result is abnormal)
-specific gravit y -red blood cells
- pH -white blood cells
-glucose -epi[INVESTIGATOR_1663]
-protein -crystals
-blood* -casts
-ketones - bacteria
-bilirubin -any other findings
-urobilinogen
-nitrite*
-leukocy te esterase*
*If the dipstick result is abnormal, then flow cy tometry  or microscopy  will be used to 
measure sediment. In case of discordance between the dipstick results and the flow 
cytometric results, the sediment will be examined microscopi[INVESTIGATOR_1306] y.
CCI
R092670 (paliperidone palmitate)
Clinical Protocol R092670PSY3015 Amendment 3
92
Approved , Date: 11 February 2019Additional Tests
For women of childbearing potential, highly sensitive serum pregnancy  testing (for (-human 
chorionic gonadotropin) will be conducted during the Screening Phase, and u rine pregnancy  tests 
will be provided for local testi ng during the subsequent phases.
To facilitate confirmation of postmenopausal status as described in Section 4.1(Inclusion 
Criteria), study -site personnel may order anFSH testif desired (per clinical judgment) .For 
postmenopausal status, the FSH test can only be confirmatory , and cannot replace the associated 
requirement for 12 months of amenorrhea.
Urine drug screen kits (for illicit substances, including marijuana, even where legal) and alcohol 
breath tests will beprovided for local use at the time points specified in the Time and Events 
Schedules. For any subject with a positive result for alcohol or illicit substances, the study -site 
personnel should administer the relevant test again at subsequent visits (even i f not marked in the 
Time and Events Schedules) until a negative result is obtained. After a negative result is 
obtained, the subject can resume testing at the standard frequency  as indicated in the Time and 
Events Schedules. These tests should also be admi nistered whenever a relapse is suspected. 
Alcohol and illicit substances are strongl y discouraged but are not exclusionary  and are not cause
for withdrawal from the study .
9.4.3. Electrocardiogram s
Specific procedures for the 12-lead ECGs will beprovided in a separate manual. Blinded 
cardiologists at a central ECG laboratory  will read all ECGs in this study .
During the collection of ECGs, subjects should be in a quiet setting without distractions (eg, 
television, cell phones). Subjects should rest in a supi[INVESTIGATOR_21683] 5minutes before 
ECG collection and should refrain from talking or moving arms or legs. If blood sampling or 
vital sign measurement is scheduled for the same time point as ECG recording, then the 
procedures should be performed in the following order: ECGs, vital signs, blood draw.
During the Screening Phase, the 2required ECGs should be recorded at least [ADDRESS_22959] -read report is available before Visit 2; 
therefore, the Time and Events Schedules show the Screen ing Phase to extend through Day -2 
(not Day -1), to allow at least a day for ECG reading and reporting . On Day [ADDRESS_22960] (ie, the first day  of the Transition Phase for subjects without prestudy  PP1M 
or PP3M stability , or the first day of the Maintenance Phase for subjects with prestudy  PP1M or 
PP3M stability ), a third ECG should be recorded and compared against the exclusion criteria 
before the first dose of study  medication is administered; see Section 4.2(Exclusion Criteria).
If any clinically  significant ECG abnormality  is observed during the study , then the study -site 
personnel should add ECG assessme nts for that subject at all subsequent visits (even if not 
marked in the Time and Events Schedule s) until the abnormalit y is resolved.
A printout of allECG recording smust be filed in the source document. Any clinicall y relevant 
changes that occur during the study  must be recorded on the Adverse Event section of the eCRF .
R092670 (paliperidone palmitate)
Clinical Protocol R092670PSY3015 Amendment 3
93
Approved , Date: 11 February [ZIP_CODE].4.4. Vital Signs
Vital signs include temperature, pulse/heart rate, respi[INVESTIGATOR_2842], and blood pressure . Vital signs 
should be recorded before any invasive tests, such as blood draws. Blood pressure and 
pulse/heart rate measurements should be preceded by [CONTACT_2669] 5minutes of rest in a quiet setting 
without distractions (eg, television, cell phones).
At each scheduled time point, b lood pressure and pulse/heart rate measurements will be assessed 
twice (first after at least 5minutes rest in supi[INVESTIGATOR_23731] 2minutes standing , if 
possible )with a completely  automated device. Pulse /heart ratewill be measured each time for a 
full minute to minimize the effects of variability . The automated device should consist of an 
inflatable cuff and an oscillatory  detection system. All values should be registered on a built-in 
recorder so that measurements are observer -independent. Manual techniques will be used only if 
an automated devic e is not available. Whether automated or manual, appropriatel y-sized blood 
pressure cuffs should be used for accura te reading of blood pressure. The same arm should be 
used for both supi[INVESTIGATOR_23732].
If a subject is unable to stand up or isunable to remain standing for 2minutes as a result of 
symptoms of orthostatic hypotension, then theblood pressure should be measured immediatel y 
after standing is discontinued, while the subject is in a sitting or supi[INVESTIGATOR_2547]. Attendants 
should protect subjects from falling during the evaluations.
All vital sign measurements will be recorded on the eCRF.
9.4.5. Physical Examination s
Physical examinations at the time points designated on the Time and Events Schedules include 
weight, waist circumference, and abnormalities . Height should also be measured at screening
only,in order to facilitate calculations of BMI (weight/height² as kg/m²) .
9.4.6. Extrapy ramidal Sy mptoms
The scales to assess EPS will be the AIMS for dyskinesia, the BARS for akathisia, and the SAS 
for parkinsonism, at the visits noted in the Time and Events Schedule s. Particular attention is 
given to assessing EPS around the expected timing of the maximum plasma paliperidone 
concentration after a PP6M dose .
In addition to scheduled AIMS, BARS, and SAS assessments, unscheduled assessments of these 
scales should be conducted before initiating or changing any antiparkinsonism drugs (all 
3scales) or any beta-adrenergic blockers or benzodiazepi[INVESTIGATOR_23733] (BARS only), as 
described in Section 8.2(Concomitant Therap y).
[IP_ADDRESS]. Abnormal Involuntary Movement Scale
The AIMS is included in the Early Clinical Development Evaluation Unit Assessment Manual 
from the US NIMH.13The AIMS rates 9items about dyskinesia on scale as 0 =none, 
1 =minimal, 2 =mild, 3 =moderate, and 4 =severe. It rates [ADDRESS_22961]'s awareness 
of abnormal movements as 0 = no awareness; 1 = aware, no distress; 2 = aware, mild distress; 
R092670 (paliperidone palmitate)
Clinical Protocol R092670PSY3015 Amendment 3
94
Approved , Date: 11 February [ZIP_CODE]= aware, moderate distress; and 4 = a ware, severe distress. It has 2yes/no questions about 
dental status. An example of the AIMS is provided in the Manual of Assessments.
[IP_ADDRESS]. Barnes A kathisia Rating Scale
The BARS assesses akathisia via 1objective rating and 2subjective ratings (awareness of 
restlessness and reported distress related to restlessness); each is scored from 0to 3points.3It 
also asses ses akathisia via 1globa l clinical rating scored from 0to 5points. For all items, 
anchors are provided for each value and higher scores indicate worse akathisia. An example of 
the BARS is provided in the Manual of Assessments.
[IP_ADDRESS]. Simpson Angus Scale
The SAS is led by [CONTACT_23804] (rather than by [CONTACT_23805]) to measure drug-induced parkinsonism.34
This study  uses a version of the SAS that is slightly modified from the original (where the "head 
droppi[INVESTIGATOR_007]" item was changed to "head rotation ,"to avoid injury  to the cervical spi[INVESTIGATOR_050] ), as was 
done in the Sponsor's other studies.8,9This modified SAS contains 10 items: 6items for rigidit y 
(arm droppi[INVESTIGATOR_007], shoulder shaking, elbow rigidit y, wrist rigidity , leg pendulousness, and head 
rotation ); 1compound item for gait (incorporating gait, posture, and loss of arm swing), and 
3items for tremor, glabellar tap, and salivation. An example of the SAS is provided in the 
Manual of Assessments.
9.4.7. Columbia Suicide Severity Rating Scale
TheC-SSRS is a low-burden measure of the spectrum of suicidal ideation and behavior that was 
developed in a US NIMH study to assess severity  and track suicidal events through any 
treatment , andis the prospective counterpart to the system developed by [CONTACT_23806].31The C-SSRS is a clinical interview providing a summary of both ideation and 
behavior that can be administered during any evaluation or risk assessment to identify  the level 
and type of suicidality  present. It can also be used during treatment to monitor for clinical 
worsening. The C-SSRS Baseline Version assesses suicidal behavio r and ideation over a 
lifetime, and the C-SSRS "Since Last Visit" V ersion assesses those parameters over an interval. 
The appropriate version of the C-SSRS should be administered at the time points indicated in the 
Time and Events Schedules, and at any  clinic visit associated with a suspected relapse. Examples 
of the C-SSRS (Baseline /Screening Version and "Since Last Visit" Versions) are provided in the 
Manual of Assessments.
9.4.8. Evaluations of the Injection Site
[IP_ADDRESS]. Injection Site Evaluations by  [CONTACT_23807] y used in diverse adult populations.15The VAS is a 
continuous scale on a horizontal or vertical line, usually  100-mm long, and anchored by 2verbal 
descriptors (1 for each symptom extreme).15The instructions, time period for reporting, and 
verbal descriptor anchors have varied widel y in the literature depending on the intended use of 
the scale.15In some settings, test-retest reliability  and a bility  to detect change have been 
demonstrated.15
R092670 (paliperidone palmitate)
Clinical Protocol R092670PSY3015 Amendment 3
95
Approved , Date: 11 February 2019In this study , subjects will be asked about the pain associated with the injection by [CONTACT_3553] a 
100-mm VAS, scaled from "no pain at all "to "unbearabl y painful. " (Similar VAS assessments 
were used in previous studies of PP3M.8,9) The VAS -Acute will assess pain once within 
30minutes after each injection. The VAS -Residual will assess pain at the time points days or 
weeks later as indicated in the Time and Events Schedule s; the subject does not complete a VAS 
at the End-of- Phase Visit. The VAS is scored by  [CONTACT_23808] (in millimeters) from the 
left (indicating no pain) to the place mark made by [CONTACT_423].
[IP_ADDRESS]. Injection Site Evaluations and Follow -up by [CONTACT_23809] (but not other study -site personnel ) will evaluate the injection 
sites for tenderness, e rythema/redness, and induration/swelling ,at the same time points as the 
VASs completed b y the subject, plus at the End-of- Study  Visit or at the time of early withdrawal. 
The characteristics wil l be scored as 0 = absent , 1 = mild, 2 = moderate , or 3 = severe, in 
accordance with the anchor points that are provided in the Manual of Assessments . For 
erythema/redness, a score of 0 is used for a measurement of <2.5 cm, a score of 1 is used for 2.5-
5 cm, a score of 2 is used for 5.1-10 cm ,and a score of 3 is used for>10 cm. Two dimensions of 
induration/swelling are assessed: measurement and impact on function. The dimension yielding 
the higher score will be the one selected for this assessment. Measurement scores are the same as 
those used for erythema/redness (ie, 0 = <2.5 cm, 1 = 2.5-5 cm, 2 = 5.1-10 cm, 3 = >10 cm). 
Functional scores are as follows: 0 and 1 = no interference with the subject’s usual activities, 2 = 
interferes with (but does notprevent) one or more of the subject’s usual activities, 3 = prevents 
one or more of the subject’s usual activities . Tenderness ratings are as follows: 0 = no 
tenderness, 1 = mild discomfort to touch, 2 = discomfort with movement, 3 = significant 
discomfor t at rest. The scales and anchors are a hybrid from the Sponsor's previous studies of 
PP3M,8,9and from a US FDA guidance.hThe results will be recorded on the eCRF. The 
investigator/subinvestigator should complete these assessments within 30minutes after the 
injection and at all visits marked in the Time and Events Schedule sthereafter; for any 
characteristic still rated mild, moderate, or severe at the last marked visit, the 
investigator/subinvestigator should add assessments at subsequent visits (even if not marked) 
until all of the character istics are rated absent. Clinical sites should make effort sto have the same 
individual perform all injection site evalua tions for a particular subject. This individual should 
not review the subject's VAS rating of the injection site pain.
                                                
hUS FDA. Guidance for industry: toxicity grading scale for healthy adult and adolescent volunteers enrolled in 
preventive vaccine clinical trials . www.fda.gov/downloads/BiologicsBloodVaccines/
GuidanceComplianceRegulatoryInformation/Guidances/Vaccines/ucm09 1977.pdf . Issued September 2007. 
Accessed 14 April 2017.
R092670 (paliperidone palmitate)
Clinical Protocol R092670PSY3015 Amendment 3
96
Approved , Date: [ADDRESS_22962] has an injection site adverse event that is rated as moderate or severe (see 
Section 12.1.3 [Severity  Criteria] ) and that is accompanied by [CONTACT_23810] (eg, tenderness, 
erythema/redness, and induration/swelling ), then the clinical site should perform or refer for 
ultrasonograph y of the injection siteand should refer the subject to a specialist for further 
evaluation.
For ultrasonography , the goal is to identif yphlegmonous processes that might evolve to 
overt abscesses of the gluteus and to differentiate real granulomatous reactions from less 
relevant topi[INVESTIGATOR_23734].
For referrals, c onsiderations are as follows:
Suspected cellulitis or abscess should be referr ed to a dermatologist or surgeon for consideration 
of incision and drainage procedure along with tissue microbiological samples.
Nodule, fibroma, furuncle or other noninfectious reaction with a severit y assessment of either 
moderate or severe should be referred to a dermatologist or surgeon for consideration of fine 
needle aspi[INVESTIGATOR_23735]/or tissue biopsy .
The investigator should follow any  clinicall y significant abnormalities persisting at the end of the 
study  until resolution or until reaching a clinically stable endpoint.
9.5. Benefit -risk Evaluations
Evaluations alread y defined for efficacy  and safety  will be used for the benefit -risk assessment. 
Benefit will be evaluated as described in Section [IP_ADDRESS] (Relapse Criteria) , and will include 
relapse per allcause s, relapse per psychiatric hospi[INVESTIGATOR_059], or relapse per PANSS total score . 
Risk will be evaluated as described in Section 9.4(Safety  Evaluations), and will include the 
following: adverse events overall ;adverse events of special interest (eg, from thelistin 
Section 1.1[Background]) ; adverse events that are serious or that lead to discontinuation; clinical 
laboratory  tests (for risk of hyperprolactinemia or hypergl ycemia); ECGs (for risk of QTcF 
increase >60milliseconds); and physical examinations (for risk of weight gain ≥7%). The 
benefit -risk evaluation s may  also include o ther unexpected clinicall y relevant adverse events that 
occur during the Double- blind Phase ,or that are a consequence of a pre-existing condition that 
has worsened since the start of the Double -blind Phase.
9.6. Other Exploratory  Evaluations
9.6.1. Healthcare Resource Utilization Questionnaire
The Healthcare Resource Utilization (HRU) questionnaire was designed to assess utilization of 
the following resources: hospi[INVESTIGATOR_059] (refers to ≥1 night stay), emergency  room visits without 
hospi[INVESTIGATOR_059], day or night clinic stays, outpatient treatment, as well as daily  living conditions 
and productivity  of the subject.24The questionnaire will be used in thisstudy  as an exploratory  
tooland has been modified with recall periods appropriate to the study . Study -sitepersonnel will 
administer the questionnaire. If possible, for a given subject, the same person should administer 
this scale at all visits. The subject will be the primary  provider of the information, but additional 
outside information should also be included as available, including information from any
caregivers . Any resource utilization that is required by  [CONTACT_23811] 
R092670 (paliperidone palmitate)
Clinical Protocol R092670PSY3015 Amendment 3
97
Approved , Date: 11 February 2019questionnaire. Example sof the HRU questionnaire s (baseline assessment and postbaseline 
assessment) are provided in the Manual of Assessments.
9.6.2. Involveme nt Evaluation Questionnaire
The Involvement Evaluation Questionnaire ( IEQ)was designed to measure levels of caregiver 
consequences among family  members and friends of subjects with schizophrenia.35The version 
of the IEQ to be used in this study  will contain 5questions about the demographics of the 
caregiver, and will pose the 31standard items in the IEQ, and will exclude the "supplementary " 
questions . The 31standard questions are answered on 5-point Likert response scale sto address 
consequences among 4dimensions (tension, supervision, worry ing, and urging). Data are 
available to support its reliability .35The IEQ should be completed by a designated caregiver for 
the subject . The designated caregiver who will be completing the questionnaire is someone who 
is mutually  agreed upon betwe en the subject and the investigator, should not be a paid caregiver 
but may be a famil y member , significant other, or friend who provides at least 1hour of support 
tothe subject per week . The same individual should complete the questionnaire throughout the 
study  and should attend study  visits when the IEQ is scheduled to be completed. In order to 
support the interpretation of the data and further explore the impact of caregiving, supplemental 
questions about the sociodemographics, time spent caregiving, and health care utilization of the 
caregiver will be collected from the designated caregiver at the times the IEQ is administered 
according to the Time and Events Schedule s. This IEQ may be completed by [CONTACT_23812], based on availability  of the caregiver. If 
a subject has no caregiver providing at least 1hour of support per week , then the IEQ may be 
omitted .Examples of the IEQ (baseline assessment and postbaseline assessment) are provided in 
the Ma nual of Assessments ; along with the comments about the IEQ recall periods.
9.6.3. Concomitant Substances Questions
Use of nicotine will be questioned as indicated in the Time and Events Schedule s. Examples of 
the questions are provided in the Manual of Assessments.
9.6.4. Illness Management and Recovery Scale
The Illness Management and Recovery  (IMR)scale (client self-report version) for schizophrenia 
and other severe mental illnesses was developed as part of the US National Implementing 
Evidence -based Practices Project and is made available by [CONTACT_23813].30The IMR scale asks subjects to consider the past 3 months and 
to rate 15items about personal goals, knowledge of mental illness, involvement with significant 
others, impaired functioning, symptoms, stress, copi[INVESTIGATOR_007] , relapse prevention, hospi[INVESTIGATOR_059], 
medication, and use of drugs and alcohol. The response range for each item is from 1 to 5 points, 
with higher scores indicating better outcomes. An example of the IMR scale (client self-report 
version) is provided in the Manual of Assessments. This study  uses a version of the IMR that is 
slightly  modified from the original, to make the recall periods more appropriate to the study .
R092670 (paliperidone palmitate)
Clinical Protocol R092670PSY3015 Amendment 3
98
Approved , Date: 11 February [ZIP_CODE].6.5. Schizophrenia Quality of Life Scale (Revision 4)
The Schizophrenia Quality  of Life Scale (SQLS) was initially  developed using items generated 
from in- depth patient interviews (ie, the perspective of patients was used to develop the SQLS).[ADDRESS_22963] recent version (Revision 4) has been translated into dozens of languages through 
standardization procedures.22
The SQL S (R evision 4)has 33items covering topi[INVESTIGATOR_23736] y. 
Response options are never, rarely, sometimes, often, or alway s. Scoring algorithm syielda 0to 
100scale, with higher scores indicating lower quality  of life. The factor structure and internal 
reliability  have been verified in patients with schizophrenia in the Netherlands and further 
replicated in patients with schizophrenia in the [LOCATION_008] and Taiwan.22,27
An example of the SQL S(Revision 4) is provided in the Manual of Assessments.
10. SUBJECT COMPLETION /DISCONTINUA TION OF STUDY DRUG /
WITHDRA WAL FROM THE STUDY
An End-of- Phase Visit (as outlined in the Time and Events Schedules) may be conducted as an 
Early Withdrawal Visit ifa subject isunable to complete aphase before reaching randomization, 
or unable to progress between phases before reaching randomization, or unable to complete the 
Double- blind Phase .An End-of- Phase Visit (as outlined in the Time and Events Schedules) may 
be conducted as an End-of-Study  Visit if a subject is completing the Double -blind Phase (see 
Section 10.1 [Completion]). 
10.1. Completion
A subject will be considered as having completed the study if he or she has had a relapse durin g 
the Double- blind Phase and has completed all End-of- Study  Visit assess ments, or has remained 
relapse -free during the Double- blind Phase and has completed all End-of- Study  Visit 
assessments .The definition for completing the Double -blind Phase is the same as for completing 
the study .The Follow -up Phase, when applicable, is supplementary  after study  completion.
10.2. Discontinuation of Study Drug /Withdrawal From the Study
Discontinuation of Study Drug
A subject will not be automatically  withdrawn from the study  if he or she discontinue streatment 
before the end of the treatment regimen. A subject's study  drug must be discontinued ifthe 
investigator believes that for safet y reasons or tolerability  reasons (eg,adverse event) it is in the 
best interest of the subject to discontinue study drug, or if t he subject becomes pregnant .
If a subject discontinues after receiving at least 1dose of open -label study  drug but before 
receiving any double -blind study  drug, then End-of-Study  Visit assessments should be 
obtained and no Follow -up Phase is applicable .
If a subject discontinues after receiving at least 1 dose of double -blind study  drug , then:
R092670 (paliperidone palmitate)
Clinical Protocol R092670PSY3015 Amendment 3
99
Approved , Date: 11 February 2019If possible, the scheduled assessments (including PKsamples ) should be continued through the 
relevant 6-month cycle of assessments (Visits 7to20, or Visits 20to33) .If the subje ct has not 
completed at least 1 year of the Double -blind Phase, then either :
oThe subject may, if preferred, continue with assessments (but without study  drug 
administra tion) until Visit 33 a (the End-of- Study  Visit ), or
oThe subject may, if preferred, complete Visit [ADDRESS_22964] assessment of the relevant 6-month cy cle (ie, Visit 20or 33) should 
be conducted as an End -of-Study  Visit. 
oIf it is not feasible for scheduled assessments to be continued through the relevant 
6-month cycle of assessments, then End-of- Study  assessments should be obtained 
as soon as possible. The subject should then, if willing, enter the Follow -up Phase 
until [ADDRESS_22965] will be withdrawn from the stud y for any of the following reasons:
Lost to follow -up.
Withdrawal of consent .
The blind is broken by [CONTACT_093] .
Treatment with concomitant antips ychotic medication when relapse criteria arenot met but, 
in the investigator 's judgment, a concomitant antipsy chotic medication is necessary  for the 
subject 's well being, and viable alternatives are either not available or have been exhausted .
The subject fails to meet criteria for entry  to Maintenance Phase.
The subject fails to meet criteria for entry  to Double -blind Phase.
For subjects in the Transition Phase:
If the dose at Visit 2e is different than the dose at Visit 2d.
If the dose at Visit 2d or 2e is <100 mgeq.
If the dose is 50 mgeq. at any  time.
For subjects in the Maintenance Phase:
If the dose at Visit 2f is different from the preceding dose or is not a dose equivalent of 
the preceding dose.
When a subject withdraws before completing the study , the reason for withdrawal is to be 
documented in the eCRF and in the source document. Study  drug assigned to the withdrawn 
subject may  not be assigned to another subject. Subjects who withdraw will not be replaced.
R092670 (paliperidone palmitate)
Clinical Protocol R092670PSY3015 Amendment 3
100
Approved , Date: 11 February 2019If a subject withdraws from the study  after receiving at least [ADDRESS_22966] is willing to complete that visit .
If a subject withdraws from the study  after receiving at least 1dose of double -blind study 
drug but before the end of the Double- blind Phase , then End-of- Phase Visit / Early  
Withdrawal Visit assessments should be obtained if the subject is willing to complete that 
visit, even if the subject is with drawing consent to complete an y other visits. Thereafter:
If the subject is withdrawing consent, then the subject's study  participation is complete .
If the subject is withdrawing for a reason unrelated to consent, then the subject should enter the 
Follow -up Phase.
Loss to Follow -up
If a subject is lost to follow -up, every  reasonable effort must be made by  [CONTACT_1758] -site personnel 
to contact [CONTACT_23814]/withdrawal. The measures 
taken to follow up must be d ocumented.
10.3. Antipsychotic Therapy After the Study or in the Follow -up Phase
Open -label Treatment : Poststudy
If a subject discontinues or withdraws from the study  in the Transition Phase or Maintenance 
Phase, then he or she may be considered for poststudy  treatment with PP1M, PP3M, or another 
LAI antipsy chotic at an interval appropriate to the open -label identity  of the last study  dose, as 
described in the approved prescribing information. Oral antipsy chotic medications, if 
appropriate, may be restarted regar dless of the timing of the last study  injection. However, 
consideration should be given to the long-acting nature of paliperidone palmitate when the oral 
antipsy chotic medication and dose(s) are selected. At the End-of- Phase Visit / Early  Withdrawal 
visit and thereafter, the poststudy  treatment after open -label treatment is at the discretion of the 
subject's ph ysician; the study  no longer follows these subjects.
Double -blind Treatment : Poststudy or Follow -up Phase
After discontinuation, withdrawal, or completion ofthe study  in the Double- blind Phase, 
investigators /treating physicians may choose to continue treatment with paliperidone palmitate , 
switch to treatment with a different LAI antipsy chotic treatment , or switch to oral antipsy chotic 
treatment . Treatment selection is at the discretion of the subject's physician and is not a study  
medication . However, given the double -blind conditions and durations of activity  expected from 
PP6M and PP3M, recommendations (not requirements) for poststudy  or Follow -up Phase 
treatment schedules are provided in Figure 5and Table 7 and Table 8below.
R092670 (paliperidone palmitate)
Clinical Protocol R092670PSY3015 Amendment 3
101
Approved , Date: 11 February 2019Figure 5: Post Study Medication Algorithm
Risperidon e or
PaliperidoneAnother oral PP1M or PP3M Another LAI
Timing: find row in 
Table [ADDRESS_22967] study 
medication injection
Oral 
supplementation : 
per investigator 
judgment1
Dose : per 
investigator 
judgmentLAIORA L
Dosing per 
investigator 
judgment.1Timing of starting 
oral at discretion of 
investigator. 
Dose 
recommendations 
in Table 8.1Double Blind 
PhaseTransition or 
Maintenance Phase 
(Open Label)When Did Subject Discontinue?
Follow 
instructions per 
local label
What is desired post -
study medication?
1: Given the prolonged half -life of PP6M/3M/1M, 
oral medication dosing should be titrated up/down 
depending on investigator judgment and timing of 
the last injection.Timing: find row in Table [ADDRESS_22968] 
study medication injection
Oral supplementation : 
supplement with oral RIS/PALI 
until next injection. See Table 8 
for oral dose.1
Dose : Dose for first post double -
blind injection of PP1M/3M see 
Table 8 .
R092670 (paliperidone palmitate)
Clinical Protocol R092670PSY3015 Amendment 3
102
Approved , Date: 11 February 2019Table 7: Timing of Resumption of PP1M/3M after the Double -blind Study or in Follow -Up Phase
Visit # Day1Study 
Medication 
InjectionTime to wait 
until next 
PP1M/PP3M 
injection 
(days)2Visit # Day1Study 
Medication 
InjectionTime to wait 
until next 
PP1M/PP3M 
injection 
(days)2
7b 1PP6M or 
PP3M [ZIP_CODE] 185 178
8 3 177 22 204 159
9 22 158 23 211 152
10 29 151 24 218 145
11 36 144 25 242 121
12 6012026 274Placebo or 
PP3M89
13 92Placebo or 
PP3M 8827 302 61
14 120 60 28 330 33
15 148 32 29 337 26
16 155 25 30 344 19
17 162 18 31 351 12
18 169 11 32 358 5
19 176 4 33 365 0
20 183PP6M or 
PP3M0Footnotes: 1: Does not include visit window 2: Timing 
of resumption of oral antipsychotic may be at any time 
depending on investigator judgment
Table 8: Switching Conversion Table (Oral and LAI Paliperidone and Oral Risperidone )
PP1M PP3MPP6MOral 
Paliperidone Oral 
Risperidone
Moderate Dose Group:100 mg eq .350 mg eq .700 mg eq.9 mg/da y 3-4 mg/day 
Higher Dose Group: 
.150 mg eq .525 mg eq . 1000 mg
eq.12 mg/day 5-6 mg/day
Footnote: this provides a suggested starting dose of oral medications. The timing of 
the last injection must be taken into account, and oral dose adjusted as clinically 
warranted. 
10.4. Process for Planned Study Closure
The calendar date of the end of Study R092670PSY3015 will be determined when a sufficient 
number of subjects have been randomized to the Double- blind Phase. To ensure that subjects can 
be assessed for 6months after their last potential PP6M injection but cannot have End-of- Study
Visits after the calendar date that marks the end of the study , subjects will not receive injections 
that are potentially  PP6M after the last subject randomized receives hisor her last potential 
PP6M injection. The process for determining the calendar date of the end of the stud y and further 
explanation of the timing of End-of- Study Visits is described below.
Throughout the study , the Sponsor will monitor the number of subjects in the Transition, 
Maintenance, and Double -blind Phases. The Sponsor will notify  all sites to close screening and 
R092670 (paliperidone palmitate)
Clinical Protocol R092670PSY3015 Amendment 3
103
Approved , Date: [ADDRESS_22969] been enrolled toachieve the 
target number (549 randomized) needed for participation in the Double- blind Phase. Subjects 
alread y participating in the Transition and Mainte nance Phases will continue to progress through 
the study  as described in the Time and Events Schedule s, including progress into the Double-
blind Phase if eligibility  criteria are met as described in Section 4.4(Criteria for Entry  Into the 
Double- blind Phase) . Study  R092670PSY3015 will conclude when the last subject to be 
randomized and remain in the study  completes 12 months of the Double- blind Phase, which will 
be marked b y completion of Visit 33a
During the Double- blind Phase, only the odd-numbered (ie,1st, 3rd) injections are potentially 
PP6M .
11. STATISTICA L METHODS
Statistical analy sis will be done by [CONTACT_23815]. A general 
description of the statistical methods to be used to anal yze the efficacy  and safet y data is outlined 
below. Specific details will be provided in the SAP.
11.1. Subject Information
The p opulations for efficacy  analyses, the double -blind intent -to-treat analysis population and the 
per-protocol analysis population , are described in Section 11.3 (Efficacy  Analyses). Other 
analysis populations will bedefined in a manner similar to a previous study  of PP3M,8and may 
include sets such as the following: the open -label intent -to-treat analysis population , the all 
randomized analy sis population , and the safety  analysis population . Full details will be provided 
in the SAP .
11.2. Sample Size Determination
The sample size for the Double- blind Phase of the study  is 549randomized subjects , based on 
determi nations toprovide a minimum of 80% power for the primary  endpoint . The sample size 
determination includes the assumptions that the expected survival rate (percentage of subjects 
remaining relapse -free at 12 months) in the PP3M group is 85%, and that the 1-sided 
significance level should be 2.5%. Given these assumptions, 549subjects randomized in a 
2:1ratio (PP6M:PP3M) are required to demonstrate with 80% power that PP6M is no worse than 
PP3M by  a noninferiority  margin of 10% for the percentage of subject s remaining relapse -free at 
12months. This assumes that the efficacy  observed in the PP3M group will be similar to the 
efficacy  observed in the previous PP3M registrational Phase 3 studies (R092670PSY3011 and 
R092670PSY3012). The noninferiorit y margin of 10% and statistical methods for this analysis
were selected based on the Sponsor's previous studies and on advice from experts and health 
authorities, as follows:
Inthe Sponsor's previous placebo- controlled relapse prevention studies with oral 
paliperidone ER/PR, PP1M ,and PP3M ,9,18,21a Kaplan -Meier estimate indicated that the 
meta -analytic estimate of treatment benefit of paliperidone over placebo was 42.1% (95% 
confidence interval: 28.4% to 55.8%).19
R092670 (paliperidone palmitate)
Clinical Protocol R092670PSY3015 Amendment 3
104
Approved , Date: 11 February 2019A panel of experts in the field of schizophrenia relapse prevention studies was convened to 
obtain recom mendations for the clinical non inferiority  margin to be used in this study . Using 
a modified Delphi approach, the mean value obtained after anon ymous voting for the 
noninferiority  margin was 13.4% (median 13.0%; range 10% to 20%).19This clinical 
judgment based on expert opi[INVESTIGATOR_23737] ; in accordance with the relevant USFDA 
guidance,ithe maximum was therefore set at 13.0%.19
Prior scientific advice from the Committee for Medicinal Products for Human Use had 
recommended a noninferiority  margin of 10%.19
For all of the above reasons, an effect of 10% wa s chosen as the margin.
Further details are available in a separate statistical support document .19
The study  design assumes discontinuation rate sduring the Transition and Maint enance Phase sof 
20% for subjects who entered the study  with previous PP1M or PP3M stabilit yand 40% for 
subjects who entered the study  without previous PP1M or PP3M stability .The study  design also 
assumes adropout rate of 10% during the Double- blind Phase (where the dropout rate also 
accounts for subjects excluded due to protocol violations) .Given these assumptions for
discontinuation, the study  targets approximately  840 subjects to enter the 
Transition/ Maintenance Phase.
11.3. Efficacy  Analyses
11.3.1. Primary  Hypothes isand Efficacy  Analyses
The primary  hypothesis is that the efficacy  of PP6M is noninferior to PP3M for preventing 
relapse in subjects with schizophrenia who were previously  stabilized on corresponding doses of 
PP1M or PP3M .
[IP_ADDRESS]. Double -blind Intent -to-Treat A nalysis Population
[IP_ADDRESS].1. Primary  Estimand
1.The population is restricted to those who are stabilized on either PP1M or PP3M during the 
Maintenance Phase and meet the inclusion/exclusion criteria.
2.The variable is time to a relapse event ,and will be defined during the Double -blind Phase if
the subject experiences a relapse during the Double- blind P hase.
3.The inter current effects are none, regardless of whether or not major protocol deviation shad 
occurred .
4.The population -level summary is the difference in Kaplan -Meier estimate at Month 12 of 
relapse -free proportions between the 2 treatment groups.
                                                
iUS FDA. Non-inferiority clinical trials to establish effectiveness: guidance for industry.
www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm202140.pdf . 
Issued Novemb er2016. Accessed 15 May 2017.
R092670 (paliperidone palmitate)
Clinical Protocol R092670PSY3015 Amendment 3
105
Approved , Date: 11 February 201911.[IP_ADDRESS]. Primary  Efficacy  Analyses
All subjects who receive at least 1dose of study drug during the Double -blind Phase will be 
included in the double -blind intent -to-treat population. The primary  endpoint is time to relapse in 
the Double -blind Phase, as described in Section [IP_ADDRESS] (Primary  Endpoint) .Subjects who meet 
at least 1of the criteria for relapse (see Section [IP_ADDRESS] [Relapse Criteria]) during theDouble-
blind Phase at the time of study  completion for the primary  analysis will be considered to have 
had a relapse event. Subjects who do not have a relapse event in the Double -blind Phase will be 
considered as censored. T he statistics to test the primary  hypothesis arebased on the percentage 
of subjects who remain relapse -free at Month 12 in the PP6M andPP3M groups per Kaplan -
Meier estimate for the Double -blind Phase. The analy sis will consider whether the lower limit of 
the 95% confidence interval of the difference in relapse -free rates between PP6M and PP3M 
exceeds thenoninferiority  margin of -10%. The standard error estimates will be based on 
Greenwood 's formula. The null and alternative hypotheses use a 1-sided α=0.025 level, and are 
written as follows:
Null Hy pothesis:  (% relapse -free) PP6M  - (% relapse -free) PP3M ≤ -10%
Alternative Hy pothesis:  (% relapse -free) PP6M  - (% relapse -free) PP3M > -10%
[IP_ADDRESS].3. Sensitivity Analysesfor Primary  Efficacy
Additional sensitivity  analyses with the double -blind intent -to-treat population will be performed 
to evaluate impact of censoring for subjects who withdraw from the Double -blind Phase before
Month [ADDRESS_22970] across 
various geographic regions will also be evaluated.
[IP_ADDRESS]. Per-protocol A nalysis Population
[IP_ADDRESS].1. Estimand
The primary  efficacy  analysis will also be performed on the per-protocol analy sis population . 
The estimand of the per -protocol anal ysis population is defined by  [CONTACT_13673]:
1.The population is restricted to those who are stabilized on either PP1M or PP3M during the 
Maintenance Phase and meet the inclusion/exclusion criteria.
2.The variable is time to first occurrence of a relapse event, and will be defined if a subject 
experiences a relapse during the Double -blind Phase.
3.The intercurrent events are major protocol violations that may  impact efficacy ; these include 
errors in treatment assignment, errors in the delivery  of active medication, or use of 
prohibited medications.
4.The population -level summary is the difference in Kaplan -Meier estimate at Month 12 of 
relapse -free proportions between the 2 treatment groups.
[IP_ADDRESS].2. Analyses
The analysis performed on the per-protocol analysis population will be based on the comparison 
between 2 treatment groups in subjects without the aforementioned intercurrent events ; that is, in 
R092670 (paliperidone palmitate)
Clinical Protocol R092670PSY3015 Amendment 3
106
Approved , Date: [ADDRESS_22971] efficacy  such as errors in the deliver y 
of active treatment , errors in treatment assignment , or use of prohibited medication . The 
noninferiority  analysis with 10% noninferiority  margin as specified in Section [IP_ADDRESS] (Double -
blind Intent-to-Treat Analy sis Population ) will be repeated on the per-protocol analysis 
population .
11.3.2. Secondary  Efficacy  Analyses
Clinically  assessed secondary  efficacy  analyses include maintaining symptom control , 
functioning personall y and socially ,and achieving remission ineach group (PP6M or PP3M, 
each sorted by [CONTACT_15994]) .The secondary  efficacy  analyses will be conducted using thedouble -
blind intent -to-treat analysis population .
Maintaining Symptom Control: For the Double -blind Phase, a nalysis of change in PANSS 
total and factor scores andin the CGI-S scores will be made based on a mixed model for 
repeated measurement analy sis that will include a random effect for subject and fixed effects 
terms for treatment, visit (as a categorical variable), country , baseline score, and treatment -
by-visit interaction. For the Maintenance Phase , descriptive summaries (sorted by [CONTACT_23816]1M or 
PP3M dose groups) will also be provided.
Functioning Personally and Socially: Analy ses of the PSP scores will be similar tothe 
analyses for maintaining sy mptom control ,as described in the bul let above .
Achieving Remission : For single observations, transitory  symptomatic remission isdefined 
as having a simultaneous score of mild or less ( ≤3points) on thefollowing 8 items from the 
PANSS : the positive -symptom items P1(delusions), P2(conceptual disorganization), 
P3(hallucinatory  behavior); the negative -symptom items N1(blunted affect), N4(social 
withdrawal), and N6(lack of spontaneity ); and the general -psychopathology items 
G5(mannerisms/posturing) and G9(unusual thought content ).2For multiple observations, 
durable symptomatic remission is defined asmeeting those remission criteri afor a 6-month 
period.2For each treatment group, the number and percentage of subjects achieving durable 
symptomatic remission at the end of the Double -blind Phase will be presented. The point 
estimate and 2-sided 95% confidence interval will be provided for the relative risk using a 
Mantel -Haenszel test controlling for country . The count and percentage of remission status 
at each Double- blind Phase outcome time point will be presented by[CONTACT_23817]- blind Phase baseline. Point estimates and 2-sided 
95% confidence interval will also be provided for subjects meeting the remission criteria at 
each time point (including at the end of the study ).Time to remission and maintenance of 
remission for longer than the [ADDRESS_22972] -reported secondary  efficacy  analyses (ie, ofthe SPSR and the TSQM -9 outcomes) may
be detailed in aseparate report (outside the standard SAP and CSR).
11.4. Pharmacokinetic and Pharmacody namic Analy ses
Descriptive statistics will be calculated for the plasma concentrations of paliperidone and 
paliperidone palmitate and for the derived PK parameters, as applicable. Statistics will include 
sample size, mean, standard deviation, coefficient of variation, geometric mean, median, 
minimum, and maximum. Population PK analy sis of plasma concentration -time data of 
R092670 (paliperidone palmitate)
Clinical Protocol R092670PSY3015 Amendment 3
107
Approved , Date: 11 February 2019paliperidone will be performed using nonlinear mixed- effects modeling for PP6M , possibly  
using m odels previous ly developed from PP3M studies.
Mean and/or median plasma paliperidone concentration -time profiles will be plotted. Individual 
plasma concentration -time profiles may also be plotted. Plasma paliperidone concentrations and 
summary  statistics m ay be presented graphicall y as scatter plots or box plots to support subgroup 
or meta -analyses.
The study  will include a Sponsor -blinded interim PK analy sis of available paliperidone 
concentration data at the time when at least 6 months of double -blind treatment has been 
completed by [CONTACT_23818] 140(26%) of 549randomized subjects .The objective of this interim 
analysis is to verify  that the observed PK properties of PP6M are conform ingto the expected PK
behavior of PP6M. The following anal yses will be conducted :
1. A ssess whether the observed concentrations of paliperidone after injection of PP6M are 
consistent with previous population PK predictions;
2.Assess whether PK sampling times need to be adjusted to fully  characterize the PK behavior 
of PP6M . (These potential changes would be communicated to study  sites via a protocol 
amendment.)
An internal independent analyst (not associated with the study  team)or an external vendor will 
be granted access to the treatment assignment information of the subjects included in the 
analysis. The external vendor or study -independent analyst will work in a secured environment 
to ensure no accidental unblinding of the Sponsor. To further ensure no accidental unblinding of 
the Sponsor, the data transfer to the internal independent analyst or external vendor will be done 
in a blinded way  by [CONTACT_23819] y subject identifiers.
No unblinding information will be shared with the Sponsor throughout this process prior to 
locking of the database. No efficacy  or safet y data measures will be included in this analysis. 
However, the Sponsor -blinded PK analy sis will include a selection of demographic information 
needed for evaluation of PK (eg, potential PK covariates such as body  weight, age, sex, 
creatinine clearance, and race) and will include information about study  drug administration 
(volume, dose, muscle site, and history of similar parameters from the Maintenance Phase) . The 
procedural steps to enable the Sponsor -blinded P K analysis will follow theSponsor 's internal 
operating procedures.
In addition, a snapshot date for PK samples to be anal yzed will be defined, if required, to allow a 
further Sponsor -blinded PK analysis prior to database lock. Samples collected before this date 
will be analyzed for paliperidone concentrations and will be included in the population PK 
analysis. Samples collected after the snapshot date will be analyzed at a later date, and will be 
included in a population PK re -analy sis when they  become available after database lock.
After database lock, PK-PD analyses may be performed. For safety  outcomes, PK-PD 
relationships may be evaluated in terms of any potential clustering of adverse events around the 
timing of the maximum plasma paliperidone concentration after a dose ofPP6M. For efficacy 
outcomes such as relapse, PK-PD relationships may be evaluated, if appropriate.
R092670 (paliperidone palmitate)
Clinical Protocol R092670PSY3015 Amendment 3
108
Approved , Date: 11 February 2019The population PK analysis andthe PK-PD analy seswill be detailed in one or more separate 
methods plans and one or more separate results reports .
11.5. Safety  Analyses
11.5.1. Adverse Events
The verbatim terms used in the eCRF by [CONTACT_23820] (MedDRA). Treatment -emergent adverse 
events are adverse events with onset during the treatment phase or that are a consequence of a 
pre-existing condition that has worsened since baseline. All reported adverse events will be 
included in the analy sis. For each adverse event, the percentage of subjects who experience at 
least 1occurrence of the given event will be summarized by [CONTACT_1570]. In addition, 
comparisons between treatment groups will be provided if appropriate.
Summaries, listings, datasets, or subject narratives may be provided, as appropriate, for those 
subjects who die, who discontinue treatment due to an adverse event, or who experience a severe 
or a serious adverse event. Analyses of the adverse events of special interest , as described in 
Section 1.1(Background), will be described in the SAP.Adverse events will be analy zed 
separately  for the open -label phases (Transition Phase and Maintenance Phase) and forthe
Double -blind Phase .
11.5.2. Clinical Laboratory  Tests
Laboratory  data will be summarized by [CONTACT_23821]. Reference ranges and markedl y 
abnormal results (specified in the SAP) will be used in the summary of laboratory  data. 
Descriptive statistics will be calculated for each laboratory  analyte at baseline and for observed 
values and changes from baseline at each scheduled time point. A listing of subjects with any 
laboratory  results outside the reference ranges will be provided. A listing of subjects with any 
markedl y abnormal laboratory results will also be provided.
11.5.3. Electrocardiogram s
The effects on cardiovascular variables will be evaluated by [CONTACT_23822]. These tables will include observed values and changes from baseline 
values ( with the prerandomization ECG used as baseline).
The ECG variables that will be analy zed include heart rate, PR interval, QRS interval, QT 
interval, and corrected QT (QTc) interval using the following correction methods: QT interval 
corrected according to the linear -derived formula (QTcLD) as the primary  method, as well as 
according to Bazett's formula (QTcB) and according to Fridericia's formula (QTcF) as 
supplemental metho ds.4,17,33
In the Double -blind Phase, descriptive statistics of QTc intervals and changes from baseline will 
be summarized at each scheduled time point. The criteria for abnormal QTc interval values will 
R092670 (paliperidone palmitate)
Clinical Protocol R092670PSY3015 Amendment 3
109
Approved , Date: 11 February 2019be based on the classification from the relevant ICH guidelinej(normal as ≤450 milliseconds, or 
elevated as >450, >480, or >500 milliseconds). Similarly , the percentage of subjects with 
increases in QTc of normal as ≤30 milliseconds or elevated as 30to 60milliseconds or 
>60milliseconds will also be summarized at each time point.
All clinically  relevant abnormalities in ECG waveform that are changes from the baseline 
readings will be reported .
11.5.4. Vital Sign s
Descriptive statistics of vital sign values and changes from baseline will be summarized at each 
scheduled time point. The percentage of subjects with values beyond clinically  important limits 
will be summarized.
Afrequency  table of the occurrence of orthostatic hypotension will be presented. Orthostatic 
hypotension isdefined as a decrease in systolic (>20 mm Hg) or diastolic (>10 mm Hg) blood 
pressure after standing for at least 2 minutes that is associated with a n increase in pulse /heart rate 
of >15 bpm compared with supi[INVESTIGATOR_6358].12
11.5.5. Physical Examination s
Physical examination findings will be summarized at each scheduled time point. Descriptive 
statistics will be calculated at baseline and for observed values and changes from baseline at each 
scheduled time point. Frequency  tabulations of the abnormalities will be made.
11.5.6. Extrapy ramidal Sy mptom Scales
The results of the EPS scales (AIMS , BARS, and SAS) will be summarized descriptively  at each 
time point. See also Section 11.5.1 (Adverse Events) for anal yses of EPS -related adverse events.
11.5.7. Columbia Suicide Severity Rating Scale
C-SSRS Baseline/Screening Form will be used at screening. C-SSRS Since Last Visit Form will 
be used at other visits, as per Time and Events Schedules. Suicide -related thoughts and behaviors 
based on the C -SSRS scale will be s ummarized by [CONTACT_23762].
11.5.8. Evaluations of the Injection Sites
The results of the evaluations by [CONTACT_23823] y at each time point.
                                                
jICH. ICH Harmonized Tripartite Guideline E14: Clinical evaluation of QT/QTc interval prolongation and 
proarrhythmic potential for non -antiarrhythmic drugs. 
www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Effic acy/E14/E14_Guideline.pdf . 
Dated 12May 2005. Accessed 14 March 2017.
R092670 (paliperidone palmitate)
Clinical Protocol R092670PSY3015 Amendment 3
110
Approved , Date: [ADDRESS_22973] one statistician. After eachreview meeting , the 
Anticipated Event Review Committee will make recommendations regarding reporting of 
anticipated events, as described in Section 12.3.1 (All Adverse Events) and Attachment 3.
11.6. Benefit -risk Analyses
Efficacy  and safety  outcomes for thebenefit -risk analysis will be considered inthe Double-b lind 
Phase ;ie, excluding results that may arise from treatment with PP1M or PP3M during the 
Transition or Maintenance Phase s.All general rules and conventions from the statistical methods 
section will be applied to the benefit -risk analyses, unless otherwise noted in the SAP.
 the benefit -risk analy seswill be based on 
the efficacy  and safety  outcomes previously  used for the PP3M formulation.[ADDRESS_22974] of the risk 
difference between PP6M and PP3M and the size of a hypothetical population (eg, 
1,000 patients). This can be interpreted as the additional number of patients in this hypothetical 
population who would experience a particular event when treated with PP6M minus that in the 
same popu lation receiving PP3M . For benefit -risk assessment, point estimates will be shown 
with 95% confidence intervals; however, statistical tes ts on risk differences will not be specified.
Tabular and graphical display s of data may be created. Important benefits and risks are listed in 
Section 9.5(Benefi t-risk Evaluations).
11.7. Other Exploratory  Analyses
If applicable, exploratory  analyses may be described in one or more separate methods plans 
(outside the standard SAP) and one or more separate results reports (outside the standard CSR).
12. ADVERSE EVENT REPORT ING
Timely, accurate, and complete reporting and analy sis of safety  information from clinical studies 
are crucial for the protection of subjects, investigators, and the Sponsor, and are mandated by 
[CONTACT_23824]. The Sponsor has established Standard Operating Procedures in 
conformity  with regulatory  requirements worldwide to ensure appropriate reporting of safet y 
information; all clinical studies conducted by [CONTACT_23825].
CCI
R092670 (paliperidone palmitate)
Clinical Protocol R092670PSY3015 Amendment 3
111
Approved , Date: [ADDRESS_22975] administered a 
medicinal (investigational or noninvestigational) product. An adverse event does not necessaril y 
have a causal relationship with the treatment. An adverse event can therefore be any  unfavorable 
and unintended sign (including an abnormal finding), sy mptom, or disease temporally  associated 
with the use of a medicinal (inv estigational or noninvestigational) product, whether or not related 
to that medicinal (investigational or noninvestigational) product. (Definition per ICH .)
This includes any  occurrence that is new in onset or aggravated in severit y or frequency  from the 
baseline condition, or abnormal results of diagnostic procedures, including laboratory  test 
abnormalities.
Note: The Sponsor collects adverse events starting with the signing of the ICF (refer to 
Section 12.3.1 [All Adverse Events] for time of last adverse event recording).
Serious Adverse Event
A serious adverse event based on ICH and EU Guidelines on Pharmacovigilance for Medicinal 
Products for Huma n Use is any  untoward medical occurrence that at an y dose:
Results in death
Is life -threatening
(The subject was at risk of death at the time of the event. It does not refer to an event that 
hypothetically  might have caused death if it were more severe.)
Requires inpatient hospi[INVESTIGATOR_1081]
Results in persistent or significant disability /incapacity
Is a congenital anomal y/birth defect
Is a suspected transmission of an y infectious agent via a medicinal product
Is Me dicall y Important*
*Medical and scientific judgment should be exercised in deciding whether expedited reporting is 
also appropriate in other situations, such as important medical events that may not be 
immediately  life-threatening or result in death or hospi[INVESTIGATOR_23738]. 
These should usually  be considered serious.
Unlisted (Unexpected) Adverse Event/Reference Safety Information
An adverse event is considered unlisted if the nature or severity  is not consistent with the 
applicable product reference safet y information. For paliperidone palmitate , the expectedness of 
an adverse event will be determined b y whether or not it is listed in the Investigator's Brochure.
R092670 (paliperidone palmitate)
Clinical Protocol R092670PSY3015 Amendment 3
112
Approved , Date: 11 February 2019Adverse Event Associated With the Use of the Drug
An adverse event is considered associated with the use of the drug if the attribution is possible, 
probable, or very  likel y by [CONTACT_23826] 12.1.2 (Attribution Definitions ).
12.1.2. Attribution Definitions
Not Related
An adverse event that is not related to the use of the drug.
Doubtful
An adverse event for which an alternative explanation is more likely, eg,concomitant drug(s), 
concomitant disease(s), or the relationship in time suggests that a causal relationship is unlikely .
Possible
An adverse event that might be due to the use of the drug. An alternative e xplanation, 
eg,concomitant drug(s), concomitant disease(s), is inconclusive. The relationship in time is 
reasonable; therefore, the causal relationship cannot be excluded.
Probable
An adverse event that might be due to the use of the drug. The relationshi p in time is suggestive 
(eg,confirmed by [CONTACT_23827]). An alternative explanation is less likely, eg,concomitant 
drug(s), concomitant disease(s).
Very Likely
An adverse event that is listed as a possible adverse reaction and cannot be reasonabl y explaine d 
by [CONTACT_4867], eg,concomitant drug(s), concomitant disease(s). The relationship 
in time is very  suggestive (eg, it is confirmed b y dechallenge and rechallenge).
12.1.3. Severity Criteria
An assessment of severity  grade will be made using the following general categorical 
descriptors:
Mild: Awareness of symptoms that are easily  tolerated, causing minimal discomfort and not 
interfering with every day activities.
Moderate: Sufficient discomfort is present to cause interference with normal activity .
Severe: Extreme distress, causing significant impairment of functioning or incapacitation. 
Prevents normal every day activities.
The investigator should use clinical judgment in assessing the severit y of events not directly  
experienced b y the subject (eg, laboratory  abnormalities).
R092670 (paliperidone palmitate)
Clinical Protocol R092670PSY3015 Amendment 3
113
Approved , Date: 11 February 201912.2. Special Reporting Situations
Safety  events on a Sponsor study  drugthat may require expedited reporting or safet y evaluation 
include, but are not limited to:
Overdose of a S ponsor study  drug .
Suspected abuse/misuse of a Sponsor study  drug .
Accidental or occupational exposure to a Sponsor study  drug .
Any failure of expected pharmacologic action (ie, lack of effect) of a S ponsor study  drug .
Unexpected therapeutic or clinical benefit from use of a S ponsor study  drug .
Medication error involving a Sponsor product (with or without subject/patient exposure to 
the S ponsor study  drug , eg, name [CONTACT_2976]) .
Exposure to a Sponsor study  drug from breastfeeding .
Exposure to a Sponsor study  drug during pregnancy ; see Section 12.3.3 (Pregnancy ).
Special reporting situations should be recorded in the eCRF. Any special reporting situation that 
meets the criteria of a serious adverse event should be recorded on the serious adverse event page 
of the eCRF.
12.3. Procedures
12.3.1. All Adverse Events
All adverse events and special reporting situations, whether serious or nonserious, will be 
reported from the time a signed and dated ICFis obtained until completion of the subject's last 
study -related procedure ,which may include contact [CONTACT_20687] -up of safet y. Serious adverse 
events, including those spontaneously  reported to the investigator within 6months after the last 
dose of study  drug, must be reported using the Serious Adverse Event Form. The Sponsor will 
evaluate an y safet y information that is spontaneously  reported b y an investigator bey ond the time 
frame specified in the protocol.
All events that meet the definition of a serious adverse event will be reported as serious adverse 
events, regardless of whether they are protocol -specific assessments. As permitted per local 
regulations, a nticipated events will be record ed and reported as described in Attachment 3.
All adverse events, regardless of seriousness, severity , or presumed relationship to study  drug, 
must be recorded using medical terminology  in the source document and the eCRF. Whenever 
possible, diagnoses should be given when signs and symptoms are due to a common etiology 
(eg, cough, runny nose, sneezing, sore throat, and head congestion should be reported as "upper 
respi[INVESTIGATOR_23739]"). Investigators must record in the eCRF their opi[INVESTIGATOR_23740] . All measures required for adverse event 
management must be recorded in the source document and reported according to Sponsor 
instructions.
R092670 (paliperidone palmitate)
Clinical Protocol R092670PSY3015 Amendment 3
114
Approved , Date: 11 February 2019The Sponsor assumes responsibility  for appropriate reporting of adverse events to the regulatory 
authorities. The Sponsor will also report to the investigator (and the head of the investigational 
institute where required) all suspected unexpected serious adverse reactions (S[LOCATION_003]Rs) . For 
anticipated events reported as individual serious adverse events the Sponsor will make a 
determination of relatedness in addition to and independent of the investigator’s assessment. The 
Sponsor 'sAnticipated Event Review Committee will periodically  evaluate the accumulating data 
and, when there is sufficient evidence and the Sponsor has determined there is a reasonable 
possibility  that the drug caused a serious anticipated event, they will submit a safety  report in 
narrative format to the investigators (and the head of the investigational institute where required ). 
The inves tigator (or Sponsor where required) must report S[LOCATION_003]R s to the appropriate 
Independent Ethics Committee/I nstitutional Review Board (IEC/IRB) that approved the protocol 
unless otherwise required and documented by [CONTACT_6179]/I RB. A S[LOCATION_003]R will be reported to 
regulatory  authorities unblinded. Participating investigators and IEC/IRB will receive a blinded 
S[LOCATION_003]R summary , unless otherwise specified.
For all studies with an outpatient phase, including open -label studies, the subject must be 
provided with a "wallet (study)card" and instructed to carry  this card with them for the duration 
of the study  indicating the following:
Study number
Statement, in the local language(s), that the subject is participating in a clinical study
Investigator's name [INVESTIGATOR_1238] 24-hour contact [CONTACT_23828]
Local Sponsor's name [INVESTIGATOR_1238] 24-hour contact [CONTACT_23828] (for medical staff only )
Site number
Subject number
Any other information that is required to do an emergency  breaking of the blind
12.3.2. Serious A dverse Events
All serious adverse events occurring during thestudymust be reported to the appropriate 
Sponsor contact [CONTACT_23829] -site personnel within [ADDRESS_22976] be completed and signed by a physician from the study  site, 
and transmitted to the Sponsor within 24 hours. The initial and follow -up reports of a serious 
adverse event should be made b y facsimile (fax).
All serious adverse events that have not resolved by [CONTACT_2054] , or that have not 
resolved upon discontinuation of the subject's participation in the study , must be followed until 
any of the following occurs:
The event resolves
The event s tabilizes
R092670 (paliperidone palmitate)
Clinical Protocol R092670PSY3015 Amendment 3
115
Approved , Date: 11 February 2019The event returns to baseline, if a baseline value/status is available
The event can be attributed to agents other than the study  drug or to factors unrelated to 
study  conduct
It becomes unlikely  that any additional information can be obtained (subject or health care 
practitioner refusal to provide additional information, lost to follow -up after demonstration 
of due diligence with follow-up efforts)
Suspected transmission of an infectious agent by a medicinal product will be reported as a 
serious adverse event. Any event requiring hospi[INVESTIGATOR_059] (or prolongation of hospi[INVESTIGATOR_059]) 
that occurs during the course of a subject's participation in a study  must be reported as a serious 
adverse event, except hospi[INVESTIGATOR_23741]:
Study -designated hospi[INVESTIGATOR_602].
Hospi[INVESTIGATOR_23742] (eg, social reasons 
such as pending placement in long -term care facility ).
Surgery  or procedure planned before entry  into the study  (must be documented in the 
eCRF ). Note: Hospi[INVESTIGATOR_23743], and where 
the underl ying condition for which the hospi[INVESTIGATOR_23744] ,will 
not be considered serious adverse events. Any  adverse event that results in a prolongation of 
the originall y planned hospi[INVESTIGATOR_23745] a new serious adverse event.
The cause of death of a subject in a study, whether or not the event is expected or associated with 
the study  drug , is considered a serious adverse event.
See also Section 9.3.1 (Evaluations) regarding collection of PK samples associated with serious 
adverse events.
12.3.3. Pregnancy
All initial reports of pregnancy  in female subjects or partners of male subjects must be reported 
to the Sponsor by [CONTACT_1758] -site personnel within 24 hours of their knowledge of the event using 
the appropria te pregnancy  notification form. Abnormal pregnancy  outcomes (eg, spontaneous 
abortion, fetal death, stillbirth, congenital anomal ies, ectopic pregnancy ) are considered serious 
adverse events and must be reported using the Serious Adverse Event Form. Any subject who 
becomes pregnant during the study  must be promptly  withdrawn from the study  and discontinue 
further stud y drug.
Because the effect of the study  drug on sperm is unknown, pregnancies in partners of male 
subjects included in the study will be repor ted as noted above.
Follow -up information regarding the outcome of the pregnancy  and any  postnatal sequelae in the 
infant will be required .
R092670 (paliperidone palmitate)
Clinical Protocol R092670PSY3015 Amendment 3
116
Approved , Date: 11 February 201912.4. Contact[CONTACT_23830] (and corresponding telephone numbers) of the individuals who should becontact[CONTACT_23831] y issues or questions regarding the study  are listed in the Contact [CONTACT_23832](s), which will be provided as a separate document.
13. PRODUCT QUA LITY COMP LAINT HA NDLING
A product quality  complaint (PQC) is defined as any suspi[INVESTIGATOR_23746] a product defect related to 
manufacturing, labeling, or packaging, ie, any dissatisfaction relative to the identity , quality , 
durability , or reliability  of a product, including its labeling or package integrit y. A PQC may 
have an impact on the safet yand efficacy  of the product. Timely , accurate, and complete 
reporting and analysis of PQC information from studies are crucial for the protection of subjects, 
investigators, and the Sponsor, and are mandated by [CONTACT_23824]. The 
Sponsor has established procedures in conformity  with regulatory  requirements worldwide to 
ensure appropriate reporting of PQC information; all studies conducted by [CONTACT_23833].
13.1. Procedu res
All initial PQCs must be reported to the Sponsor by [CONTACT_1758] -site personnel within [ADDRESS_22977] report the 
PQC to the Sponsor according to the serious adverse event reporting timelines (refer to 
Section 12.3.2 [Serious Adverse Events ]). A sample of the suspected product should be 
maintained for further investigation if requested by [CONTACT_1034].
13.2. Contact[CONTACT_23834] (and corresponding telephone numbers) of the individuals who should be contact[CONTACT_23835](s), which will be 
provided as a separate document.
14. STUDY DRUG INFORMA TION
14.1. Physical Description of Study Drugs
Study  drugs will be supplied in prefilled s yringes, as follows:
PP1M:
50 mg eq. (78 mg) in 0.5 mL
75 mg eq. (117 mg) in 0.75 mL
100 mg eq .(156 mg) in 1.0 mL
150 mg eq. (234 mg) in 1.5 mL
R092670 (paliperidone palmitate)
Clinical Protocol R092670PSY3015 Amendment 3
117
Approved , Date: 11 February 2019PP3M :
350 mg eq. (546 mg) in 1.75 mL
525mg eq. (819 mg) in 2.625 mL
PP6M :
Placebo: The placebo consists of 20% I ntralipid (200 mg/mL) injectable emulsion. It has the 
same milky -white appeara nce as the active compound ,and was used as placebo in the 
Sponsor's previous studies of PP3M.
The study  drug will be manufactured and provided under the responsibility  of the Sponsor. Refer 
to the I nvestigator's Brochure for a list of excipi[INVESTIGATOR_840].
14.2. Packaging
The study  drug will be packaged in individual subject kits. Each kit will consist of a safet y 
need le, instructions for use, and a blister- packed, prefilled s yringe assembled with a plunger rod.
14.3. Labeling
Labels will contain blanks for the subject’s identificat ion number and the investigator’s name. 
These will be filled in when the study  drug is dispensed to a subject.
Study  drug labels will contain information to meet the applicable regulatory requirements.
14.4. Preparation, Handling, and Storage
All study drug and matching placebo must be stored at controlled temperatures as instructed by 
[CONTACT_23836] .
14.5. Drug A ccountability
The unblinded s tudy drug administrator (see Section 5[Treatment Allocation and Blinding]) is 
responsible for ensuring that all study  drug received at the site is inventoried and accounted for 
throughout the study . The study  drug administered to the subject must be documented on the 
drug accountability  form. All study  drug will be stored and disposed of according to the 
Sponsor's instructions. Study-site personnel must not combine contents of the study  drug 
containers.
Study  drug must be handled in strict accordance with the protocol and the container label, and 
must be stored at the study  site in a limited -access area or in a locked cabinet under appropriate 
environmental conditions. Unused study  drugmust be available for verification by [CONTACT_1034]'s 
study -site monitor during on-site monitoring visits. The return to the Sponsor of unused study  
drug will be documented on the drug return form. When the study  site is an authorized 
CCI
CCI
R092670 (paliperidone palmitate)
Clinical Protocol R092670PSY3015 Amendment 3
118
Approved , Date: [ADDRESS_22978] also be documented on 
the drug return form.
Potentially  hazardous materials (such as used ampules, needles, syringes ,and vials containing 
hazardous liquids) should be disposed immediately  in a safe manner . Therefore , these will not be 
retained for drug accountability  purposes.
Study  drug should be dispensed under the supervision of the investigator or a qualified member 
of the study -site personnel , or by a hospi[INVESTIGATOR_307]/clinic pharmacist. Study  drug will be supplied only 
to subjects participating in the study . Returned study  drug must not be dispensed again, even to 
the same subject. Study  drug may not be relabeled or reassigned for use by [CONTACT_23837]. The 
investigator agrees neither to dispense the study  drug from, nor store it at, any site other than the 
study  sites agreed upon with the Sponsor.
15. STUDY -SPECIFIC MATERIA LS
The investigator will be provided with the following materials:
Documentation:
Investigator 'sBrochure
Locally  approved prescribing information and patient information for the marketed study  drugs 
(oral paliperidone, PP1M ,and PP3M ) that precede the investigational study  drug (PP6M) in this 
study . Investigators should provide subjects with the appropriate patient information files that are 
relevant to their treatment paths through the stud y.
Manual s:
oFor assessment s (ie, questionnaires and scales)
oFor ECGs
oFor biological samples (including for laboratory  tests, PK samples)
oFor IWRS
oFor electronic data capture completion guidelines
Study-site investigational product binder
Supplies:
Blood collection tubes, storage tubes, preprinted labels (or tubes labeled with preprinted labels), 
and related supplies for the collection and shipment of biological samples (including for 
laboratory  tests, PK samples ). These supplies will be provided by [CONTACT_23838] (where 
different central laboratories may  be used for different sample ty pes, such as one for PK samples, 
etc).
Urine and routine blood collection kits
Urine pregnancy test kits
Urine drug screen test kit
Alcohol breath test
R092670 (paliperidone palmitate)
Clinical Protocol R092670PSY3015 Amendment 3
119
Approved , Date: [ADDRESS_22979] their decision to continue 
participation. They  will be told that their consent to participate in the study is voluntary  and may 
be withdrawn at any time with no reason given and without penalt y or loss of benefits to which 
they would otherwise be entitled. Only subjects who are fully  able to under stand the risks, 
benefits, and potential adverse events of the study, and provide their consent voluntarily  will be 
enrolled.
Primary  study -specific ethical concerns and study -specific mitigations are as follows:
Changing medications:
For subjects with prestudy PP1M or PP3M stability, aconcern may be associated with changing 
from an antipsy chotic that had been providing acceptable levels of efficacy  and tolerability 
before the study  to a new investigational antipsychotic within the study . This risk is limited in 
the current study  by [CONTACT_23839], not the active substance, of the 
antipsy chotic .
For subjects with prestudy injectable risperidone stability , the above risk is limited in the current 
study  by [CONTACT_23840] (substituting the combination of parent molecule [risperidone] 
and metabolite [paliperidone] for the metabolite [paliperidone] alone).
For subjects with reason to changetheir prestudy oral antips ychotic, the above concern does not 
apply ; they will be enrolled only per valid reason to change their previous antipsy chotic 
(including problems with efficacy , safety ,or tolerability , or per preference for a LAI
medication ).
For all subjects, the study  also allows subjects to continue taking other nonantipsy chotic 
medications that they had been using at entry  to the study , to initiate or make changes to 
nonantipsy chotic medications during study  (within some limitations), and to receive 
supplementation with oral antipsy chotics during the study  (within some limitations) .
Long -acting formulation : Aconcern may be associated with the long-acting nature of the 
study  drug. If an adverse event occurs during treatment with an oral ant ipsychotic, then dosing 
can be stopped , which results in rapid elimination from the body  and often a resolution of the 
adverse event over a similar time course . If an adverse event occurs during treatment with a 
LAIantips ychotic, then the plasma concentra tions may bemaintained for months after the 
injection ;elimination of the drug cannot be accelerated to facilitate resolution of the adverse 
event. However, many of the expected adverse events can be managed with pharmacological 
intervention (eg, beta-blockers for akathisia or anticholinergics for EPS). Moreover, eligible 
study  subjects will already  have been using LAIformulations before enrolling in the study ; the 
study  does not introduce a new risk of this nature , but only extends the duration in which the 
risk is present.
High doses : A concern may beassociated with the high doses of the investigational study 
drug. The Sponsor has performed PK simulations to select these doses, and has considered the 
R092670 (paliperidone palmitate)
Clinical Protocol R092670PSY3015 Amendment 3
120
Approved , Date: 11 February 2019acceptabilit y of the PP6M exposures based on comparison with paliperidone and risperidone 
data from previous studies. The results indicated that exposures at the proposed PP6M dose 
levels should yield tolerabilit y that is similar to existing paliperidone and risperidone 
formulations. Beyond those aggregate analyses, the Sponsor also considered individual cases 
of subjects who had high exposures to PP3M during previous studies, and found that high 
concentrations of paliperidone were well tolerated. Still, the current study  include s extra safety  
assessments around the time of expected peak plasma paliperidone levels.
Large volumes : A concern may be associated with the large volumes of the intramuscular 
injections. The Sponsor has consulted nursing guidelines for the acceptability  ofthese 
volumes, and has accordingl y restricted the administration of PP6M into the gluteal muscle. 
The study  also includes structured assessments of the injection sites and guidelines for 
handling an y associated adverse events.
The volume of blood to be collected in this study  is not considered to pose an ethical concern or a 
special risk. The volume to be collected over any 6-month period of the study  is less than the 
volume collected in a single day (with an allowed 2-month frequency ) associated with a 
charitable blood donation .1
More generall y, the study also includes many  safety  assessments and eligibility  criteria designed to 
ensure that the population is appropriate for enrollment and is carefull y assessed throughout the 
study .
16.2. Regulatory  Ethics Compliance
16.2.1. Investigator Responsibilities
The investigator is responsible for ensuring that the study  is performed in accordance with the 
protocol, current ICH guidelines on Good Clinical Practice (GCP), and applicable regulatory  and 
country -specific requirements.
Good Clinical Practice is an international ethical and scientific qualit y standard for designing, 
conducting, recording, and reporting studies that involve the participation of human subjects. 
Compliance with this standard provides public assurance that the rights, safety , and well -being of 
study  subjects are protected, consistent with the principles that originated in the Declaration of 
Helsinki,and that the study  data are credible.
16.2.2. Independent Ethics Committee or Institutional Review  Board
Before the start of the study , the investigator (or Sponsor where required) will provide the 
IEC/IRB with current and complete copi[INVESTIGATOR_23747] (as required by [CONTACT_13125]) :
Final protocol and, if applicable, amendments
Sponsor -approved ICF(and any  other written materials to be provided to the subjects)
Investigator's Brochure (or equivalent information) and amendments/addenda
Sponsor- approved subject recruiting materials
R092670 (paliperidone palmitate)
Clinical Protocol R092670PSY3015 Amendment 3
121
Approved , Date: 11 February 2019Information on compensation for study -related injuries or payment to subjects for 
participation in the study , if applicable
Investigator's curriculum vitae or equivalent information (unless not required, as 
document ed by [CONTACT_6179]/IRB)
Information regarding funding, name [CONTACT_19618], institutional affiliations, other potential 
conflicts of interest, and incentives for subjects
Any other documents that the I EC/IRB requests to fulfill its obligation
This study  will beundertaken only after the IEC/I RB has given full approval of the final 
protocol, amendments (if any, excluding the ones that are purely  administrative, with no 
consequences for subjects, data or study  conduct , unless required locally ), the ICF, applicable
recruiting materials, and subject compensation programs, and the Sponsor has received a copy  of 
this approval. This approval letter must be dated and must clearly identify the IEC/IRB and the 
documents being approved.
During the study  the investigator (or Sponsor where required) will send the following documents 
and updates to the IEC/IRB for their review and approval, where appropriate:
Protocol amendments (excluding the ones that are purel y administrative, with no 
consequences for subjects, data or study conduct)
Revision(s) to ICFand any  other written materials to be provided to subjects
If applicable, new or revised subject recruiting materials approved b y the Sponsor
Revisions to compensation for study -related injuries or payment to subjects for participation 
in the study , if applicable
New edition(s) of the Investigator's Brochure and amendments/addenda
Summaries of the status of the study  at intervals stipulated in guidelines of the IEC/IRB (at 
least annuall y)
Reports of adverse events that are serio us, unlisted/unexpected, and associated with the 
study  drug
New information that may adversel y affect the safet y of the subjects or the conduct of the 
study
Deviations from or changes to the protocol to eliminate immediate hazards to the subjects
Report of deaths of subjects under the investigator's care
Notification if a new investigator is responsible for the study  at the site
Development Safet y Update Report and Line Listings, where applicable
Any other requirements of the IEC/I RB
For all protocol amendments (excluding the ones that are purel y administrative, with no 
consequences for subjects, data or study conduct), the amendment and applicable ICFrevisions 
must be submitted promptly  to the IEC/I RB for review and approval before implementation of 
the change(s).
R092670 (paliperidone palmitate)
Clinical Protocol R092670PSY3015 Amendment 3
122
Approved , Date: [ADDRESS_22980] once a year, the IEC/I RB will be asked to review and reapprove this study , where 
required.
At the end of the study , the investigator (or Sponsor where required) will notify  the IEC/I RB 
about the study  completion (ifapplicable, the notification will be submitted through the head of 
investigational institution) .
16.2.3. Informed Consent
Each subject (not a legal representative , but the subject himself or herself )must give written 
consent according to local requirements after the nature of the study  has been fully explained. 
The ICF(s) must be signed before performance of any study -related activity . The ICF(s) that 
is/areused must be approved by [CONTACT_19597]/IRB and be in a 
language that the subje ct can read and understand. The informed consent should be in 
accordance with principles that originated in the Declaration of Helsinki, current ICH and GCP 
guidelines, applicable regulatory  requirements, and Sponsor policy .
Before enrollment in the study ,the investigator or an authorized member of the study -site 
personnel must explain to potential subjects the aims, methods, reasonably anticipated benefits, 
and potential hazards of the study , and any discomfort participation in the study  may entail. 
Subje cts will be informed that their participation is voluntary  and that they may withdraw 
consent to participate at any time. They  will be informed that choosing not to participate will not 
affect the care the subject will receive for the treatment of his or her disease . Subjects will be 
told that alternative treatments are available if they refuse to take part and that such refusal will 
not prejudice future treatment. Finally , they will be told that the investigator will maintain a 
subject identification register for the purposes of long-term follow up if needed and that their 
records may be accessed by [CONTACT_23841] S ponsor personnel without 
violating the confidentiality  of the subject, to the extent permitted by [CONTACT_6983](s) or 
regulations. By [CONTACT_23842] .It also denotes that the 
subject agrees to allow his or her study  physician to recontact [CONTACT_23843] , if needed.
The subject will be given sufficient time to read the ICF and the opportunity  to ask questions. 
After this explanation and before entry  into the study , consent should be appropriatel y recorded 
by [CONTACT_19720]'s personally  dated signature. After havin g obtained the consent, a copy 
of the ICFmust be given to the subject.
If the subject is unable to read or write, an impartial witness should be present for the entire 
informed consent process (which includes reading and explaining all written information ) and 
should personally  date and sign the ICFafter the oral consent of the subject is obtained .
A separate ICF will also be signed by  [CONTACT_423]'s designated unpaid caregiver (such as a famil y 
member, significant other, or friend, with knowledge of the subject) who is willing to complete 
the IEQ assessments and who is willing to support the investigator and subject during other study 
assessments if requested. The designated caregiver must sign the ICF prior to the first baseline 
assessment. In case no designated caregiver is available for a subject or in case the designated 
R092670 (paliperidone palmitate)
Clinical Protocol R092670PSY3015 Amendment 3
123
Approved , Date: [ADDRESS_22981] includes explicit consent for the processing of 
personal data and for the investigator /institution to allow direct access to his or her original 
medical records (source data/documents) for study -related monitoring, audit, IEC/IRB review, 
and regulatory  inspection. This consent also addresses the transfer of the data to other entities 
and to other countries.
The subject has the right to request through the investigator access to his or her personal data and 
the right to request rectification of any data that are not correct or complete. Reasonable steps 
will be taken to respond to such a request, taking into consideration the nature of the request, the 
conditions of the study , and the applicable laws and regulations.
In addition, the Sponsor cannot make decisions as to the significance of any findings resulting 
from exploratory  research. Therefore, exploratory research data will not be returned to subjects 
or investigators, unless required by [CONTACT_23844]. Privacy  and confidentiality  of data 
generated in the future on stored samples will be protected by [CONTACT_23845].
16.2.5. Country Selection
This study  will only be conducted in those countries where the intent is to launch or otherwise 
help ensure access to the developed product if the need for the product persists , unless explicitly  
addressed as a specific ethical consideration in Section 16.1 (Study -specific Design 
Considerations ).
17. ADMINISTRA TIVE REQUI REMENTS
17.1. Protocol A mendments
Neither the investigator nor the Sponsor will modify  this protocol without a formal amendment 
by [CONTACT_1034]. All protocol amendments must be issued by [CONTACT_1034], and signed and dated 
by [CONTACT_093]. Protocol amendments must not be implemented without prior IEC/I RB 
approval, or when the relevant competent authority has raised any grounds for nonacceptance, 
except when necessary to eliminate immediate hazards to the subjects, in which case the 
R092670 (paliperidone palmitate)
Clinical Protocol R092670PSY3015 Amendment 3
124
Approved , Date: [ADDRESS_22982] be promptly  submitted to the IEC/I RB and relevant competent authority . 
Documentation of amendment approval by  [CONTACT_23846]/IRB must be provided to the 
Sponsor. When the change(s) involves only logistic or administrative aspects of the study, the 
IEC/IRB ( where required) only  needs to be notified.
During the course of the study , in situations where a departure from the protocol is unavoidable, 
the investigator or other physician in attendance will contact [CONTACT_23847] (s), which will beprovided as a separate
document . Except in emergency  situations, this contact [CONTACT_23848]. In all cases, contact [CONTACT_23849]. The data recorded 
in the eCRF and source documents will reflect any departure from the protocol, and the source 
documents will describe this departure and the circumstances requiring it.
17.2. Regulatory  Documentation
17.2.1. Regulatory  Approval/Notification
This protocol and any amendment(s) must be submitted to the appropriate regulatory  authorities 
in each respective country , if applicable. A study may not beinitiated until all local regulatory 
requirements are met.
17.2.2. Required Prestudy  Documentation
The following documents must be provided to the Sponsor before shipment of study  drug to the 
study site:
Protocol and amendment(s), if an y, signed and dated by [CONTACT_458] .
A copy of the dated and signed (or sealed, where appropriate per local regulations) , written 
IEC/IRB approval of the protocol, amendments, ICF, any recruiting materials, and if 
applicable, subject compensation programs. This approva l must clearly  identify  the specific 
protocol by [CONTACT_23850] (or sealed, where appropriate per local 
regulations) by [CONTACT_23851].
Name [CONTACT_23875]/IRB, including a current list of the IEC/IRB membe rs and 
their function, with a statement that it is organized and operates according to GCP and the 
applicable laws and regulations. If accompanied by a  letter of explanation, or equivalent, 
from the IEC/I RB, a general statement may be substituted for this list. I f an investigator or a 
member of the study -site personnel is a member of the IEC/IRB, documentation must be 
obtained to state that this person did not participate in the deliberations or in the 
vote/opi[INVESTIGATOR_23748].
Regulatory  authority  approva l or notification, if applicable .
Signed and dated statement of investigator (eg, Form FDA 1572), if applicable .
Documentation of investigator qualifications (eg, curriculum vitae).
Completed investigator financial disclosure form from the principal invest igator, where 
required .
R092670 (paliperidone palmitate)
Clinical Protocol R092670PSY3015 Amendment 3
125
Approved , Date: 11 February 2019Signed and dated Clinical Trial Agreement, which includes the financial agreement.
Any other documentation required by  [CONTACT_427].
The following documents must be provided to the S ponsor before enrollment of the first subject :
Completed investigator financial disclosure forms from all subinvestigators .
Documentation of subinvestigator qualifications (eg, curriculum vitae).
Name [CONTACT_23876] , and a dated copy  of 
current labo ratory  normal ranges for these tests, if applicable .
Local laboratory  documentation demonstrating compe tence and test reliability  (eg, 
accreditation/license), if applicable .
17.3. Subject Identification, Enrollment, and Screening Logs
The investigator agrees to complete a subject identification and enrollment log to permit easy 
identification of each subject during and after the study . This document will be reviewed by [CONTACT_23852] -site contact [CONTACT_23853].
The subject identification and enrollment log will be treated as confidential and will be filed by 
[CONTACT_23854]. To ensure subject confidentialit y, no copy  will be made. All 
reports and communications relating to the study  will identify  subjects by [CONTACT_23855] (as allowed by [CONTACT_427]) . In cases where the subject is not randomized 
into the study , the date seen and date of birth (as allowed by  [CONTACT_427]) will be used.
The investigator must also complete a subject screening log, which reports on all subjects who 
were seen to determine eligibility  for inclusion in the study .
17.4. Source Documentation
At a minimum, source document s consistent in the type and level of detail with that commonly  
recorded at the study  site as a basis for standard med ical care must be available for the following: 
subject identification, eligibility , and study  identification; study  discussion and date of signed 
informed consent; dates of visits; results of safety and efficacy  parameters as required by [CONTACT_12695]; record of all adverse events and follow -up of adverse events; concomitant medication; 
drug receipt/dispensing/return records; study  drug administration information; and date of study 
completion and reason for early discontinuation of study  drug or withdraw al from the study , if 
applicable.
The author of an entry  in the source documents should be identifiable.
Specific details required as source data for the study  and source data collection methods will be 
reviewed with the investigator before the study  and w ill be described in the monitoring 
guidelines (or other equivalent document).
An electronic source system may be utilized, which contains data traditionally  maintained in a 
hospi[INVESTIGATOR_23749] (eg, electronic source documents ) as well as 
R092670 (paliperidone palmitate)
Clinical Protocol R092670PSY3015 Amendment 3
126
Approved , Date: [ADDRESS_22983]'s source document s. Data must be entered into 
eCRF in English. The eCRF must be completed as soon as possible after a subject visit and the 
forms should be available for review at the next sched uled monitoring visit.
All subjective measurements (eg, pain scale information or other questionnaires) will be 
completed by [CONTACT_23856].
If necessary , queries will be generated in the electronic data capture tool. If corrections to an
eCRF are needed after the initial entry  into the eCRF, this can be done in either of the following
ways:
Investigator and s tudy-site personnel can make corrections in the electronic data capture tool 
at their own initiat ive or as a response to an auto- query  (generated by [CONTACT_23857]) .
Sponsor or Sponsor delegate can generate a query  for resolution by [CONTACT_23858] -site personnel.
17.6. Data Quality  Assurance /Quality  Control
Steps to be taken to ensure the accuracy  and reliability  of data include the selection of qualified 
investigators and appropriate study  sites, review of protocol procedures with the investigator and 
study -sitepersonnel before the study , andperiodic monito ring visits by [CONTACT_1034]. Written 
instructions will be provided for collection, handling, storage, and shipment of samples.
Guidelines for eCRF completion will be provided and reviewed with study -sitepersonnel before 
the start of the study . The Sponsor will review eCRF sfor accuracy  and completeness during on-
site monitoring visits and after transmission to the Sponsor; any discrepancies will be resolved 
with the investigator or designee, as appropriate. After upload of the data into the study  database 
they will be verified for accuracy  and consistency  with the data sources.
R092670 (paliperidone palmitate)
Clinical Protocol R092670PSY3015 Amendment 3
127
Approved , Date: [ADDRESS_22984] Retention
In compliance with the ICH/GCP guidelines, the investigator/institution will maintain all eCRF s
and all source documents that support the data collected from each subject, as well as all study  
documents as specified in ICH/GCP Section 8, Essential Documents for the Conduct of a 
Clinical Trial, and all study  documents as specified by [CONTACT_23859](s). 
The investigator/institution will take measur es to prevent accidental or premature destruction of 
these documents.
Essential documents must be retained until at least 2years after the last approval of a marketing 
application in an ICH region and until there are no pending or contemplated marketing 
applications in an ICH region or until at least 2years have elapsed since the formal 
discontinuation of clinical development of the investigational product. These documents will be 
retained for a longer period if required by [CONTACT_23860]. It is the responsibility  of the Sponsor to inform the 
investigator/institution as to when these documents no longer need to be retained.
If the responsible investigator retires, relocates, or for other reasons withdraws from the 
responsibility  of keepi[INVESTIGATOR_13274], custody  must be transferred to a person who will 
accept the responsibility . The Sponsor must be notified in writing of the name [CONTACT_23877]. Under no circumstance shall theinvestigator relocate or dispose of any study  
documents before having obtained written approval from the Sponsor.
If it becomes necessary  for the Sponsor or the appropriate regulatory  authority  to review any 
documentation relating to this study , the investigator /institution must permit access to such 
reports.
17.8. Monitoring
The Sponsor will use a combination of monitoring techniques (central, remote, or on-site 
monitoring )to monitor this study .
The Sponsor will perform on-site monitoring visits as freque ntly as necessary . The monitor will 
record dates of the visits in a study -site visit log that will be kept at the study  site. The first post -
initiation visit will be made as soon as possible after enrollment has begun. At these visits, the 
monitor will compar e the data entered into the eCRF with the source documents (eg,
hospi[INVESTIGATOR_307]/clinic/phy sician’s office medical records) . The nature and location of all source 
documents will be identified to ensure that all sources of original data required to complete the 
eCRF are known to the Sponsor and study -site personnel and are accessible for verification by 
[CONTACT_23861] -site contact. If electronic records are maintained at the study site, the method 
of verification must be discussed with the study -site personnel .
Direct access to source document s(medical records) must be allowed for the purpose of 
verify ing that the recorded data are consistent with the original source data. Findings from this 
review will be discussed with the study -site personnel . The Sponsor expects that, during 
monitoring visits, the relevant study -site personnel will be available, the source document swill 
R092670 (paliperidone palmitate)
Clinical Protocol R092670PSY3015 Amendment 3
128
Approved , Date: [ADDRESS_22985] for data identified by  [CONTACT_23862].
17.9. Study Completion/Termination
17.9.1. Study Completion (End of Study )
The study  is considered completed with the last visit for the last subject participating in the 
study . Poststudy  followup information, eg,as described in Section 12.3.1 (All Adverse Events) ,
will not be considered to be part of a "last visit" and will not be included in the study  database. 
The final data from the study site will be sent to the Sponsor (or designee) after completion of 
the final subject visit at that study  site, in the time frame specified in the Clinical Trial 
Agreement.
17.9.2. Study Termination
In addition to the planned closure at 12months after the last subject has been randomized in the 
Double- blind Phase, the Sponsor reserves the right to close the study site or terminate the study  
at any time for any reason at the sole discretion of the Sponsor. Study sites will be closed upon 
study  completion. Astudy site is considered closed when all required documents and study  
supplies have been collected and a study -site closure visit has been performed.
The investigator may initiate study -site closure at any time, provided there is reasonable cause 
and sufficient notice is given in advance of the intended termination.
Reasons for the early closure of astudy site by [CONTACT_23863]:
Failure of the investigator to comply  with the protocol, the requirements of the IEC/I RB or 
local H ealth A uthorities, the Sponsor's procedures, or GCP guidelines
Inadequate recruitment o f subjects b y the investigator
Discontinuation of further study  drug development
17.10. On-Site A udits
Representatives of the Sponsor's clinical quality  assurance department may visit the study  site at 
any time during or after completion of the study  to conduct an audit of the study  in compliance 
with regulatory  guidelines and company  policy . These audits will require access to all study 
records, including source documents, for inspection. Subjec t privacy  must, however, be 
respected. The investigator and study -site personnel are responsible for being present and 
R092670 (paliperidone palmitate)
Clinical Protocol R092670PSY3015 Amendment 3
129
Approved , Date: 11 February 2019available for consultation during routinely  scheduled study -site audit visits conducted by [CONTACT_23864].
Similar auditing procedures may also be conducted by [CONTACT_23865], either as 
part of a national GCP compliance program or to review the results of this study  in support of a 
regulatory  submission. The investigator should immediately  notify  the Sponsor if he or shehas
been contact[INVESTIGATOR_530] b y a regulatory agency  concerning an upcoming inspection.
17.11. Use of Information and Publication
All information, including but not limited to information regarding paliperidone palmitate or the 
Sponsor's operations (eg,patent application, formulas, manufacturing processes, basic scientific 
data, prior clinical data, formulation information) supplied by  [CONTACT_23866], and any data, generated as a result of this study , are considered 
confidential and remain the sole property  of the Sponsor. The investigator agrees to maintain this 
information in confidence and use this information only to accomplish this study , and will not 
use it for other purposes without the Sponsor's prior written consent.
The investigator understands that the information developed in the study will be used by [CONTACT_23867]. To permit the 
information derived from the clinical studies to be used, the investigator is obligated to provide 
the S ponsor with all data obtained in the study .
The results of the study  will be reported in a CSR generated b y the Sponsor and will contain data 
from all study  sites that participated in the study as per protocol . Recruitment performance or 
specific expertise related to the nature and the important assessment parameters of the study  will 
be used to determine a coordinating investigator. Study  subject identifiers will not be used in 
publication o f results. Any work created in connection with performance of the study  and 
contained in the data that can benefit from copyright protection (except any publication by [CONTACT_23868]) shall be the propert y of the Sponsor as author and owner of 
copy right in such work.
Consistent with Good Publication Practices and International Committee of Medical Journal 
Editors guidelines, the Sponsor shall have the right to publish such primary  (multicenter) data 
and information without approval from the investigator. The investigator has the right to publish 
data specific to the study  siteafter the primary  data are published. If an investigator wishes to 
publish information from the study , a copy of the manuscript must be provided to the Sponsor 
for review at least 60days before submission for publication or presentation. Expedited reviews 
will be arranged for abstracts, poster presentations, or other materials. If requested by [CONTACT_23869], the investigator will withhold such publication for up to an additional 
60days to allow for filing of a patent application. In the event that issues arise regarding 
scientific integrit y or regulatory  compliance, the Sponsor will review these issues with the 
investigator. The Sponsor will not mandate modifications to scientific content and does not have 
the right to suppress information. For multicenter study  designs and substudy  approaches, 
secondary  results generally  should not b e published before the primary  endpoints of a study  have 
R092670 (paliperidone palmitate)
Clinical Protocol R092670PSY3015 Amendment 3
130
Approved , Date: [ADDRESS_22986] been submitted for publication, within 12months of the 
availability  of the final data (tables, listings, graphs), or the Sponsor confirms there will be no 
multicenter study  publication. Authorship of publications resulting from this study  will be based 
on the guidelines on authorship, such as those described in the Uniform Requirements for 
Manuscripts Submitted to Biomedical Journals, which state that the named authors must have 
made a significant contribution to the design of the study  or analysis and interpretation of the 
data, provided critical review of the paper, and given final approval of the final version.
Registration of Clinical Studies and Disclosure of Results
The Sponsor will register and disclose the existence of and the results of clinical studies as 
required b y law.
R092670 (paliperidone palmitate)
Clinical Protocol R092670PSY3015 Amendment 3
131
Approved , Date: 11 February 2019REFERENCES
1. American Red Cross. Donation FAQs. www.redcrossblood.org/print/donating -blood/donation -faqs. 
Accessed 13March 2017.
2. Andreasen NC, Carpenter WT Jr, Kane JM, Lasser RA, Marder SR, Weinberger DR. Remission in 
schizophrenia: proposed criteria and rationale for consensus. Am J Psychiatry. 2005;162:441 -449.
3. Barnes TR. A rating scale for drug -induced akathisia. Br J Psychiatry . 1989;154:672 -676.
4. Bazett HC. An analysis of the time -relations [hip] of electrocardiograms. Heart. 1920;7:353 -370.
5. Bharmal M, Payne K, Atkinson MJ, Desrosiers MP, Morisky DE, Gemmen E. Validation of an abbreviated 
Treatment Satisfaction Questionnaire for Medication (TSQM- 9) am ong patients on antihypertensive 
medications. Health Qual Life Outcomes. 2009;7:36.
6. Bloch Y, Mendlovic S, Strupi[INVESTIGATOR_23750] S, Altshuler A, Fenning S, Ratzoni G. Injections of depot antipsychotic 
medications in patients suffering from schizo phrenia: do they hurt? J Clin Psychiatry. 2001; 62:855 -859.
7. Clinical Overview. Paliperidone palmitate 3 -month prolonged release suspension for injection for the treatment 
of schizophrenia. Janssen Research & Development, LLC ( 09Jul2015).
8. Clinical Study R eport R092670PSY3011. A randomized, multicenter, double -blind, non -inferiority study of 
paliperidone palmitate 3 month and 1 month formulations for the treatment of subjects with schizophrenia. 
Janssen Research & Development, LLC (10 Jun2015).
9. Clinical St udy Report R092670PSY3012. A randomized, multicenter, double- blind, relapse prevention study 
of paliperidone palmitate 3 -month formulation for the treatment of subjects w ith schizophrenia. Janssen 
Research & Development, LLC ( 02 Sep 2014).
10. Cocom an A, Murra y J. Intramuscular injections: a review of best practice for mental health nurses. J Psychiatr 
Ment Health Nurs. 2008;15:424 -434.
11. Development Safety Update Report: JNJ -16232411 (paliperidone) / JNJ -16977831 (paliperidone palmitate). 
Period covered by [CONTACT_23870]: 01 January 2016 to 31 December 2016. Janssen Research & Development, LLC 
(22Feb2017).
12. Engstrom JW, Martin JB. Disorders of the autonomic nervous system. In: Braunwald E, Fauci AS, Kasper DL, 
Hauser SL, Longo DL, Larry J, eds. Harrison's Principle s of Internal Medicine, 15th ed. New  York, NY: 
2001;2416 -2410.
13. Guy W. ECDEU (Early Clinical Development Evaluation Unit) Assessment Manual for Psychopharmacology. 
Rockville, MD: US Department of Health and Human Services; 1976.
14. Hahn EA, Beaumont JL, Pi[INVESTIGATOR_23751], et al. The PROMIS satisfaction with social participation measures 
demonstrated responsiveness in diverse clinical populations. J Clin Epi[INVESTIGATOR_5541]. 2016;73:135 -141.
15. Hawker GA, Mian S, Kendzerska T, French M. Measures of adult pain. Arthritis Care Res. 
2011;63(Suppl 11):S240 -S252. 
16. Higashi K, Medic G, Littlewood KJ, Diez T, Granström O, De Hert M. Medication adherence in 
schizophrenia: factors influencing adherence and consequences of nonadherence, a systematic literature 
review. Ther Adv Psychopharmacol . 2013;3:200 -218.
17. Hodges M, Salerno D, Erlien D. Bazett’s QT correction review ed: evidence that a linear QT correction for 
heart rate is better. J Am Coll Cardiol. 1983;1:694.
18. Hough D, Gopal S, Vijapurkar U, Lim P, Morozova M, Eerdekens M. Paliperidone pal mitate maintenance 
treatment in delaying the time -to-relapse in patients with schizophrenia: a randomized, double -blind, placebo -
controlled study. Schizophr Res. 2010;116:[ADDRESS_22987] for the maintenance treatment 
of schizophrenia .Janssen Research & Development, LLC (02Aug 2017) .
20. Kay SR, Fiszbein A, Opler LA. The Positive and Negative Syndrome S cale (PANSS) for schizophrenia. 
Schizophr Bull. 1987;13:261 -276.
R092670 (paliperidone palmitate)
Clinical Protocol R092670PSY3015 Amendment 3
132
Approved , Date: 11 February 201921. Kram er M, Simpson G, Ma ciulis V, et al. Paliperidone extended -release tablets for prevention of symptom 
recurrence in patients with schizophrenia: a randomized, double -blind, placebo -controlled study. J Clin 
Psychopharmacol. 2007;27:6 -14.
22. Kuo PJ, Chen -Sea M, Lu RB, et al. Validation of the Chinese version of the Schizophrenia Quality of Life 
Scale Revision 4 (SQLS -R4) in Taiw anese patients with schizophrenia. Qual Life Res. 2007;16:1533 -1538.
23. Lacro JP, D unn LB, Dolder CR, Leckband SG, Jeste DV. Prevalence of and risk factors for medication 
nonadherence in patients with schizophrenia: a comprehensive review of recent literature. J Clin Psychiatry. 
2002;63:892 -909.
24. Leal A, Rosillon D, Mehnert A, Jarema M, Remington G. Healthcare resource utilization during 1 -year 
treatment with long -acting, injectable risperidone. Pharmacoepi[INVESTIGATOR_9697]. 2004;13:811 -816.
25. Levitan BS, Andrews EB, Gilsenan A, et al. Application of the BRAT framework to case studies: observations 
and insights. Clin Pharmacol Therap. 2011;89:217 –224.
26. Levitan BS. A con cise display of multiple end points for benefit -risk assessment. Clin Pharmacol Therap. 
2011;89:56 –59.
27. Martin CR, Allan R. Factor structure of the Schizophrenia Quality of Life Scale Revision 4 (SQLS -R4). 
Psychol Health Med. 2007;12:126 -134.
28. McEvoy JP. Ris ks versus benefits of different types of long -acting injectable antipsychotics. J Clin Psychiatry. 
2006; 67(suppl 5):[ADDRESS_22988], Magliano L, Brambilla L, Ugolini S, Pi[INVESTIGATOR_23752] R. Development, reliability, and acceptability of a new 
version of the DSM -IVSocial and Occupational Functioning Assessment Scale (SOFAS) to assess routine 
social functioning. Acta Psychiatr Scand. 2000;101:323 -329.
30. Mueser KT, Meyer PS, Penn DL, Clancy R, Clancy DM, Salyers MP. The Illness Management and Recovery 
program: rationale, development, and preliminary findings. Schizophr Bull. 2006;32(Suppl 1):S32 -S43.
31. Posner K, Brow n GK, Stanley B, et al. The Columbia Suicide Severity Rating Scale: initial validity and 
internal consistency findings from three multisite studies with adolescents and adults. Am J Psychiatry. 
2011;168:1266 -1277.
32. Rhee Y -S, Park C -W, DeLuca PP, Mansour HM. Sustained -release injectable drug delivery. Pharm Technol. 
2010;Supplement:s6 -s13.
33. Sagie A, Larson MG, Goldberg RJ, Bengston JR, Levy D. An improved method for adjusting the QT interval 
for heart rate (the Framingham Heart Study). Am J Cardiol. 1992;70:[ADDRESS_22989]. 
1970;212:11 -19.
35. van Wijngaarden B, Schene AH, Koeter M, et al. Caregiving in schizophrenia: development, internal 
consistency and reliability of the Involvement Evaluation Questionnaire -European Version. Br J Psychiatry 
Suppl. 2000;s21 -s27.
36. Weiden PJ, Kozma C, Grogg A, Locklear J. Partial compliance and risk of rehospi[INVESTIGATOR_23753]. Psychiatr Serv. 2004;55:886 -891.
R092670 (paliperidone palmitate)
Clinical Protocol R092670PSY3015 Amendment 3
133
Approved , Date: 11 February 2019
ATTACHMENTS
Attachment 1:Guidelines for the Intramuscular Injection of Paliperi done Palmitate or Placebo 
During the Double -blind Phase
In theDouble- blind Phase , these guidelines should be used. In the Transition Phase and the Maintenance
Phase , the guidelines in the prescribing information for PP1M and PP3M should be used.
For each dose, a study -site personnel member must shake the syringe 
vigorously with the tip facing up and with a loose wrist for at least [ADDRESS_22990] 
15seconds to resuspend the dose.
The full content of t he syringe should be injected ,slowly .
During the Double -blind Phase, injections will rotate across sides of the body (left or right), as shown in
Table 5, but the image below show slandmarks for only [ADDRESS_22991] and sacrum. Then imagine draw ing a line to the greater 
trochanter of the femur. Administer the i njection in the upper -outer area bordered by [CONTACT_23871]. Injections should be administered in the dorso -gluteal injection site only. Ventrogluteal 
injections are not permitted.

R092670 (paliperidone palmitate)
Clinical Protocol R092670PSY3015 Amendment 3
134
Approved , Date: 11 February 2019Attachment 2:Relapse Criteria for PA NSS Total Score
A prespecif ied minimum change in PANSS total score is one of the possible qualify ing criteria 
for relapse. The table below correlates a subject's score at randomization tothe minimum 
posttreatment score during the Double- blind Phase that would meet the relapse criterion. If a 
subject's score during the Double- blind Phase is greater than or equal to the value in the second 
column , then thesubject should be considered for relapse . The relapse should then be re-
evaluated for confirmation at a visit 3 to 7dayslater (previously  unscheduled , if necessary ).
Criteria for Relapse According to PANSS Total Score
Score at Randomization Relapse Criterion Score
≤40 Points Increase of 10 points
30a40
31 41
32 42
33 43
34 44
35 45
36 46
37 47
38 48
39 49
40 50
>40Points Increase of 25%
41 44
42 45
43 47
44 48
45 49
46 50
47 52
48 53
49 54
50 55
51 57
52 58
53 59
54 60
55 62
56 63
57 64
58 65
59 67
60 68
61 69
62 70
63 72
64 73
65 74
66 75
67 77
68 78
69 79
≥70Points Not eligible to enter study or to continue to 
Double -blind Phase
Key: PANSS =Positive and Negative Syndrome Scale .
aA score of [ADDRESS_22992] possible value on the PANSS.
R092670 (paliperidone palmitate)
Clinical Protocol R092670PSY3015 Amendment 3
135
Approved , Date: 11 February 2019Criteria for Relapse According to PANSS Total Score
Note: The percent change is calculated after subtracting [ADDRESS_22993] score on the PANSS:
%	         =	        	      −      	  	             
      	  	              −30	×100
R092670 (paliperidone palmitate)
Clinical Protocol R092670PSY3015 Amendment 3
136
Approved , Date: 11 February 2019Attachment 3:Anticipated Events for Study R092670PSY3015
Anticipated Event
An anticipated event is an adverse event (serious or nonserious) that commonly occurs as a consequence 
of the underlying disease or condition under investigation (disease related) or background regimen.
For the purposes of this study the following events will be considered anticipated events:
 Schizophrenia
 Psychotic disorder
 Hallucination, auditory
 Hallucination, visual
 Hallucination
 Paranoia
 Delusion
 Apathy
 Substance use
Reporting of Anticipated Events
All adverse events will be recorded in the eCRF regardless of whether considered to be anticipated events 
and will be reported to theSponsor asdescribed in Section 12.3.1 (All Adverse Events ). Any anticipated 
event that meets serious adverse event criteria will be reported to the Sponsor as described in 
Section 12.3.2 (Serious Adverse Events ). These anticipated events are exempt from expedited reporting as 
individual single cases to Health Authorities. However ,if based on an aggregate review, it is determined 
that an anticipated event is possi bly related to study drug, the Sponsor will report these events in an 
expedited manner.
Anticipated Event Review Committee
An Anticipated Event Review Committee will be established to perform reviews of prespecified 
anticipated events at an aggregate level. The Anticipated Event Review Committee is a safety committee 
within the Sponsor 's organization that is independent of the Sponsor 's study team. The Anticipated Event 
Review Committee will meet to aid in the recommendation to the Sponsor 's study team as to whether 
there is a reasonable possibility that an anticipated event is related to the study drug.
Statistical Analysis
Details of statistical analysis of anticipated events, including the frequency of review and threshold to 
trigger an aggregate analysis of anticipated events will be provided in a separate Anticipated Events 
Safety Monitoring Plan.
R092670 (paliperidone palmitate)
Clinical Protocol R092670PSY3015 Amendment 3
137
Approved , Date: 11 February 2019INVESTIGA TOR AGREEME NT
[COMPANY_003]
[COMPANY_003]
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 1
Approved , Date: 20 April 2020Janssen Research & Development *
Clinical Protocol
COVID -19 Appendix
A Double -blind, Randomized, Active- controlled, Parallel -group Study of 
Paliperidone Palmitate 6- Month Fo rmulation
Protocol R092670PSY3015 ; Phase 3
Amendment 3/[LOCATION_003] -1
R092670 (paliperidone palmitate)
*Janssen Research & Development is a global organization that operates through different legal entities in 
various countries. Therefore, the legal entity acting as the Sponsor for Janssen Research & Development 
studies may vary, such as, but not limited to Janssen Biotech, Inc.; Janssen Products, LP; Janssen 
Biologics, BV; Janssen -Cilag International NV; Janssen Pharmaceutica NV ;Janssen, Inc; Janssen 
Sciences Ireland UC; or Janssen Research & Development, LLC. The term "Sponsor "is used throughout 
the prot ocol to represent these various legal entities; the Sponsor is identified on the Contact [CONTACT_23756].
This study will be conducted under [LOCATION_002] ( US)Food & Drug Administration (FDA) 
Investigational New Drug ( IND)regulations (21 Code of Federal Regulations [CFR] Part 312).
EudraCT Number :2017 -001941 -28
Status: Approved
Date: 20 April 2020
Prepared by: [CONTACT_12945] & Development, LLC
EDMS number: EDMS- RIM-[ZIP_CODE], 1.0
Local: EDMS- ERI-130495167, 5.0
Compliance: This study will be conducted in compliance with Good Clinical Practice (GCP), and applicable regulatory 
requirements.
Confidentiality Statement
The information provided herein contains Company trade secrets, commercial or financial information that the Company 
customarily holds close and treats as confidential.  The information is being provided under the assurance that the recipi[INVESTIGATOR_23754], regulations , rules, protective orders or otherwise.
[STUDY_ID_REMOVED]
R092670 (paliperidone palmitate) Clinical Protocol R092670PSY3015 Amendment 3 /[LOCATION_003] -1
COVID -19 Appendix
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 2
Approved , Date: 20 April 2020PROTOCOL A MENDMENTS
DOCUMENT HISTORY
Document Date
Amendment 3/[LOCATION_003] -[ADDRESS_22994] 2017
Amendment 3/[LOCATION_003] -1, 20 April 2020
Overall Rationale for the Amendment: To provide guidance on changes to study conduct and 
assessments due to restrictions and limitations during the COVID -[ADDRESS_22995] and assessments 
during the COVID -19 
pandemic.
R092670 (paliperidone palmitate) Clinical Protocol R092670PSY3015 Amendment 3 /[LOCATION_003] -1
COVID -19 Appendix
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 3
Approved , Date: [ADDRESS_22996] DURING THE COVID- 19 PA NDEMIC
It is recognized that the Coronavirus Disease 2019 (COVID -19) pandemic may  have an impact on 
the conduct of this clinical study  due to, for example, social distancing, self-isolation/quarantine 
by [CONTACT_19611] -site personnel; travel restrictions/limited access to public p laces, 
including hospi[INVESTIGATOR_600]; study  site personnel being reassigned to critical tasks. 
In alignment with recent health authority  guidance s to address the potential impact of COVID -[ADDRESS_22997] the health and well- being of participa nts and site staff. 
Scheduled visits that cannot be conducted in person at the study  site will be performed to the extent 
possible remotely /virtually  or delay ed within the allowed visit window. At each contact, 
participants will be interviewed to collect safet y data. Key efficacy  endpoint assessments should 
be performed if required and as feasible. Participants will also be questioned regarding general 
health status to fulfill any phy sical examination requirement. 
Every  effort should be made to adhere to protocol -specified assessments for participants on study 
intervention, including follow up. Modifications to protocol -required assessments may be 
permitted after consultation between the participant and investigator, and with the agreement of 
the sponsor. Missed assessments/visits will be captured in the clinical trial management s ystem as 
protocol deviations. Discontinuations of study interventions and withdrawal from the stud y due to 
COVID -19 should be documented in the case report form (CRF). 
The sponsor will continue to monitor the conduct and progress of the clinical study , and any 
changes will be communicated to the sites and to the health authorities according to local guidance.  
If a participant has tested positive for COVID -19, the investigator should contact [CONTACT_456]’s 
responsible medical monitor to discuss plans for study  intervention and follow -up. Modifications 
made to the study  conduct as a result of the COVID -19 pandemic will be summarized in the clinical 
study  report.
R092670 (paliperidone palmitate) Clinical Protocol R092670PSY3015 Amendment 3 /[LOCATION_003] -1
COVID -19 Appendix
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 4
Approved , Date: 20 April 2020GUIDANCE SPECIFIC T O THIS PROTOCOL:
Subject Visits/Assessments: If a subject cannot visit the research site in person, the sponsor 
recommends that any assessments that may be captured remotel y for that particular visit be 
collected. This collection should be performed remot ely by [CONTACT_23872], delegated site staff. These 
remote assessments could be conducted via telephone (or videoconference, eg, Facetime, 
Skype, if possible) with subjects in their homes. Please ensure that the remote method is 
allowable per local regulations. Assessments that could be completed include a review of 
adverse events, concomitant medications, clinical interviews, evaluation of relapse criteria, 
and questionnaires. Please note, the visit windows included in the Time and Events Schedule 
are still applic able. 
Administration of study drug: All subjects in the R092670PSY3015 study  have received 
all injections of study  drug; therefore, there will be no interruptions in administration of 
study  drug. 
Study assessments:
oRelapse assessment: Please evaluate as many  elements of the relapse criteria as 
possible. The Positive and Negative Syndrome Scale for Schizophrenia (PANSS) 
total score is the most important element for assessment of relapse. After the PANSS 
has been administered, the investigator or delegate must perform a review to 
determine if the relapse criteria have potentially  been met (per Section [IP_ADDRESS] and 
Attachment 2). If so, a confirmation visit will need to be conducted as outlined in 
Section [IP_ADDRESS] and Attachment 2. The confirmation visit may be performed 
remotely .
oEvaluation of secondary  and exploratory  endpoints (Personal and Social 
Performance scale , Clinical Global Impression -Severity , Columbia Suicide Severity 
Rating Scale , Healthcare Resource Utiliza tion Questionnaire, Involvement 
Evaluation Questionnaire, Schizophrenia Qualit y of Life Scale , Illness Management 
and Recovery , 9-item Treatment Satisfaction Questionnaire for Medication , 
Satisfaction With Participation in Social Roles ): Many  of the assess ments for 
evaluation of secondary  and exploratory  endpoints may be collected remotely . Please 
collect as much information as possible.
oPhysical examinations, vital signs, scales to assess extrapy ramidal symptoms 
(Abnormal Involuntary  Movement Scale, Barnes Akathisia Rating Scale, Simpson 
Angus Scale), electrocardiograms, collection of pharmacokinetic/ blood samples, 
pregnancy  tests, and laboratory assessments may not be possible to collect as part of 
the remote visit.
oIt must be documented in the CRF if a visit occurs remotely due to COVID -19. 
Missed assessments/protocol deviations:
oMissed assessments will be captured in the clinical trial management system as 
protocol deviations. All protocol deviations will be recorded as either major or minor
protocol deviations in the clinical trial management system using the current Major 
Protocol Deviation Criteria document.
R092670 (paliperidone palmitate) Clinical Protocol R092670PSY3015 Amendment 3 /[LOCATION_003] -1
COVID -19 Appendix
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 5
Approved , Date: 20 April 2020oRemote visits , missed visits, out of window visits, and missing assessments due to 
COVID -19-related issues will be recorded as minor protocol deviations. 
Early Withdrawal: If a  subject is lost to follow -up, or is unwilling to have any remote 
assessments performed, then he/she would be considered an early withdrawal. Please attempt 
to contact [CONTACT_11253], text message, email or through a relative, if possible. 
Consider certified mail as an option to contact a subject before declaring him/her as being lost 
to follow -up. 
COVID -19 Illness in Subjects:
If a subject in this study becomes symptomatic, the sponsor suggests that Coronavirus 
infection be confirmed with reverse transcriptase polymerase chain reaction (RT-PCR)
using diagnostic test kits. This should be performed using locall y approved laborator y 
kits and reported to the local health authorities as required.
Positive test results for Coronavirus as well as any associated symptoms should be 
recorded as adverse event s, and if the subject is hospi[INVESTIGATOR_057], the event should be captured 
as a serious adverse event. Similarly , hospi[INVESTIGATOR_23755] (HRUQ) form at the next visit , if applicable .
Please notify  the treating physician of the subject’s participation in Study  
R092670PSY3015, and d etails of the study  treatments in a blinded fashion .
Monitoring: In addition to subject study  visits, monitoring visits and data cleaning activities 
need to be completed prior to final database lock. On-site monitoring visits may not be 
possible due to loc al regulations, restrictions and guidance. In these cases, the Site Manager 
(and Independent Drug Monitor) will arrange to conduct site monitoring visits and activities 
remotely . Site closeout visits will be postponed until Site Managers and Independent Drug 
Monitors are able to return to the site to complete final closeout activities.
R092670 (paliperidone palmitate) Clinical Protocol R092670PSY3015 Amendment 3 /[LOCATION_003] -1
COVID -19 Appendix
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 6
Approved , Date: 20 April 2020INVESTIGA TOR AGREEME NT
[COMPANY_003]
[COMPANY_003]